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same effect. The sensitivity of these tests to the effects of alcohol has often not 
been completely ascertained, and concentration- or dose-effect relationships 
have only rarely been systematically reported. An overview of the sensitivity 
and dose responsiveness of different cns-tests to the effects of alcohol would 
be useful for future studies focusing on acute alcohol effects or drug-alcohol 
interaction studies, and could constitute a useful collection of tests to evalu-
ate the acute effects of alcohol on the cns. Chapter 2 of this thesis contains a 
systematic review, which attempts to determine the alcohol sensitivity for the 
large number of cns tests that is described in the literature.
Another methodological problem in acute alcohol studies is the huge vari-
ability in the alcohol exposure profiles that are encountered in such studies. 
Individuals vary as much as 3- to 4-fold in systemic concentrations and meta-
bolic rates after alcohol administration (Ramchandani et al., 2006). Many fac-
tors contribute to this variability, including doses and administration modes, 
the amount and rate of prior alcohol exposure, drinking history and food in-
take, differences in gastric emptying, liver volume, blood flow, race, age and 
gender (Ramchandani et al., 2006). Besides, most of the effects of alcohol 
are concentration- and time-dependent (Hiltunen et al., 2000; Vogel-Sprott, 
1979), and interpretation of the results can be complex if plasma levels change 
over time, particularly when this is not recorded accurately. This is a problem 
for many types of alcohol research, including drug interaction studies. A ma-
jor part of this thesis is devoted to the development and validation of an alco-
hol administration mode that allows the investigators to attain stable plasma 
levels of alcohol at a predetermined level in each individual. Few studies of 
alcohol effects or drug interactions are performed at pseudo-steady state lev-
els, or under other conditions in which these complexities are regulated. In 
many cases, alcohol exposure is merely controlled by adaptation of the dose 
to weight, and sometimes to gender or other demographic variables (Wilkin-
son, 1980). Measurements of the alcohol effects are usually performed at fixed 
time intervals after intake, and the number of samples is small. Often, breath 
alcohol levels (brac) are measured, but efforts to maintain constant levels are 
rare. A major reason for this lack of methodological stringency is the com-
plexity and variability of alcohol’s pharmacokinetic characteristics.
Alcohol (or ethanol) is probably the most commonly used drug worldwide 
( Jang and Harris, 2007), and is mainly consumed for its mild euphoric and 
disinhibitory effects. For the most part, alcohol is a central nervous system de-
pressant, although it may have biphasic effects (Pohorecky, 1982). Low doses 
of alcohol often have stimulant properties and increase sociability. In the non-
alcoholic, typical effects of low alcohol levels (50 mg/dl) include talkativeness, 
relaxation and tension reduction. Higher blood levels (above 100 mg/dl) sig-
nificantly impair mental and cognitive ability including judgement, and there is 
depression of sensory-motor functioning. As blood ethanol levels exceed 200 
mg/dl sensory and cognitive functioning is markedly impaired and at 300 mg/
dl most individuals would be stuporous. At higher concentrations (ld₅₀ = 400 
mg/dl), alcohol is lethal due to severe depression of respiratory function or 
other complications, such as aspiration of vomit (Pohorecky and Brick, 1988).
The effects of alcohol can partly be explained by its increasing effect on 
membrane fluidity and its subsequent disturbance of otherwise strictly regu-
lated ion channels and electrolyte balances (Pohorecky and Brick, 1988). Ad-
ditionally (or consequently), alcohol’s central nervous system (cns) effects 
are mediated through actions on a variety of neurotransmitters. Dopamine, 
serotonine, glutamate, noradrenaline and gamma-aminobutyric acid (gaba) 
are primarily involved. gaba a-receptors are among the most widely distrib-
uted neurotransmitter systems in the brain, and alcohol causes an allosteric 
enhancement of these inhibitory ion channels. This could explain why many 
of the effects of alcohol are related to cns-depression. Research shows that 
alcohol also tends to interfere with opioid receptor binding (Pohorecky and 
Brick, 1988). There is a complex interplay between these excitatory and inhibi-
tory systems. The numerous transmitters involved in alcohol’s action explain its 
diverse effects and the large number of drug interactions with both prescribed 
and illicit drugs (McIntosh and Chick, 2004).
These acute cns-effects have already been extensively investigated. 
Numerous tests and methods are currently used in such studies to investigate 
the different effects of alcohol. This diversity reflects the wide range of effects 
caused by alcohol and its large biomedical and psychosocial impact, but does 
not explain or justify why so many different tests are used even to study the 
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its selection was largely based on our own literature findings (i.e. chapter 2). 
The cns-effects of alcohol under pseudo-steady state conditions were 
quantified in this study, to investigate the profile and time-dependence of 
cns-effects during stable (pseudo-steady state) alcohol levels.
The clamping method might also be an appropriate tool to compare groups. 
Both pharmacodynamic differences and differences in alcohol metabolism 
can be explored between certain subgroups (e.g. male/female; alcoholics/
non-alcoholics; Caucasians/Japanese) without confounding differences in 
alcohol levels. It is generally assumed that Japanese people are more sensitive 
to alcohol compared to Caucasians (Shibuya et al., 1989). This is at least partly 
related to genetic differences in pharmacokinetics, since a high proportion 
of Japanese have a relative aldehyde dehydrogenase (aldh) deficiency 
(Chan, 1986). Differences in body posture and in lifestyle (food and/or use of 
medication) may further influence the kinetics of alcohol (Duranceaux et al., 
2008). Repeated exposure to alcohol may also induce tolerance to its effects 
(Bennett et al., 1993), and avoidance of alcohol or other differences in habitual 
use patterns could contribute to an increased sensitivity. Since the alcohol 
clamp by-passes most of these factors, we tried to directly compare alcohol 
metabolism and cns-effects between Caucasians and Japanese subjects in 
a subsequent study (chapter 5). Besides, efforts were made in this study to 
expand and to fine-tune the clamping procedure: steady-states were clamped 
at multiple levels (on different occasions) and initial infusion rates were 
customized to individual demographic characteristics, to avoid overshoots.
In cns drug research it is rarely possible to reliably characterize and 
differentiate drugs on the basis of one single functional test. Profiles of cns-
effects using a test battery usually provide more distinctive information, 
but this clearly depends on the breadth of scope of the test battery. The 
information is only reliable if the battery covers the cns functions that 
are primarily affected by one drug and much less so or differently by the 
other. However, cns-functions are hardly ever determined by a single 
neuropharmacological mechanism. Hence, functional assessments are 
bound to show overlap between different drugs classes, and to be affected 
by non-pharmacological factors like motivation, fatigue and other aspects of 
In an attempt to reduce experimental variance during alcohol studies, 
O’Connor et al. developed a method to keep alcohol plasma levels within 
close limits using an oral loading dose followed by an intravenous infusion 
(O’Connor, 1998). The O’Connor method is based upon the theory that for 
substances with marked saturable elimination in the relevant concentration 
range (like alcohol), an approximately linear relationship exists between the 
applied infusion rate and the resulting change in alcohol concentration or 
brac. When alcohol elimination is fully saturated, it is excreted at a constant 
rate, independent of concentration (Michaelis-Menten kinetics). Therefore, 
when the input is changed, this will result in a proportional change in alcohol 
concentration. The change in alcohol level required to achieve the target 
concentration can then be used to back-extrapolate the infusion rate that 
corresponds to, and should hence lead to this necessary change. This method 
was described as the Indiana brac clamp. 
In this thesis, the original clamping paradigm was modified, with the 
aim of creating a comparably reliable technique, but one that would be less 
intensive for the operator and the study subject. In this way, the alcohol 
administration mode would be more feasible for concomitant cns research 
in larger numbers of subjects. The oral loading dose was replaced by an 
intravenous loading dose to increase experimental control. Also, the time 
interval between breath samples was increased to facilitate the integration of 
multiple cns-measurements into the course of the clamp. Simulations were 
used to optimize the different phases of the infusion regimen. Additionally, to 
simplify the execution of the procedure for a larger number of operators after 
minimal training, the new paradigm was converted into a spreadsheet-based 
program. These alterations resulted in a new alcohol clamping paradigm, 
which was tested and simultaneously compared to another procedure for 
maintaining alcohol at a pre-set plasma level (chapter 3).
Subsequently, a study was performed to investigate whether an intensive 
battery of cns measurements could be performed during the course of the 
new clamping method without interference with or by the alcohol clamping 
procedure and with the stability of the alcohol levels (chapter 4). This battery 
consisted of cns-tests that were highly sensitive to the effects of alcohol and 
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activity, which results in reduced tremor amplitude, whereas the frequency 
remains unaffected (Koller and Biary, 1984; Koller, 1991). In a search for novel 
pharmacological treatment options a gaba a α2,3 subtype-selective partial 
agonist and a histamine-3 receptor inverse agonist were investigated in two 
different studies for their efficacy to reduce tremor symptoms (chapter 7 and 
8). In both studies, the alcohol clamp was introduced and served as a positive 
control. In contrast to most controlled trials in which the effect of alcohol on 
et is being studied, we attempted to obtain fixed alcohol levels for a prolonged 
period of time to induce a stable stimulus that would minimize the variability.
An obvious application of the alcohol clamp in drug development, is its 
use during ethanol interaction studies. The stability and predictability of the 
clamp reduces the variability that is inherent to most other modes of ethanol 
administration. This increases the reliability of the statistical analyses of an 
interaction, and reduces the risks of unexpectedly high pharmacokinetic 
levels and pharmacodynamic effects in the presence of other drugs with 
metabolic or central nervous system drug effects. In chapter 9, we employed 
the alcohol clamp for an interaction study with a novel d₃-antagonist. 
This thesis describes the development of a novel alcohol clamp (chapter 
3), a new method to obtain stable plasma levels of alcohol and its applica-
tion in cns-research. The method might have several advantages that were 
explored in subsequent studies described in this thesis. The stability of the 
alcohol clamp was used to examine functional effect profiles and time-de-
pendence of different cns-effects (chapter 4). The tests to examine these ef-
fects were chosen based upon a prior review of the literature, during which 
the most sensitive cns-tests were selected (chapter 2). Hereafter, we studied 
the alcohol clamping method as a tool to compare alcohol disposition capaci-
ties between different (ethnic) populations and as a tool to compare their 
different cns-responses to multiple stable alcohol levels. We also investigated 
whether the clamping method could be useful as a future benchmarking en-
tity in cns-research, based on its fmri effects on the brain at rest (chapter 6) 
and its efficacy on tremor symptoms (chapter 7 and 8). Finally, we employed 
the method in an interaction study with a compound that is in development 
for addictive disorders including alcoholism (chapter 9).
psychological and physical well-being. A generally applicable methodology 
for repeated measurements of direct drug effects on the entire cns, without 
task-related interactions and a priori models, would constitute a major 
improvement in cns drug development. Resting-state functional magnetic 
resonance imaging could satisfy many of these requirement, and was hence 
hypothesized to be a promising technique for pharmacological research. We 
investigated whether different psychoactive substances cause drug-specific 
effects in functional brain connectivity during resting-state (chapter 6). Both 
alcohol and morphine were selected for this purpose, because of their well-
known cns-effects, which show functional similarities (on attention and 
mood) as well as distinctions (on respiration, heart rate, motor function and 
others). Stable drug levels are preferred in this proof-of-concept study to 
assist in the calibration of the resting state technique. Therefore, the alcohol 
clamp was used here to produce stable and prolonged alcohol levels with 
minimal variability, as well as a target-controlled morphine infusion.
Alcohol is a well-know drug in medicine and in society. The effects of al-
cohol can therefore be used as a frame of reference for compounds that share 
some functional aspects with alcohol. Some drugs affect performance, and it 
could be useful to compare these impairments to the effects of alcohol, at a 
level with a recognized functional impact - for instance based on legal driv-
ing limits. Another example is to use a well-known therapeutic effect of al-
cohol as a benchmark for the effects of a novel drug with a similar putative 
therapeutic effect. This approach was chosen for the development of two new 
drugs for essential tremor (et), which in many patients is improved by alco-
hol. et is one of the most common neurological disorders among adults, and 
is the most common tremor disorder (Louis et al., 1998; Louis, 2001; Louis, 
2005). Current pharmacological treatment act symptomatically and have vari-
able effectiveness (Chen and Swope, 2003). Moreover, the occurrence of side 
effects, like sedation, weight gain and cognitive impairment, limit their use. 
Estimations indicate that alcohol is effective in approximately 70% of et pa-
tients (Lou and Jankovic, 1991; Koller et al., 1994). This finding is confirmed by 
controlled studies where alcohol was administered acutely (Growdon et al., 
1975; Koller and Biary, 1984). It most likely acts via a reduction of central over-
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chapter 2
Functional biomarkers for the acute effects 
of alcohol on the central nervous system in 
healthy volunteers
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receptors and possibly inhibition of central L-type Ca+2 channels (Little, 
1991; Weight et al., 1992). Although alcohol is classified as a sedative drug, it 
can also have stimulant effects (Charness et al., 1989; Little, 1991; Samson and 
Harris, 1992). The concentration- and time-dependence of its inhibitory and 
stimulatory properties in humans has not yet been fully elucidated, partly due 
to the complicated and variable pharmacokinetics of alcohol, but also to the 
lack of standarised tests for the cns-effects of ethanol.
Alcoholic beverages are used commonly and worldwide ( Jang and 
Harris, 2007), and the cns-effects of acute alcohol administration have been 
frequently quantified, a wide range of methods are used in such studies to 
study the different effects of alcohol. The sensitivity of these tests to the effects 
of alcohol has often not been completely ascertained, and concentration- or 
dose-effect relationships have only rarely been systematically reported. An 
overview of the sensitivity and dose-responsiveness of different cns-tests 
to the effects of alcohol would be useful for future studies focusing on acute 
alcohol effects or drug-alcohol interaction studies, and would constitute a 
useful collection of tests to evaluate the acute effects of alcohol on the cns.
A biomarker is described as a characteristic that is measured and evaluated 
as an indicator of normal or pathologic biological processes or pharmacologic 
responses to a therapeutic intervention (Colburn, 2003). A biomarker can be 
any response measure that shows a clear, consistent response to meaningful 
doses, across studies from a sufficient number of different research groups. 
A dose-response relationship and a plausible relationship between the 
biomarker and the pharmacology of alcohol provide indications that a 
biomarker reflects pharmacological activity. Previously, these criteria were 
used to evaluate the usefulness of cns-tests (or functional biomarkers) for 
the effects of antipsychotic drugs (de Visser et al., 2001), benzodiazepines (de 
Visser et al., 2003), selective serotonin reuptake inhibitors (ssri’s) (Dumont 
et al., 2005), 3,4-methyleendioxymethamfetamine (mdma) (Dumont and 
Verkes, 2006) and Δ9-tetrahydrocannabinol (thc) (Zuurman et al., 2008) in 
healthy subjects. In general, these systematic reviews showed that only a 
small number of tests actually display proper characteristics for a meaningful 
abstract
background The central nervous system (cns) effects of acute alcohol 
administration have been frequently assessed. Such studies often use a wide 
range of methods to study each of these effects. Unfortunately, the sensitivity 
of these tests  has not completely been ascertained.
methods A literature search was performed to recognize the most useful 
tests (or biomarkers) for identifying the acute cns-effects of alcohol in 
healthy volunteers. All tests  were grouped in clusters and functional domains. 
Afterwards, the effect of alcohol administration on these tests was scored 
as improvement,  impairment or as no effect. Furthermore,  dose-response 
relationships were established.
results A total number of 218 studies, describing 342 different tests (or 
test variants) were evaluated. Alcohol affected a wide range of cns-domains. 
Divided attention, focused attention, visuo-motor control and scales of 
feeling high and of subjective drug effects were identified as the most sensitive 
functional biomarkers for the acute cns-effects of alcohol. 
conclusions The large number of cns-tests that are used to determine the 
effects of alcohol interferes with the identification of the most sensitive ones 
and of drug-response relationships. Our results may be helpful in selecting 
rational biomarkers for studies investigating the acute cns-effects of alcohol 
or for future alcohol-interaction studies.
introduction  
Ethyl alcohol, or ethanol causes dose-dependent central nervous system 
(cns) depression, which culminates in a state of general unconsciousness 
at high plasma concentrations (Little, 1991). Prior investigations indicate 
that the predominant mechanism of cns depression involves selective 
alcohol interactions with ion channels that include allosteric enhancement 
of inhibition mediated by gamma-aminobutyric acid a (gaba-a) receptors, 
antagonism of excitation by n-methyl-d-aspartic acid (nmda) glutamate 
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com prehensive cns-effect profile. Subsequently, inappropriate terms (e.g. ‘in 
vitro’, ‘withdrawal’ or ‘deaths’) were excluded from the search by using the ‘not’ 
search option. To obtain a manageable data-set, the search was limited to ‘adult: 
19-44 years’, ‘English’, ‘publication date from 1980 to 2008’ and ‘humans’. The 
complete search query, which yielded 1263 publications, is provided in table 1.
All publications obtained using this strategy underwent a thorough 
selection process. Initially, all articles were manually screened by title. 
Articles with irrelevant titles, given the selected search terms were discarded. 
Remaining articles were carefully studied and those that did not comply with 
the main objectives of this review (e.g. studies describing chronic alcohol 
effects) were discarded. In addition, studies investigating alcohol effects 
under specific artificial circumstances or conditions (e.g. sleep restriction, 
hypoxemia or anxiety paradigms), and studies dealing with more drugs or 
substances than alcohol alone (i.e. interaction studies), were not selected for 
further analysis, even if part of the design complied with the requirements 
of this review. Also, studies investigating a specific group of subjects other 
than regular healthy adult volunteers (e.g. heavy drinkers, patients or certain 
professionals) were disregarded. Studies in which such populations were 
discussed have been excluded from our analysis, as in our opinion such 
populations exhibit different responses to similar doses of alcohol compared 
to ‘healthy volunteers’ and thus may negatively bias our results (e.g. pilots are 
supposed to have faster baseline reaction times in tests that measure reaction 
time speed and alcoholics probably show less effects in studies measuring 
subjective effects). Thereby, we only excluded tests that were also frequently 
reported in healthy volunteers (but with different results) rather than tests 
that were specifically used in these special populations. Furthermore, 
studies with fewer than twelve participating healthy volunteers were also 
disregarded. Finally, papers that only mentioned the dose of alcohol instead 
of the blood alcohol concentration (bac) or the equivalent breath alcohol 
concentration (brac) were excluded, since these studies are less suitable for 
accurate analysis of the relationships between alcohol levels and effects. 
At the end of this process, 218 titles were found eligible for review, which 
were subsequently evaluated based on the items summarized in table 2. The 
effect biomarker, that these tests differ between the various drug classes, 
and that most of these biomarkers belong to a small number of functional 
cns-domains: attention, memory, visuomotor and motor performance, 
subjective effects and certain neurophysiological tests (eye movements, 
electroencephalography). In addition, some drug classes cause specific 
neuroendocrine responses.
In an attempt to structure and subsequently evaluate the wide diversity of 
functional biomarkers for the cns-effects of ethanol, an extensive literature 
search was performed. Because of an apparent lack of standardization 
between the studies (even for the same tests), a structured procedure 
described previously was adopted, which includes progressive condensation 
of the tests into clusters of related tests and into domains of cns-functions, 
prior to the analyses (de Visser et al., 2001; de Visser et al., 2003; Dumont et 
al., 2005; Dumont and Verkes, 2006). The criteria mentioned for meaningful 
biomarkers were eventually applied to the results. All effects of alcohol other 
than on the cns (e.g. on the liver) were excluded, except neuro-endocrine 
responses. The primary objective of the current review is to present a 
systemic overview of the usefulness of the different cns-tests described in 
the literature, which allow a reliable assessment of the acute cns-effects of 
alcohol in healthy adult volunteers. Accurate tests to measure the acute effect 
of alcohol on the cns are vital when the effect of alcohol in combination with 
a cns-drug is being studied. The results of this review may also be useful 
to rationally select sensitive cns-test for drug/alcohol interaction studies, 
which are often required for registration of  new cns drugs.
methods
Structured literature evaluation
‘Ethanol’ (mesh), ‘effect’ and ‘cns’ were used as pivotal keywords to con-
struct a MedLine search. This search included a large number of studies that 
were irrelevant for the specific primary objective of this review. Therefore, a 
wide range of specific cns-functions was added to these keywords to ensure a 
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quantifications of the statistical significance levels for each individual dose. 
In these cases, efforts were made to estimate the individual dose effects from 
graphs or tables provided in the article. If this was impossible, only the largest 
average effect was assumed to be significant (in case of overall statistical 
significance) and smaller effects were considered non-significant.
Grouping of individual test results
Because of an apparent lack of standardization between the studies even for 
the same tests, a structured procedure was adopted as described previously 
(de Visser et al., 2001; de Visser et al., 2003; Dumont et al., 2005; Dumont and 
Verkes, 2006) in order to obtain a meaningful overview. This approach allowed 
the preservation of individual study data in early stages, followed by a progres-
sive condensation of results into logical test clusters and functional (cns) do-
mains. For example, all tests that determine the ability to discriminate flash- or 
flicker frequencies were grouped as the test cluster flicker discrimination and 
were subsequently categorized under the corresponding cns-domain atten-
tion. A compendium of neuropsychological tests from Spreen et al. (Spreen 
and Stretton, 1998) was primarily consulted to group functional tests into clus-
ters of related tests or test variants. Additionally, the compendium of Lezak 
et al. (Lezak et al., 2004) was frequently consulted. Occasionally, a specific 
test was not described in these compendia. In these cases, the author’s clas-
sification was followed or if necessary the test was clarified using other litera-
ture sources and classified by consensus. Tests and clusters were grouped fur-
ther into domains that represent higher aggregates of integration of subjec-
tive, neuropsychological, neuroendocrine and neurophysiological functions. 
The neuropsychological domain is generally subdivided into executive func-
tions, memory, attention, motor functions, language and perception (Spreen 
and Stretton, 1998). For each test (or cluster), the compendia were also used 
to determine which cns-function was principally assessed by the test. Some 
tests provided different parameters with information on more than one func-
tional domain. The results of the effects of a single test on different domains 
were scored separately, and the secondary effects were marked.
results were captured into a Microsoft Excel® database. During this process 
the effect of alcohol on every individual test was scored, tests were grouped 
and alcohol levels were categorized.
Individual test results
Based on previous reviews (de Visser et al., 2001; de Visser et al., 2003; Dumont 
et al., 2005; Dumont and Verkes, 2006), it was anticipated that in most 
cases no consistent quantitative results could be obtained from individual 
tests, because of the large diversity of methods, parameters and treatments. 
Therefore, the ability of a test to detect a statistically significant difference 
from placebo or baseline was scored as ‘+’ (improvement/increase), ‘=’ (no 
significant effect) or ‘-‘ (impairment/decrease). Subjective assessments of 
effects that were signs of improved cns-function or that most users would 
consider pleasurable (e.g. increase of a high or drug effect scale) were scored 
as an improvement/increase; symptoms of cns-depression or less desirable, 
adverse effects (e.g. increase of sedation or reduction of alertness) as an 
impairment/decrease. For physiological responses like changes in hormone 
levels or eeg-power a functional interpretation was not always obvious, 
and these results were scored as increases (+), decreases (-) or as no change 
(=), according to the direction of the reported effects. The total amounts of 
(+), (-) and (=) were determined within each cluster and percentages were 
calculated. Afterwards, these percentages were visually inspected to detect 
whether alcohol mainly impaired, improved or had no effect on a certain 
cluster. Subsequently, the sensitivity of each domain to alcohol was evaluated 
by inspection of the number of clusters within a certain domain that was 
clearly affected by alcohol.
Some studies explicitly reported the use of several different tests in 
the methods section, without presentation of the results, for no apparent 
reason, such as a separate publication. To avoid bias due to underreporting of 
negative results, it was assumed that these tests had not shown any significant 
effects and were scored accordingly. In some studies with different drug 
doses, overall significances were reported for drug effects, without (post hoc) 
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In this way, the most frequently used tests and alcohol dosages could be 
compared for dose-dependency. For individual tests, the number of studies or 
the variability of alcohol levels were too small to determine meaningful dose-
effect relationships. To obtain an overview of dose-effects, alcohol levels were 
pooled into ‘lower’, ‘medium’ and ‘higher’ levels. The levels were determined 
after inspection of the reported alcohol levels, but before relationships with 
pharmacodynamic tests were examined. The ‘medium’ level was chosen 
to be a bac or brac of 0.5 g∙l-1 - 0.7 g∙l-1, because this resulted in an even 
distribution of studies across alcohol levels. This mid-range also included 
the legal driving limits for most western countries, and it would be useful to 
show which functional biomarkers are able to detect alcohol effects at this 
legal level. The ‘lower’ and ‘higher’ levels were all bac/brac’s outside the 
medium range. This approach allowed the identification of tests or clusters 
that showed a consistent response across studies and alcohol concentrations.
Several studies reported the effects of both ascending or descending 
alcohol levels. In these cases, we considered a certain test to be effective in 
detecting alcohol effects, when at least one of both limbs was significantly 
affected. In addition, it was the intention to evaluate the effect of increasing 
or decreasing alcohol levels on individual tests that showed a consistent dose-
response relationship and were measured frequently enough.
results
Study characteristics
General study characteristics are reported in table 3.
Subject characteristics
The mean number of participants was 31 (23 males and 8 females). The mean 
age of participants was not reported in 35% of the cases. The mean age for all 
remaining articles was 24.8 years (range: 19 – 42 years).
The effects of alcohol on multifactorial assessments like the Profiles of 
Mood States (poms) (McNair et al., 1971), the Addiction Research Center 
Inventory (arci) (Haertzen, 1965) or the Bond & Lader Visual Analogue 
Scales (vas) (Bond and lader, 1974) were frequently reported. Subscales 
of such inventories were grouped together if they fell in the same cluster. 
Sometimes, individual subjective scales (and variants) were reported that 
could be regarded as variants from a basic form (e.g. subscales that are also 
part of more comprehensive tools like the Bond & Lader vas). Such scales 
were clustered according to the original scale with which they corresponded 
(e.g. into scale alertness, scale mood or scale calmness in case of a Bond & 
Lader subscale). Within such clusters, all scales showing a significant effect 
were grouped, whereas all scales showing no effect were grouped separately. 
In this way, scales within the same cluster that showed mixed results were also 
scored equivocally. 
Comprehensive scoring instruments like the arci, the poms or the Drug 
Effect Questionnaire (deq) (Mintzer and Griffiths, 1999) can be subdivided 
into different subjective clusters (e.g. scale craving or scale alertness), but 
these subscales were not always reported separately. In these cases, the re- 
sults of the composite scores were presented as part of the overall scale drug 
effect cluster for the deq and arci and the scale mood cluster for the poms. 
A similar procedure was followed for driving tests. In some cases the effects 
on a driving task were reported as effects on separate cns-functions like 
divided attention, reaction time and motor function. These driving tasks were 
grouped accordingly. However, when an overall composite driving score was 
reported, driving tests were grouped under the cluster driving.
Categorization of alcohol levels
The chance that a test will detect a difference from placebo is expected to 
increase with the alcohol level (measured through bac and/or brac). To 
investigate this possibility, it was determined for each individual test whether 
the proportion of statistically significant effects increased with bac/brac. 
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corresponding cns-domains. Overall calculated significant alcohol effects 
(i.e. impairment/decrease (-), no significant change (=) or improvement/
increase (+)) on each cluster are shown together with the publications 
in which these effects were described. Table 6 shows that alcohol mainly 
caused either no effect or functional impairments. Impairments were most 
pronounced in the clusters divided attention, digit symbol substitution 
test-like (dsst-like), motor control, postural stability, visuo-motor control, 
scale performance and in auditory/verbal memory: immediate recall. These 
clusters were reported frequently enough (>10 times) to allow some general 
interpretations. Saccadic eye movements were also impaired in 90% of all 
cases, but these were described only seven times. 
Individual memory tests sometimes showed improvements in delayed 
recall or recognition (between 10 and 33%, table 6), but never on tests of 
immediate or short term memory. In each of these studies, alcohol had been 
administered prior to the presentation of learning material. This is in line with 
the literature, which suggest that memory for information learned before the 
consumption of alcohol can be retroactively facilitated (Parker et al., 1980; 
Parker et al., 1981).
Overall increases in effects were mainly found on the domain subjective 
experience. The clusters scale high and drug effect showed distinct increases of 
their subjective scores. In contrast, several different clusters of the subjective 
experience domain did not change much (marked as (=) in table 6) following 
alcohol administration (e.g. scales aggression, alertness, calmness, mood, and 
fatigue). The clusters production and semantics (language domain) were also 
hardly affected by alcohol. Because the effects of alcohol on the functional 
domain (neuro)endocrine and on several different clusters like production, 
scale depression, sleep, visual perception and electro-encephalography 
alpha (eeg alpha) were reported in only a small number of studies (<10), 
solid conclusions cannot be drawn on the sensitivity of these functional 
biomarkers. 
Alcohol characteristics
In the majority of the cases (98%), alcohol was orally administered. In only 
2% of all studies an intravenous administration procedure was described. 
Doses were not reported in 18 articles (8%). The calculated mean dose that 
was administered during trials was 0.69 g∙kg-1 (sd: 0.25 g∙kg-1). brac was 
measured in 199 studies (91%), whereas bac was used as a parameter in only 
13 studies (6%). Six studies (3%) reported both values jointly. bac and brac 
were pooled together to calculate the mean alcohol concentration, which was 
0.65 g∙l-1 (sd: 0.20 g∙l-1).
cns tests
This review yielded 342 different tests to assess the acute cns-effects of 
alcohol. Table 4 shows a distribution of the test frequencies across the 
literature search, indicating that a sizeable majority of all the described tests 
was used only once (69.3%) or no more than five times (89.2%). Tests that 
were used more than 10 times in the overall data-set are summarized in table 
5. This arbitrary cut-off was used to get an indication of the most frequently 
used tests. The results of such solitary tests cannot be used to draw general 
conclusions about acute alcohol effects. Only scale intoxication was used 
frequently enough (26 times) to allow an individual analysis of alcohol 
responsiveness, but in all other cases tests needed to be clustered to increase 
numbers sufficiently for a more general interpretation.
Clustered alcohol effects
Individual tests were grouped into predefined clusters in an attempt to 
facilitate the general interpretation of the results. Table 6 summarizes the 
progressive condensation of all individual tests into clusters with their 
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perception was only occasionally reported across different research groups, 
a mild dose-related deterioration was observed at the highest dose level.
discussion 
A large number of tests are used in the literature to measure the acute cns 
effects of alcohol, even for the same effect. As with similar reviews for other 
drug classes (de Visser et al., 2001; de Visser et al., 2003; Dumont et al., 2005; 
Dumont and Verkes, 2006; Zuurman et al., 2008), there were even more tests 
than articles: 342 in 218 publications. Almost 70% of all reported tests were 
only used once, and close to 90% was used five times or less. This lack of stan-
dardisation limits the comprehension of the effects of drugs on the cns. For 
alcohol, this is complicated further by complex (saturable) pharmacokinet-
ics (with large intersubject variability related to induction of clearance, sex 
and other genetic factors), tolerance and withdrawal effects, drug and food 
interactions and differences between patient populations (alcoholics, drug 
abusers, social anxiety disorder, etc.). Understanding these complexities, and 
their functional consequences for social and problematic drinking, would be 
facilitated by the use of a limited number of well-characterised biomarkers 
for different alcohol effects, reflecting a range of relevant functions. With this 
background, tests were grouped into test clusters and functional domains. 
Prior reviews indicate that this technique served as a helpful tool in evaluating 
functional biomarkers for other drug effects (de Visser et al., 2001; de Visser 
et al., 2003; Dumont et al., 2005; Dumont and Verkes, 2006; Zuurman et al., 
2008). Although this methodology inevitably led to the loss of certain infor-
mation, it resulted in a structured and comprehensive overview of the cns-
effects of alcohol. 
As far as possible, we used neuropsychological compendia (Spreen and 
Stretton, 1998; Lezak et al., 2004) ill, some categorization we undertook 
might seem arbitrary. The short memory test for example, was captured 
under executive functions instead of memory (as one might expect from the 
test name). Although this seems confusing at first sight, it is completely in line 
Dose-response relationships
The ability to show clear dose-response relationships is an important 
requirement for a meaningful drug-effect biomarker (de Visser et al., 2001; de 
Visser et al., 2003; Dumont et al., 2005; Dumont and Verkes, 2006). The dose 
also determines the sensitivity of a test for a drug, and the chance to detect an 
effect. Therefore, tests and clusters were examined for potential relationships 
to ethanol dose. An arbitrary cut-off of ten reports per dose level for at least 
two levels was used to study the dose-response relationships for the most 
frequently reported clusters (table 7). Divided attention, scale high and scale 
drug effect were among the most sensitive clusters to detect alcohol effects, 
since a majority of tests were affected at the lowest alcohol dose levels. Many 
test clusters showed an increased proportion of significant drug effects at 
higher dose levels (table 7). The most convincing dose-response impairments 
were found for focused attention (7% of the tests within this cluster were 
impaired in the <0.5 g∙l-1 level, increasing to 62% at 0.5 – 0.7 g∙l-1 and 74% 
with levels >0.7 g∙l-1), divided attention, reaction time, inhibition, working 
memory and visuo-motor control. Clear dose-related effects were also found 
for the cluster scale drug effect. 
We made efforts to evaluate the effect of increasing and decreasing alcohol 
levels on individual tests that showed a consistent dose-response relationship 
and were reported frequently enough. Unfortunately, only few of these 
studies did address this issue. We therefore restricted our review to the main 
objective of creating an overview of the most sensitive cns-tests to measure 
the acute effects of alcohol.
All 15 scales of the cluster subjective high that were tested at the 0.5 - 0.7 g∙l-
1 level increased after alcohol administration. Although they were only tested 
9 times under high dose circumstances throughout the studies, all observed 
subjective high scales were affected by alcohol at this level. The effects on 
other frequently reported clusters described in table 7 either increased 
hardly with dose (e.g. evoked potential and scale craving) or were not clearly 
dose-related (scale calmness, scale mood and scale alertness). While visual 
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clusters in the subjective experience domain. Both scales increased dose-
dependently, and showed effects in over 90% of the cases in the highest dose 
category. Many different subjective scales (or scale variants) are currently 
used in literature to measure subjective alcohol experience, but this review 
shows that only a few of those scales (subjective high and drug effects) are 
actually able to accurately measure the subjective effects of alcohol. Scales of 
calmness, mood and alertness seem to be less  sensitive to alcohol.
The sensitivity of many clusters could not be assessed, because they were 
not reported frequently enough to allow an accurate evaluation (e.g. critical 
flicker fusion, visual perception and all the (neuro)endocrine clusters), al-
though some of these uncommon clusters showed promising results (e.g. sac-
cadic eye movements, eeg alpha and eeg theta). Clusters like semantics and 
scale aggression do not seem to be valuable biomarkers for alcohol effects, be-
cause the majority of the tests show no effect after alcohol administration in 
healthy volunteers. Some clusters showed significant overall alcohol effect in 
only a modest proportion of studies, like inhibition (50%) and working mem-
ory (53%). These executive tasks were measured frequently enough to allow a 
subdivision according to dose levels, which revealed larger percentages in the 
highest dose category of >0.7 g∙l-1 (64 and 75% respectively). This indicates 
that alcohol effects (particularly at higher doses) can be masked for clusters 
that do not contain enough tests across the different doses to allow dose cat-
egorization. An important issue concerning tests within clusters like imme-
diate recall (auditory/verbal memory), working memory and visuo-motor 
control is that all these functions may be affected by attention and concen-
tration (Spreen and Stretton, 1998). Attention tasks show an effect in 73-79% 
of cases at higher alcohol doses. Divided attention was even more sensitive, 
yielding significant results at low doses in over half the cases. The strong influ-
ence of alcohol on attention should be taken into account when looking at 
the results of other test clusters and functional domains that rely on attention. 
Despite its infrequent appearance throughout our search, all tests 
assessing  overall driving performance (i.e. cluster driving) were impaired 
under alcohol. Driving performance is an executive task that to a large extent 
relies on (visuo-)motor control and focused/divided attention. The most 
with the neuropsychological compendia we used. These authors state that the 
short memory test should be considered as a working memory (or executive) 
task rather than a pure memory task, because it is governed by brain areas that 
are also related to planning, organizing and time orientation. Longer-term 
memory tests in a stricter sense require much more hippocampal activity.
Tests within the most sensitive clusters as shown in table 6, which also 
show a clear dose-response relationship as shown in table 7 are considered 
most valuable. Thus, divided attention tests (i.e. attention domain), visuo-
motor control tests (i.e. motor domain) and subjective drug effect tests (i.e. 
domain subjective effects) are the most sensitive functional biomarkers 
for the acute effects of alcohol on the cns in healthy volunteers (at least 
according to the results of our review). Most clusters of the attention domain 
were clearly affected by alcohol. The cluster divided attention showed a 
higher sensitivity to alcohol compared to clusters like reaction time and 
focused attention, since these tests could detect lower alcohol levels. Tests 
within the divided attention cluster are more complex than those measuring 
simple reaction time or focused attention, and it is likely that lower doses of 
alcohol will have a larger impact on a more complex task than on a simpler 
version. Tests within the cluster reaction time can still be useful biomarkers, 
since 73% showed impairments at higher alcohol levels (>0.7 g∙l-1), but 
they are less suitable to measure the impact of lower exposure. Similarly, 
executive clusters like working memory and inhibition are also quite capable 
of detecting alcohol effects at high doses (on average in 75% and 64% of the 
cases respectively).
Alcohol clearly impaired the three clusters of the motor domain, but only vi-
suo-motor control tests were reported frequently enough at the different dose 
levels to allow a dose-response analysis. Although the effects on motor con-
trol and postural stability look promising, these tests can only be considered 
validated cns-biomarkers for alcohol effects if dose-response relationships are 
established. Alcohol effects on visuo-motor control were identified at concen-
trations >0.5 g∙l-1 and a dose-dependent impairment was observed. The clus-
ter visuo-motor control fulfilled the criteria as a useful functional biomarker. 
Scales of subjective high and drug effects were by far the most sensitive 
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sensitive functional biomarkers to detect alcohol effects at the average legal 
driving level (i.e. the medium dose level) include tests of visuo-motor control 
as well as scales of subjective high and drug effect, followed by focused and 
divided attention. For visuo-motor control, the pursuit rotor task (a tracking 
task) was the most appropriate method to detect alcohol effects around the 
driving limit, at least in a laboratory setting. It is not surprising therefore, that 
all of the ten driving tests included in our review showed an effect of alcohol, 
including the two cases that studied the effects of a low dose. Reaction time 
is another aspect of driving, but individual reaction time tests only showed 
an impairment at medium levels in only half of the cases. This function seems 
less suitable to demonstrate the impact of alcohol on driving proficiency in a 
medico-legal setting.
In summary, the most sensitive functional biomarkers for the acute cns-
effects of alcohol that were identified in this review are divided attention, 
focused attention, visuo-motor control, scale high and scale drug effect. 
Furthermore, reaction time, working memory and inhibition are also 
considered useful, but only at higher alcohol doses. Driving tasks also seemed 
to be sensitive to even low levels of alcohol, but this complicated setup was 
not used very frequently in the literature. The impairing effects of alcohol 
on the clusters dsst-like, motor control, postural stability and immediate 
recall (auditory/verbal memory) are noteworthy, but clear dose-effect 
relationships could not be established.
This review describes a systemic literature search aimed to assess the 
sensitivity and usefulness of functional biomarkers to demonstrate acute 
cns-effects of alcohol in healthy volunteers. The results of this review may 
be helpful in selecting rational biomarkers for studies investigating the acute 
cns-effects of alcohol or for future alcohol-interaction studies. The results 
also show that many different biomarkers are currently used, when a certain 
cns effect of alcohol is studied, and that such studies would greatly benefit 
from a certain degree of standardization. 
table 1 search query
Search query
(effect or effects) and (‘ethanol’[mesh] not (patient or patients or genetic or genetics 
or disease or diseases or preclinical or ‘in vitro’ or death or deaths or traffic or law or  
laws or injury or injuries or hangover or withdrawal or chronic or sexual or sexuality or  
aggressive or aggression or mri or fmri)) and (‘central nervous system’[mesh] or  
neurophysiology or neuroendocrine or neuropsychology or subjective or behaviour or 
cognitive or cognition or performance or executive or attention or visuomotor or psycho-
motor or motor or memory or sensory or auditory or visual or language or perception) 
limits: entrez date from 1980 to 2008, humans, English, adult: 19-44 years
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table 4 frequency distribution of 342 tests used in 218 
acute alcohol studies






table 5 tests used more than 10 times
Test name Number
Visual Analogue Scale (vas): Scale Intoxication 26
Choice Reaction Time Task 16
Go/No Go Test 15
Profile of Mood States (poms): Scale Depression/Dejection/Elation/
(Positive) Mood
14
Digit Symbol Substitution Test (dsst) 13
Profile of Mood States (poms): Scale Anxiety/Confidence/Unsure/
Tension/Arousal/Composed
13
Pursuit Rotor Task 13
Beverage Rating Scale Scale Intoxication 12
Biphasic Alcohol Effects Scale (baes): Scale Sedation 11
Biphasic Alcohol Effects Scale (baes): Scale Stimulation 11
Profile of Mood States (poms): Scale Anger/Friendliness/Hostility/
Agreeable
11
Profile of Mood States (poms): Scale Confusion/Vigour/Bewilderment/
Activity/Clearheadedness
11
Profile of Mood States (poms): Scale Fatigue/Inertia/Tired/Energetic 11
Subjective Intoxication Level 11
table 6 progressive condensation of all reported tests, 
into their corresponding clusters and domains (in bold)
The overall cluster effects are reported together with the articles in which they are 
reported. “+” reflects an improvement or increase, “=” reflects no significant effect 
and “-“ reflects an impairment or decrease as measured by the corresponding test. 
Whenever tests provided different parameters with information on more than one 
functional domain, effects were scored separately, and the secondary effects were 
marked (*). Some tests were reported more than once within the same reference 
(e.g. at several dose levels).
Language  
Cluster Test (-) (=) (+) References (frequency)
Production Speech Performance, Speech Test, Voice Onset 
Time
33 67 0 (Clarici et al., 1995), (Clarici et al., 1993), 
(Hollien et al., 2001), (Swartz, 1992) (n=4)
Semantics Backwards Reading Task (semantic priming), 
Lexical Decision Task, Mill Hill Vocabulary 
Test, Multiple Selective Vocabulary Test, 
Semantic Priming Task, Sentence Verification 
Task, Verbal Memory Task*, wais iii: 
Vocabulary Test, Word Categorization Task
31 69 0 (Cameron et al., 2001), (Lister et al., 1991), 
(Maylor and Rabbitt, 1988), (Maylor et al., 
1988), (Maylor et al., 1987a), (McKee et al., 
2006), (Moulton et al., 2005), (Nagoshi et al., 
1992), (Ray and Bates, 2006), (Ray et al., 2004), 
(Breitmeier et al., 2007) (n=11)
Attention  
Cluster Test (-) (=) (+) References (frequency)
Divided 
Attention
Choice Reaction Time Task (fixed 
sequences)*, Choice Reaction Time Task 
(random sequences)*, Choice Reaction Time 
Task integrated in Pursuit Rotor Task, Choice 
Reaction Time Task*, Critical Tracking Test 
(divided attention), Divided Attention Task, 
Driving Simulation Test (dual task), Primary 
Tracking Task with Secondary Visual Reaction 
Time, Pursuit Rotor Task combined with 
Visual Stimulus-Response Task, Saccadic 
Interference Task, Switching Attention Task, 
Tracking Input Manipulator*, Verbal-Manual 
Task, Visual Vigilance Task, VisuoSpatial 
Attention Task
68 29 3 (Abroms et al., 2006), (Antebi, 1982), (Clarici 
et al., 1995), (Clarici et al., 1993), (Connors 
and Maisto, 1980), (Degia et al., 2005), (Grant 
et al., 2000), (Knowles and Duka, 2004), 
(Landauer and Howat, 1983), (Maylor et al., 
1989), (Maylor and Rabbitt, 1987b), (Maylor et 
al., 1987b), (McKee et al., 2006), (Millar et al., 
1999), (Mills et al., 1996), (Mills and Bisgrove, 
1983a), (Mills and Bisgrove, 1983b), (Niaura 
et al., 1987), (Schulte et al., 2001), (Sommer et 
al., 1993), (Tiplady et al., 2001), (Zwyghuizen-
Doorenbos et al., 1990), (Breitmeier et al., 
2007), (do Canto-Pereira et al., 2007), (Rupp et 
al., 2007b) (n=25)
dsst-like Code Substitution Task, Digit Symbol 
Substitution Test (dsst), Digit Symbol Yes/No 
Test, Simple Letter Verification Task, Symbol 
Digit Substitution Test (SDST), Symbol 
Matching Task (reference key present during 
task), Verification Task
61 39 0 (Cameron et al., 2001), (de Wit et al., 1987), 
(DeWit et al., 1989), (Farquhar et al., 2002), 
(Gengo et al., 1990), (Holdstock et al., 2006), 
(Holdstock and de Wit, 1999), (Holdstock and 
de Wit, 1998), (Kennedy et al., 1993), (Kennedy 
et al., 1992), (Lukas et al., 1989), (McKee et al., 
2006), (Moulton et al., 2005), (Richards et al., 
1999), (Schweizer et al., 2006), (Schweizer et 
al., 2005), (Schweizer et al., 2004), (Tiplady 





Apparent Movement, Backward Masking, 
Bistable Stroboscopic Motion, Critical Flicker 
Fusion Test, Simultaneity Task, Velocity 
Perception Task
55 45 0 (Baker et al., 1985), (Jansen et al., 1985), (Jones 
et al., 1998), (Liguori et al., 1999), (MacCarthy 
and Tong, 1980), (Rammsayer, 1995) (n=6)
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Input Manipulator*, Varied Set Memory Task*, 
Verification Task*, Vigilance Task (acoustic 
stimulus)*, Vigilance Task (optical stimulus)*, 
Vigilance Task*, Visual Reaction Time 
test, Visual Search Task*, Visual Stimulus-
Response Task (during tracking), Visual 
Sustained Attention Task*, Visual Vigilance 
Task, Visual Vigilance Task*, VisuoSpatial 





Auditory Vigilance Task, Continuous 
Attention Task, Continuous Performance Task 
(delayed memory), Continuous Performance 
Task (delayed memory)*, Continuous 
Performance Task (immediate memory)*, 
Number Matching Pair Test, Psychomotor 
Vigilance Task, Rapid Visual Information 
Processing Task, Serial Sevens Test, Signal 
Detection Test, Sustained Attention Task, 
Vigilance Task, Vigilance Task (acoustic 
stimulus), Vigilance Task (optical stimulus), 
Visual Sustained Attention Task, Visual 
Vigilance Task, Work Performance Series
43 57 0 (Cameron et al., 2001), (Dougherty et al., 
2000), (Drake et al., 2003), (Duka et al., 1998), 
(Farquhar et al., 2002), (Linnoila et al., 1980), 
(Millar et al., 1999), (Roehrs et al., 1992), 
(Rohrbaugh et al., 1988), (Versavel et al., 2005), 
(Breitmeier et al., 2007), (Rupp et al., 2007b) 
(n=12)
Executive   
Cluster Test (-) (=) (+) References (frequency)
Creativity Purdue Creativity Test 0 100 0 (Gustafson, 1991) (n=1)
Driving Driving Simulation Test, Driving Simulation 
Test (drive only), Simulated Automobile 
Driving Task, Tracking Input Manipulator
100 0 0 (Dalrymple-Alford et al., 2003), (Gawron and 
Ranney, 1988), (Gengo et al., 1990), (Landauer 
and Howat, 1983), (Rupp et al., 2007b) (n=5)
Inhibition Anticipation Timing Task, Antisaccadic Eye 
Movement Test, Balloon Analogue Risk Task, 
Barratt Impulsiveness Scale, Continuous Per-
formance Task (delayed memory)*, Continu-
ous Performance Task (immediate memory)*, 
Continuous Performance Task*, Covert Shift 
of Attention Task, Delay Discounting Test, 
Delayed Ocular Response Task, Eriksen 
Flanker Test, Experimental Discounting 
Task, General Knowledge Test, Gibson Spiral 
Maze test*, Go/No Go Test (cued), Go/No-
Go Task, Go/No-Go Task , Go/No-Go Task 
(high cognitive load), Go/No-Go Task (low 
cognitive load), Iowa Gambling Task, New-
man Perseveration Task, Pattern Comparison 
Task*, Question-based Delay Discounting 
Task, Recognition Task, Recognition Task 
(with context cues)*, Recognition Task (with-
out context cues)*, Rectangular Maze Test*, 
Repetition-Alternation Task (shape, color, 
location), Risk-Taking Task, Signal Detection 
Task*, South Oaks Gambling Screen, Startle 
Response, Stop Signal Task, Stroop Task, 
Stroop Task: Negative Primes, Stroop Task: 
Positive Primes, Sustained Attention Task*, 
Tower of London*, Tracking Input Manipula-
tor*, Visual Sustained Attention Task*
50 46 4 (Abroms et al., 2006), (Baker et al., 1985), 
(Balodis et al., 2006), (Bartholow et al., 
2003a), (Birnbaum et al., 1980), (Blekher et 
al., 2002), (Colzato et al., 2004), (Davidson 
et al., 1997), (Degia et al., 2005), (Dougherty 
et al., 2000), (Drake et al., 2003), (Easdon et 
al., 2005), (Easdon and Vogel-Sprott, 2000), 
(Farquhar et al., 2002), (Fillmore et al., 2005), 
(Fillmore, 2004), (Fillmore and Blackburn, 
2002), (Fillmore et al., 2000b), (Fillmore et al., 
2000a), (Fillmore and Vogel-Sprott, 2000), 
(Finn et al., 1999), (Gustafson and Kallmen, 
1990), (Hutchison et al., 1997), (Jansen et al., 
1985), (Landauer and Howat, 1983), (Lane et al., 
2004), (Marczinski et al., 2005), (Marczinski 
and Fillmore, 2005b), (Marczinski and 
Fillmore, 2005a), (Marczinski and Fillmore, 
2003), (Maylor et al., 1987a), (McKee et al., 
2006), (Millar et al., 1999), (Mulvihill et al., 
1997), (Ortner et al., 2003), (Reynolds et al., 
2006), (Richards et al., 1999), (Rohrbaugh et 
al., 1988), (Schulte et al., 2001), (Schweizer et 
al., 2006), (Tiplady et al., 2001), (Weissenborn 
and Duka, 2003), (Donohue et al., 2007), 
(Phillips and Ogeil, 2007) (n=44)




Auditory Discrimination Task, Continuous 
Performance Task, Digit Span Task 
(forward), Go/No-Go Task, Go/No-
Go Task*, Inspection Time Task, Letter 
Cancellation Task, Memory Scanning Test, 
Pattern Comparison Task, Perceptual Speed 
Task, Rapid Information Processing Task, 
Rapid Visual Information Processing Task, 
Signal Detection Task, Spatial Frequency 
Discrimination Test, Tachistoscopic 
Perception Task, Test d2, Vernier 
Discrimination Task, Visual Search Task, 
Visual Stimulus-Response Task (complex), 
Visual Stimulus-Response Task (complex), 
Visual Stimulus-Response Task (simple)
50 48 2 (Baker et al., 1985), (Davidson et al., 1997), 
(Farquhar et al., 2002), (Fillmore and Vogel-
Sprott, 1997), (Fogarty and Vogel-Sprott, 
2002), (Jansen et al., 1985), (Kennedy et al., 
1993), (Kennedy et al., 1992), (Lex et al., 1988), 
(Linnoila et al., 1980), (Maylor and Rabbitt, 
1988), (Maylor et al., 1987b), (Maylor et al., 
1987a), (McKee et al., 2006), (Mills et al., 1996), 
(Moulton et al., 2005), (Nagoshi et al., 1992), 
(Ortner et al., 2003), (Reynolds et al., 2006), 
(Schweizer et al., 2005), (Schweizer et al., 
2004), (Tiplady et al., 2001), (Tzambazis and 
Stough, 2000), (Watten et al., 1998), (Wegner 
and Fahle, 1999a), (Hoyer et al., 2007) (n=26)
Reaction 
Time
Anticipation Timing Task, Auditory 
Discrimination Task*, Auditory Vigilance 
Task*, Choice Reaction Time Task, Choice 
Reaction Time Task (fixed sequences), Choice 
Reaction Time Task (random sequences), 
Complex Reaction Time Task*, Complex 
Reaction Time Test, Concept Identification 
Task, Concurrent Set Memory Task*, 
Continuous Performance Task (delayed 
memory)*, Continuous Performance 
Task (immediate memory)*, Continuous 
Performance Task*, Critical Tracking Test*, 
Digit Symbol Substitution Test (dsst), Digit 
Symbol Substitution Test (dsst)*, Digit 
Symbol Yes/No Test*, Divided Attention 
Task*, Driving Simulation Test (reaction 
time), Driving Simulation Test (dual task)*, 
Eriksen Flanker Test*, Fixed Set Memory 
Task*, Go/No Go Test (cued)*, Go/No-Go 
Task (high cognitive load)*, Go/No-Go Task 
(low cognitive load)*, Go/No-Go Task *, Go/
No-Go Task*, Lexical Decision Task*, Memory 
Scanning Test*, Mill Hill Vocabulary Test*, 
Number Matching Pair Test*, Offset Reaction 
Time Task, Omitted Auditory Stimulus 
Task, Onset Reaction Time Task, Pattern 
Recognition Task*, Psychomotor Task, Pursuit 
Tracking Task (stressalyser)*, Rapid Visual 
Information Processing Task, Rapid Visual 
Information Processing Task*, Reaction Time 
Test, Reaction Time Test (acoustic stimulus), 
Reaction Time Test (optical sequence 
of stimuli) , Reaction Time Test (optical 
stimulus) , Reaction Time Test (optical/
aucoustic stimuli), Reaction Time Test to 
Omitted Auditory Stimuli, Reaction Time Test 
to Omitted Tactile Stimuli, Reaction Time 
Test to Omitted Visual Stimuli, Repetition-
Alternation Task (shape, color, location), 
Saccadic Interference Task, Signal Detection 
Test*, Simple Auditory rt Test, Simple Letter 
Verification Task*, Simple Reaction Time 
Task, Spatial Recognition Task*, Stop Signal 
Task*, Stroop Task*, Symbol Matching Task 
(reference key present during task)*, Tracking
53 47 0 (Abroms et al., 2006), (Antebi, 1982), (Baker et 
al., 1985), (Bartholow et al., 2003a), (Beirness 
and Vogel-Sprott, 1982), (Cameron et al., 
2001), (Colzato et al., 2004), (Degia et al., 
2005), (Dougherty et al., 2000), (Drake et 
al., 2003), (Easdon et al., 2005), (Easdon and 
Vogel-Sprott, 2000), (Farquhar et al., 2002), 
(Feely and Wood, 1982), (Fillmore et al., 2005), 
(Fillmore, 2004), (Fillmore and Blackburn, 
2002), (Fillmore and Vogel-Sprott, 2000), 
(Galbraith, 1986), (Gengo et al., 1990), (Grant 
et al., 2000), (Gustafson and Kallmen, 1990), 
(Gustafson, 1986), (Hernandez et al., 2006), 
(Kennedy et al., 1993), (Kennedy et al., 1992), 
(Knowles and Duka, 2004), (Landauer and 
Howat, 1983), (Landauer and Howat, 1982), 
(Liguori et al., 1999), (Linnoila et al., 1980), 
(Marczinski et al., 2005), (Marczinski and 
Fillmore, 2005b), (Marczinski and Fillmore, 
2005a), (Marczinski and Fillmore, 2003), 
(Maylor et al., 1989), (Maylor and Rabbitt, 
1988), (Maylor et al., 1988), (Maylor and 
Rabbitt, 1987b), (Maylor et al., 1987b), (McKee 
et al., 2006), (Mulvihill et al., 1997), (Nagoshi et 
al., 1992), (Nicholson et al., 1992b), (Nicholson 
et al., 1992a), (Pishkin et al., 1983), (Post et al., 
1996), (Rammsayer, 1995), (Reynolds et al., 
2006), (Roehrs et al., 1992), (Rohrbaugh et 
al., 1988), (Ross and Pihl, 1988), (Ryan et al., 
1996), (Schulte et al., 2001), (Schweizer et al., 
2006), (Schweizer et al., 2005), (Schweizer 
et al., 2004), (Sommer et al., 1993), (Tiplady 
et al., 2001), (Tzambazis and Stough, 2000), 
(Versavel et al., 2005), (Wang et al., 1992), 
(Weissenborn and Duka, 2003), (Young and 
Pihl, 1982), (Zwyghuizen-Doorenbos et al., 
1990), (Breitmeier et al., 2007), (do Canto-
Pereira et al., 2007) (Hernandez et al., 2007), 
(Khan and Timney, 2007), (Rupp et al., 2007b) 
(n=70)
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Delayed Recognition Task (words), Hopkins 
Verbal Learning Test (words), Memory Task 
for Verbally Presented Words, Recognition 
of Depressive Mood States, Recognition 
of Elating Mood States, Recognition of 
Neutral Mood States, Recognition Task 
(names), Sentence Recognition Task (with 
context cues), Sentence Recognition Task 
(without context cues), Wilde Intelligence 
Test (memory subset), WMS-R: Paired 
Associates Learning (difficult), WMS-R: 
Paired Associates Learning (easy), Word 
Discrimination Task (delayed), Word List 
Learning (before alcohol intake), Word 
Recognition Memory Task, Word Recognition 
Task, Word Stem Completion Task (cued)
43 48 10 (Acheson et al., 1998), (Birnbaum et al., 1980), 
(Bruce and Pihl, 1997), (Cowan, 1983), (Duka 
et al., 2001), (Erblich and Earleywine, 1995), 
(McKee et al., 2006), (Mueller et al., 1983), 
(Ray and Bates, 2006), (Schweizer et al., 2006), 
(Tyson and Schirmuly, 1994), (Williams and 






Dichotic Listening Test, Free Recall Task 
(words), Immediate Recall Acquisition Task 
(words), Immediate Recall Task/Acquisition 
Task (words), Memory Task (words), Memory 
Task for Verbally Presented Words, Paired 
Associate Word Learning Task, Prose Memory 
Task, Verbal Immediate Memory Task (words), 
Verbal Short-term Memory Task (words)
67 33 0 (Clarici et al., 1993), (Duka et al., 2001), (Jones 
and Jones, 1980), (Lister et al., 1991), (McKee 
et al., 2006), (Moulton et al., 2005), (Niaura 
et al., 1987), (Ray et al., 2004), (Tracy and 
Bates, 1999), (Weintraub and Goldman, 1983), 




Cued Incidental Learning (after alcohol 
intake), Cued Incidental Learning (before 
alcohol intake), Event Frequency Task, 
Frequency of Word Occurrence Task, 
Judgement of Frequency Task, Recall of 
Depressive Mood Sates, Recall of Elating 
Mood States, Recall of Neutral Mood States, 
Stem Completion Task (automatic processes), 
Word-Stem Completion Task, Word-Stem 
Completion Task (controlled processes )
33 40 27 (Birnbaum et al., 1987), (Bruce and Pihl, 1997), 
(Duka et al., 2001), (Fillmore et al., 1999), 
(Grattan and Vogel-Sprott, 2001), (Kirchner 
and Sayette, 2003), (Lister et al., 1991), (Ray and 
Bates, 2006), (Tracy and Bates, 1999), (Tyson 
and Schirmuly, 1994) (n=10)






Complex Figure Task, Delayed Memory for 
Geographical Map (with route), Emotional 
Memory Task
40 40 20 (Acheson et al., 1998), (Knowles and Duka, 






Design Memory Task, Face Recognition Task, 
Picture Recognition Task
0 67 33 (Cowan, 1983), (Parker et al., 1981), (Schweizer 






Benton Visual Retention Test, Complex Figure 
Task, Immediate Memory for Geographical 
Map (with route)
25 75 0 (Acheson et al., 1998), (Lowe, 1983), (Wegner 
and Fahle, 1999a) (n=3)
Motor    
Cluster Test (-) (=) (+) References (frequency)
Motor 
Control
Balance Beam Test, Choice Reaction Time 
Task*, Hand Steadiness Test (eyes closed),  
One Leg Stand Test, Reaction Time Test 
(acoustic stimulus)*, Reaction Time Test 
(optical sequence of stimuli)*, Reaction
61 39 0 (Clarici et al., 1995), (Clarici et al., 1993), 
(Galbraith, 1986), (Kennedy et al., 1993), 
(Kennedy et al., 1992), (Landauer and Howat, 
1982), (Lukas et al., 1989), (McKee et al., 2006), 
(Mundt et al., 1997), (Rammsayer, 1995), 
Planning Tower of London 100 0 0 (Weissenborn and Duka, 2003) (n=1)
Reasoning/
Association
Block Design Task, Categorization Task, Con-
cept Identification Task, Conditional Associa-
tive Learning Task, Grammatical Reasoning 
Task, Logical Reasoning Task, Mathematical 
Processing Task, Mathematical Reasoning 
Task, Picture Arrangement Task, Picture 
Completion Task, Sentence Completion Task
55 45 0 (De Cesarei et al., 2006), (Duka et al., 1998), 
(Finn et al., 1999), (Kennedy et al., 1993), 
(Kennedy et al., 1992), (Lex et al., 1988), 
(Pishkin et al., 1983), (Tzambazis and Stough, 
2000) (n=8)
Set Shifting Go/No-Go Task*, Wisconsin Card Sorting 
Test
33 67 0 (Easdon and Vogel-Sprott, 2000), (Lyvers and 
Maltzman, 1991a), (Nagoshi et al., 1992) (n=3)
Spatial 
Orientation
Card Rotations Task , Little Man Task, 
Manikin Task, Manikin Test
50 50 0 (Farquhar et al., 2002), (Kennedy et al., 1993), 




Choice Reaction Time Task*, Drawing 
Squares Test, Kinaesthetic Distance Estima-
tion Test, Size Estimation Test, Speed Estima-
tion Task (without speedometer), Temporal 
Discrimination Task, Time Estimation Task, 
Time Perception Task, Time Production Task, 
Visual Distance Estimation Task
46 46 8 (Duka et al., 1998), (Farquhar et al., 2002), 
(Kearney and Guppy, 1988), (Lapp et al., 1994), 
(McNamee et al., 1980), (Rammsayer, 1995), 





Auditory Memory Task, Backwards Reading 
Task, Choice Reaction Time Task*, Complex 
Reaction Time Test, Concentration Test, 
Concurrent Set Memory Task, Continu-
ous Performance Task (delayed memory), 
Continuous Performance Task (immediate 
memory), Design Memory Task, Digit Span 
Task (backward), Fixed Set Memory Task, 
Letter-Number Test, Pattern Memory Test, 
Pattern Recognition Task, Recognition Task, 
Short Term Memory Task, Short-Term Memo-
ry for Words and Figures, Short-Term Memory 
Test, Spatial Memory Span Test, Spatial Rec-
ognition task, Spatial Working Memory Task, 
Sternberg Memory Scanning Task, Symbol 
Matching Task (reference key absent during 
task), Symbol Matching Task (reference key 
absent during task)*, Three Letters Task, 
Varied Set Memory Task, Visual Memory 
Task, wais-r: Digit Span Test (backward), 
Word Discrimination Task (immediate), Word 
Repetition Priming Task, X's and O's Task
53 47 0 (Baker et al., 1985), (Dougherty et al., 2000), 
(Drake et al., 2003), (Finn et al., 1999), 
(Grattan-Miscio and Vogel-Sprott, 2005), 
(Kennedy et al., 1993), (Kennedy et al., 1992), 
(Krause et al., 2002), (Landauer and Howat, 
1982), (Lister et al., 1991), (Marinkovic et al., 
2004), (Maylor and Rabbitt, 1987a), (McKee 
et al., 2006), (Moulton et al., 2005), (Ryan et 
al., 1996), (Schweizer et al., 2006), (Tzambazis 
and Stough, 2000), (Versavel et al., 2005), 
(Weissenborn and Duka, 2003), (Saults et al., 
2007) (n=20)
Memory      






Delayed Free Recall Test (words), Delayed 
Recall Task (words), Delayed Word Recall 
Task (24h), Free Recall Task (words), Hopkins 
Verbal Learning Test (words), Logical 
Memory Test (story), Memory for Profile of 
Mood States (poms) scores, Memory Task  
(8 letter-word pairs), Memory Task for 
Verbally Presented Words, Prose Memory 
Task, Recall for Mood States, Recall Task 
(names), Retroactive Interference Task 
(words), Wilde Intelligence Test (memory 
subset), Word List Learning (40 min. prior 
to alcohol intake), Word List Learning 
(immediately before alcohol intake)
40 30 30 (Acheson et al., 1998), (Bruce et al., 1999), 
(Cowan, 1983), (Erblich and Earleywine, 
1995), (Mann et al., 1984), (McKee et al., 2006), 
(Moulton et al., 2005), (Mueller et al., 1983), 
(Ray et al., 2004), (Schandler et al., 1984), 
(Tyson and Schirmuly, 1994), (Weissenborn 
and Duka, 2000), (Breitmeier et al., 2007) 
(n=13)
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Potential Test, Visual Evoked Potentials, 
Visual Sustained Attention Task*, Watching 
'Emotional' Pictures, Word Repetition 
Priming Task
2004), (Quintyn et al., 1999), (Rohrbaugh et 
al., 1987), (Skalka et al., 1986), (Sommer et al., 
1993), (Teo and Ferguson, 1986), (Zuzewicz, 
1981), (Franken et al., 2007) (n=16)
Eye 
Movements
Binocular Balance Test, Oculomotor 
Functioning









Caloric and Visual Supression Test, Electro-
oculography (eog), Horizontal Gaze 
Nystagmus, Vestibulo-Ocular Nystagmus Test
100 0 0 (Chiang and Young, 2007), (Harder and Reker, 
1995), (Jones and Neri, 1994), (Jones, 1993), 





Oculomotor Functioning, Smooth Pursuit Eye 
Movement Task





Delayed Ocular Response Task, Oculomotor 
Functioning, Saccadic Eye Movement Test, 
Visuomotor Reading Task
90 10 0 (Abroms et al., 2006), (Blekher et al., 2002), 
(Holdstock and de Wit, 1999), (Mundt et al., 
1997), (Nyberg et al., 2004), (Watten and Lie, 
1997), (Wegner and Fahle, 1999b) (n=7)
Sleep Multiple Sleep Latency Test (mslt), Repeated 
Test of Sustained Wakefulness (rtsw), Sleep 
Latency, Sleep Test
40 60 0
Perception     
Cluster Test (-) (=) (+) References (frequency)
Olfactory 
Perception
Odor Discrimination/Odor Memory 
Test, Olfactory Ethanol Detection Test, 
Phenyl Ethyl Alcohol Detection Threshold 
Tests, University of Pennsylvania Smell 
Identification Test
50 50 0 (Patel et al., 2004) (n=1)
Visual 
Perception
Accomodation Task, Arden Plates, Binocular 
Vision Task, Contrast Sensitivity Chart, Depth 
Perception Task, Goldmann Visual Fields , IR 
Refractometer Task, Perceptual Vision Task, 
Rod and Frame Test (visual field dependence), 
Rotating Laser Drum Task, Snellen Acuity, 
Stereo Optical Stereo Tests, Stereoscopic 
Depth Perception, Subjective Vertical/
Horizontal Test, TV Grating Contrast 
Sensitivity, Vision Test, Visual Contrast 
Sensitivity Test, Visual Field Test
52 48 0 (Nicholson et al., 1992a), (Quintyn et al., 
1999), (Skalka et al., 1986), (Wang et al., 1992), 
(Watten and Lie, 1996), (Wegner and Fahle, 
1999a), (Hafstrom et al., 2007) (n=7)
Subjective Experience   
Cluster Test (-) (=) (+) References (frequency)
Scale 
Aggression
Affect Inventory (Scale Anger/Sympathetic), 
Profile of Mood States (poms) (Scale 
Agreeable/Hostile), Profile of Mood States 
(poms) (Scale Anger), Profile of Mood 
States (poms) (Scale Anger/Friendliness), 
Profile of Mood States (poms) (Scale Anger/
Hostility), Profile of Mood States (poms) 
(Scale Friendliness), Subjective Effects of 
Alcohol Scale (SAES) (Scale Positive Social 
Influences), Visual Analogue Scale (vas) 
(Scale Irritability)
8 75 17 (DeWit et al., 1989), (Holdstock and de Wit, 
1998), (Knowles and Duka, 2004), (McKee et 
al., 2006), (Mundt et al., 1997), (Nagoshi et al., 
1992), (O'Malley and Maisto, 1984), (Pierucci-
Lagha et al., 2006), (Reynolds et al., 2006), 
(Soderlund et al., 2005), (Wilkie and Stewart, 
2005), (Zeichner et al., 1993) (n=12)
Time Test (optical stimulus)*, Reaction Time 
Test (optical/aucoustic stimuli)*, Standing 
Steadiness, Tapping Task, Tapping Task (non-
dominant hand), Tapping Task (two hands)




Body Sway, Body Sway (closed eyes), Body 
Sway (open eyes), One Leg Stand Test, Physical 
Activity Measurement (actiwatch), Sensory 
Organization Posturography Test, Steadiness 
Test, Walk and Turn Test
86 14 0 (Galbraith, 1986), (Jones and Neri, 1994), 
(Jones, 1993), (Ledin and Odkvist, 1991), 
(Liguori et al., 1999), (Lukas et al., 1989), 
(Martin et al., 1981), (Martinez and Martinez, 
2003), (Mills and Bisgrove, 1983a), (Mundt et 
al., 1997), (Nagoshi et al., 1992), (Niaura et al., 
1987), (O'Malley and Maisto, 1984), (Addicott 
et al., 2007) (n=14)
Visuo-Motor 
Control
Bead String Test, Character Writing Test, 
Continuous Tracking Task (continuous 
instability), Continuous Tracking Task 
(frequent instability), Continuous Tracking 
Task (minor instability), Coordination Test 
Steering, Critical Tracking Test, Divided 
Attention Task*, Gibson Spiral Maze Task, 
Gibson Spiral Maze test, Hand Steadiness Test, 
Hand-Eye Coordination Test, Handwriting 
Analysis, Object Assembly Task, Pegboard 
Test, Primary Tracking Task, Pursuit Rotor 
Task, Pursuit Rotor Task Modified, Pursuit 
Tracking Task (stressalyser), Rectangular 
Maze Test, Signature Task, Speed Estimation 
Task (with speedometer), Spiral Maze Task, 
Tracking Input Manipulator*, Tracking Test, 
Tracometer, Visuomotor Integration Task
78 22 0 (Asicioglu and Turan, 2003), (Beirness and 
Vogel-Sprott, 1984), (Beirness and Vogel-
Sprott, 1982), (Cameron et al., 2001), (Connors 
and Maisto, 1980), (Degia et al., 2005), 
(Farquhar et al., 2002), (Fillmore, 2003), 
(Fillmore and Vogel-Sprott, 1998), (Fillmore 
and Vogel-Sprott, 1996a), (Fillmore and 
Vogel-Sprott, 1996b), (Fillmore and Vogel-
Sprott, 1995), (Fogarty and Vogel-Sprott, 
2002), (Galbraith, 1986), (George et al., 1990), 
(Grant et al., 2000), (Harrison and Fillmore, 
2005a), (Haubenreisser and Vogel-Sprott, 
1983), (Jones and Neri, 1994), (Jones, 1993), 
(Kearney and Guppy, 1988), (Landauer and 
Howat, 1983), (Linnoila et al., 1980), (Lukas 
et al., 1989), (McKee et al., 2006), (Millar et 
al., 1999), (Nagoshi et al., 1992), (Niaura et 
al., 1987), (Roehrs et al., 1992), (Thomson and 
Newlin, 1988), (Tiplady et al., 2005), (Tiplady 
et al., 2001), (Tzambazis and Stough, 2000), 
(Versavel et al., 2005), (Vogel-Sprott and 
Fillmore, 1993), (Vogel-Sprott and Barrett, 
1984), (Vogel-Sprott et al., 1984), (Young and 
Pihl, 1982), (Zack and Vogel-Sprott, 1993), 
(Zwyghuizen-Doorenbos et al., 1990) (n=40)
Neurophysiologic
Cluster Test (-) (=) (+) References (frequency)
eeg Alpha Electro-encephalography (eeg), Magneto-
encephalography (meg)
6 38 56 (Cohen et al., 1993), (Ehlers et al., 1999),  
(Ehlers et al., 1989), (Lukas and Mendelson, 
1988), (Lukas et al., 1986b), (Nikulin et al., 
2005), (Stenberg et al., 1994) (n=7)
eeg Beta Electro-encephalography (eeg), Magneto-
encephalography (meg)
9 64 27 (Cohen et al., 1993), (Ehlers et al., 1999), 
(Nikulin et al., 2005), (Stenberg et al., 1994) 
(n=4)
eeg Delta Electroencephalography (eeg) 0 100 0 (Stenberg et al., 1994) (n=1)
eeg Theta Electro-encephalography (eeg), Magneto-
encephalography (meg)
0 22 78 (Ehlers et al., 1999), (Ehlers et al., 1989), (Lukas 




Alternating Check Task, Categorization Task*, 
Choice Reaction Time Task*, Eriksen Flanker 
Test*, Event Related Potentials (ERP), Go/
No-Go Task*, Memory Scanning Test, Odd 
Ball Paradigm, Vestibular Evoked Myogenic 
52 21 27 (Bartholow et al., 2003a), (Bartholow et 
al., 2003b), (Chiang and Young, 2007), (De 
Cesarei et al., 2006), (Easdon et al., 2005), 
(Erwin and Linnoila, 1981), (Feely and Wood, 
1982), (Krause et al., 2002), (Marinkovic et al., 
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Visual Analogue Scale (vas) (Scale Dizziness), 
Visual Analogue Scale (vas) (Scale 
Lightheadedness)




Addiction Research Center Inventory 
(arci) (Scale A), Addiction Research Center 
Inventory (arci) (Scale A/bg/mbg/lsd), 
Addiction Research Center Inventory (arci) 
(Scale A/bg/mbg/lsd/pcag), Addiction 
Research Center Inventory (arci) (Scale A/
bg/mbg/pcag/lsd), Addiction Research 
Center Inventory (arci) (Scale A/bg/pcag/
lsd), Addiction Research Center Inventory 
(arci) (Scale a/m/mbg), Addiction 
Research Center Inventory (arci) (Scale 
a/m/mbg/pcag), Addiction Research 
Center Inventory (arci) (Scale A/mbg/
pcag), Addiction Research Center Inventory 
(arci) (Scale bg/lsd ), Addiction Research 
Center Inventory (arci) (Scale bg/lsd), 
Addiction Research Center Inventory (arci) 
(Scale mbg), Addiction Research Center 
Inventory (arci) (Scale pcag), Addiction 
Research Center Inventory (arci) (Scale 
pcag/A/lsd), Beverage Rating Scale, Drug 
Effects Questionnaire (deq) (Scale Drug 
Effect), Drug Effects Questionnaire (deq) 
(Scale Feel), Drug Effects Questionnaire 
(deq) (Scale Intoxication), Drunkenness 
Scale, Likert "how drunk scale", Profile of 
Mood States (poms) (Scale Intoxication), 
Subjective Effects Questionnaire (Scale 
Intoxication), Subjective Estimations of 
Intoxication, Subjective Intoxication Level, 
Subjective Judgement of Intoxication, 
Subjective Rating Scale (Scale Inebriation), 
Visual Analogue Scale (vas) (Scale 
Drunkenness), Visual Analogue Scale (vas) 
(Scale Feel), Visual Analogue Scale (vas) 
(Scale Intoxication)
0 20 80 (Abroms et al., 2006), (Balodis et al., 2006), 
(Bartholow et al., 2003a), (Bartholow et al., 
2003b), (Cameron et al., 2001), (Davidson et 
al., 1997), (De Cesarei et al., 2006), (Duka et 
al., 1998), (Farquhar et al., 2002), (Field and 
Duka, 2002), (Fillmore et al., 2005), (Fillmore, 
2004), (Fillmore and Blackburn, 2002), 
(Fillmore, 2001), (Fillmore and Vogel-Sprott, 
1998), (Fillmore and Vogel-Sprott, 1995), 
(Gengo et al., 1990), (Holdstock et al., 2006), 
(Holdstock and de Wit, 1999), (Holdstock 
and de Wit, 1998), (Jones, 1993), (Kirchner 
and Sayette, 2003), (Landauer and Howat, 
1983), (Lane et al., 2004), (Lapp et al., 1994), 
(Liguori et al., 1999), (Lukas and Mendelson, 
1988), (Lukas et al., 1986a), (Lyvers and 
Maltzman, 1991b), (Lyvers and Maltzman, 
1991a), (MacDonald et al., 1995), (Marczinski 
et al., 2005), (Marczinski and Fillmore, 
2005b), (Marczinski and Fillmore, 2005a), 
(Marczinski and Fillmore, 2003), (Marinkovic 
et al., 2004), (Mulvihill et al., 1997), (Mundt 
et al., 1997), (Nagoshi et al., 1992), (Niaura et 
al., 1987), (Nicholson et al., 1992b), (Nyberg 
et al., 2004), (O'Boyle et al., 1994), (O'Malley 
and Maisto, 1984), (Ortner et al., 2003), 
(Pierucci-Lagha et al., 2006), (Reynolds et al., 
2006), (Richards et al., 1999), (Rohrbaugh et 
al., 1988), (Ross and Pihl, 1988), (Schweizer et 
al., 2006), (Schweizer et al., 2005), (Schweizer 
et al., 2004), (Sher, 1985), (Soderlund et al., 
2005), (Stenberg et al., 1994), (Tiplady et al., 
2001), (Wegner and Fahle, 1999a), (Wilkie and 
Stewart, 2005), (Zack and Vogel-Sprott, 1993), 
(Zeichner et al., 1993), (Franken et al., 2007), 
(Hoyer et al., 2007), (Saults et al., 2007) (n=64)
Scale Fatigue Profile of Mood States (poms) (Scale 
Energetic/Tired), Profile of Mood States 
(poms) (Scale Energy), Profile of Mood States 
(poms) (Scale Fatigue), Profile of Mood States 
(poms) (Scale Fatigue/Inertia)
14 81 5 (DeWit et al., 1989), (Holdstock and de Wit, 
1998), (Knowles and Duka, 2004), (McKee 
et al., 2006), (Nagoshi et al., 1992), (Pierucci-
Lagha et al., 2006), (Reynolds et al., 2006), 
(Soderlund et al., 2005), (Wilkie and Stewart, 
2005), (Zeichner et al., 1993) (n=10)
Scale High Drug Effects Questionnaire (deq) (Scale 
High), Profile of Mood States (poms) (Scale 
High), Subjective High Assessment Scale, 
Subjective High Assessment Scale (Scale 
High), Visual Analogue Scale (vas) (Scale 
High)
0 13 87 (Ehlers et al., 1989), (Fillmore, 2004), 
(Fillmore and Blackburn, 2002), (Fillmore, 
2001), (Holdstock et al., 2006), (Holdstock and 
de Wit, 1999), (Holdstock and de Wit, 1998), 
(Lex et al., 1988), (Liguori et al., 1999), (Lukas 
et al., 1989), (Marczinski and Fillmore, 2005b), 
(Marczinski and Fillmore, 2005a), (Marczinski
and Fillmore, 2003), (Marinkovic et al., 2004), 
(Parker et al., 1981), (Pierucci-Lagha et al., 
2006), (Reynolds et al., 2006), (Richards et al., 
1999), (Soderlund et al., 2005) (n=19)
Scale 
Alertness
Affect Inventory (Scale Powerfulness/
Energy), Biphasic Alcohol Effects Scale 
(baes) (Scale Sedation), Profile of Mood 
States (poms) (Scale Clearheaded/
Confused), Profile of Mood States (poms) 
(Scale Confusion), Profile of Mood States 
(poms) (Scale Confusion/Bewilderment/
Vigor/Activity), Profile of Mood States 
(poms) (Scale Confusion/Vigour), Profile of 
Mood States (poms) (Scale Vigour), Profile of 
Mood States (poms) (Scale Vigour/Activity/
Confusion/Bewilderment), Profile of Mood 
States (poms) (Scale Vigour/Confusion), 
Sleep Questionnaire, Stanford Sleepiness 
Scale (SSS), Subjective Effects of Alcohol 
Scale (SAES) (Scale Sedation), Subjective 
Rating Scale (Scale Activity/Drowsiness), 
Subjective Rating Scale (Scale Alertness), 
Visual Analogue Scale (vas) (Scale 
Alertness), Visual Analogue Scale (vas) 
(Scale Drowsiness), Visual Analogue Scale 
(vas) (Scale Sedation), Visual Analogue 
Scale (vas) (Scale Sleepiness)
35 60 5 (Bartholow et al., 2003b), (Bruce et al., 1999), 
(Davidson et al., 1997), (DeWit et al., 1989), 
(Fillmore et al., 2005), (Holdstock et al., 2006), 
(Holdstock and de Wit, 1999), (Holdstock 
and de Wit, 1998), (Hutchison et al., 1997), 
(Knowles and Duka, 2004), (Landauer and 
Howat, 1983), (Liguori et al., 1999), (McKee 
et al., 2006), (Mundt et al., 1997), (Nagoshi et 
al., 1992), (Nyberg et al., 2004), (O'Malley and 
Maisto, 1984), (Pierucci-Lagha et al., 2006), 
(Rammsayer, 1995), (Reynolds et al., 2006), 
(Soderlund et al., 2005), (Walsh et al., 1991), 
(Wilkie and Stewart, 2005), (Zeichner et al., 
1993), (Zwyghuizen-Doorenbos et al., 1990), 
(Addicott et al., 2007), (Rupp et al., 2007c), 
(Saults et al., 2007) (n=28)
Scale 
Calmness
Affect Inventory (Scale Afraidness), Affect 
Inventory (Scale Relaxedness), Biphasic 
Alcohol Effects Scale (baes) (Scale Stimu-
lation), Estimation of Mood Change Test 
(Scale Tense/Relaxed), Profile of Mood 
States (poms) (Scale Anxiety), Profile of 
Mood States (poms) (Scale Arousal), Profile 
of Mood States (poms) (Scale Composed/
Anxious), Profile of Mood States (poms) 
(Scale Confident/Unsure), Profile of Mood 
States (poms) (Scale Tension ), Profile of 
Mood States (poms) (Scale Tension), Profile 
of Mood States (poms) (Scale Tension/
Anxiety), Subjective Rating Scale (Scale 
Relaxation), Taylor's Manifest Anxiety Scale, 
Visual Analogue Scale (vas) (Scale Nervous-
ness), Visual Analogue Scale (vas) (Scale 
Relaxedness), Visual Analogue Scale (vas) 
(Scale Stimulatedness)
23 76 2 (Bartholow et al., 2003b), (Bruce et al., 1999), 
(Davidson et al., 1997), (DeWit et al., 1989), 
(Duka et al., 2001), (Fillmore et al., 2005), 
(Gustafson and Kallmen, 1990), (Holdstock 
et al., 2006), (Holdstock and de Wit, 1999), 
(Holdstock and de Wit, 1998), (Hutchison et 
al., 1997), (Knowles and Duka, 2004), (Liguori 
et al., 1999), (Lindman, 1985), (McKee et al., 
2006), (Nagoshi et al., 1992), (O'Malley and 
Maisto, 1984), (Pierucci-Lagha et al., 2006), 
(Rammsayer, 1995), (Reynolds et al., 2006), 
(Soderlund et al., 2005), (Weissenborn and 
Duka, 2003), (Weissenborn and Duka, 2000), 
(Wilkie and Stewart, 2005), (Zeichner et al., 
1993), (Addicott et al., 2007), (Rupp et al., 
2007c), (Saults et al., 2007) (n=28)
Scale Craving Drug Effects Questionnaire (deq) (Scale 
Like), Drug Effects Questionnaire (deq) 
(Scale Like/Want More), Drug Effects 
Questionnaire (deq) (Scale Want More), Drug 
Effects Questionnaire (deq) Scale Like/Want 
More), Visual Analogue Scale (vas) (Scale 
Desire), Visual Analogue Scale (vas) (Scale 
Like), Visual Analogue Scale (vas) (Scale 
Like/Dislike)
50 50 0 (Balodis et al., 2006), (Davidson et al., 
1997), (Duka et al., 1998), (Fillmore, 2004), 
(Fillmore and Blackburn, 2002), (Fillmore, 
2001), (Holdstock et al., 2006), (Holdstock 
and de Wit, 1999), (Holdstock and de Wit, 
1998), (Liguori et al., 1999), (Marczinski and 
Fillmore, 2005b), (Marczinski and Fillmore, 
2005a), (Marczinski and Fillmore, 2003), 
(Ortner et al., 2003), (Pierucci-Lagha et al., 
2006), (Reynolds et al., 2006), (Richards et al., 
1999), (Franken et al., 2007) (n=18)
Scale 
Depression
Affect Inventory (Scale Depression), Profile 
of Mood States (poms) (Scale Depression), 
Profile of Mood States (poms) (Scale 
Depression/Dejection), Profile of Mood States 
(poms) (Scale Elated/Depressed)
8 85 8 (Nagoshi et al., 1992), (O'Malley and Maisto, 
1984), (Pierucci-Lagha et al., 2006), (Soderlund 
et al., 2005), (Wilkie and Stewart, 2005), 
(Zeichner et al., 1993) (n=6)
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(Neuro)Endocrine     





0 0 100 (Borg et al., 1983) (n=1)
Cortisol/
ACTH
ACTH, Cortisol 0 43 57 (Holdstock et al., 2006), (Inder et al., 1995), 
(Lukas and Mendelson, 1988), (Pierucci-Lagha 




AVP, Beta-Endorphin, Cholecystokinin, 
Dopamine, Melatonin, Prolactine, Serotonin
14 71 14 (Boyer et al., 2004), (Inder et al., 1995), (Sarkola 




progesterones, Allopregnanolone, DHEA, 
DHEA-S, Estradiol, Estradiol/Estrone/
Progesterone, Luteinizing Hormone (LH), 
Pregnenolone, Progesterone, Testosterone
27 64 9 (Holdstock et al., 2006), (Pierucci-Lagha et al., 
2006), (Sarkola et al., 1999) (n=3)
Scale Mood Affect Inventory (Scale Surprisedness/
Affection/Digust/Guilt/Sexuality/Humor/
Happiness), Beck-Depression-Inventory (Scale 
Depression), Estimation of Mood Change 
Test (Scale Elated/Depressed), Mood Scale 
(Scale Pleasure/Activity/Dominance), Mood 
Sorting Test, Personality-Trait Presentation 
Task, Positive Affect/Negative Affect Schedule 
(Scale Negative Affect), Positive Affect/
Negative Affect Schedule (Scale Positive 
Affect), Profile of Mood States (poms) (Scale 
Depression), Profile of Mood States (poms) 
(Scale Depression/Elation), Profile of Mood 
States (poms) (Scale Depression/Elation/
Positive Mood), Profile of Mood States (poms) 
(Scale Elation/Positive Mood), Profile of 
Mood States (poms) (Scale Mood), Profile of 
Mood States (poms) (Scale Positive Mood), 
Profile of Mood States (poms) (Scale Tension/
Anxiety/Depression/Dejection/Anger/ 
Hostility/Vigour/Fatigue/Confusion/
Bewilderment), Rotter's Internal-External 
Scale, Subjective Effects of Alcohol Scale 
(SAES) (Scale Negative Affect), Subjective 
Mood States (Scale Mood), Subjective 
Rating Scale (Scale Joyfulness), Subjective 
Rating Scale (Scale Positive Mood), Visual 
Analogue Scale (vas) (Scale Contentedness), 
Visual Analogue Scale (vas) (Scale Mood 
Changes), Visual Analogue Scale (vas) (Scale 
Mood), Visual Analogue Scale (vas) (Scale 
Pleasantness)
5 65 30 (Bruce et al., 1999), (Cameron et al., 2001), 
(Cowan, 1983), (De Cesarei et al., 2006), 
(DeWit et al., 1989), (Duka et al., 2001), 
(Duka et al., 1998), (Farquhar et al., 2002), 
(Gustafson and Kallmen, 1990), (Gustafson 
and Kallmen, 1989), (Holdstock and de Wit, 
1998), (Hutchison et al., 1997), (Knowles and 
Duka, 2004), (Liguori et al., 1999), (Lindman, 
1985), (Lukas et al., 1986b), (McKee et al., 
2006), (Mundt et al., 1997), (O'Malley and 
Maisto, 1984), (Rammsayer, 1995), (Reynolds 
et al., 2006), (Sher, 1985), (Stenberg et al., 
1994), (Tiplady et al., 2001), (Weissenborn and 
Duka, 2003), (Weissenborn and Duka, 2000), 




Subjective Attitudes and Intentions to Drink 
and Drive
100 0 0 (MacDonald et al., 1995) (n=1)
Scale 
Performance
Affect Inventory (Scale Intelligentness), 
Alcohol Sensation Scale (Scale Impairment), 
Driving Questionnaire, Self-Evaluation of 
Performance , Subjective Estimations of 
Ability, Subjective Impairment Scale, Visual 
Analogue Scale (vas) (Scale Driving), Visual 
Analogue Scale (vas) (Scale Functional 
Integrity)
67 33 0 (Cameron et al., 2001), (Davidson et al., 
1997), (Farquhar et al., 2002), (Harrison 
and Fillmore, 2005b), (Harrison and 
Fillmore, 2005a), (Landauer and Howat, 
1983), (MacDonald et al., 1995), (Millar et 
al., 1999), (Mills and Bisgrove, 1983a), (Mills 
and Bisgrove, 1983b), (Mundt et al., 1997), 
(O'Malley and Maisto, 1984), (Tiplady et al., 
2001), (Young and Pihl, 1982) (n=14)
Scale 
Symptoms
Alcohol Sensation Scale (Scale Anesthesia), Al-
cohol Sensation Scale (Scale Central/Warm/
Dynamic/Periphery/Nausea), Alcohol Sensa-
tion Scale (Scale Sensations), Alcohol Sensa-
tion Scale (Scale Somatic Sensations), Drug 
Effects Questionnaire (deq) (Scale Nausea), 
Sensation Scale (Scale Physical Sensations), 
Sensation Scale (Scale Symptoms), Von Zers-
sen's List of Complaints (Scale Complaints)
42 58 0 (Davidson et al., 1997), (Holdstock et 
al., 2006), (O'Malley and Maisto, 1984), 
(Pierucci-Lagha et al., 2006), (Sher, 1985), 
(Breitmeier et al., 2007) (n=6)
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table 7 dose response relationships  
For clusters tested at least 10 times (except for values between brackets) with 
at least two dose levels. Results are in % per alcohol dose level. “+” reflects an 
improvement or increase, “=” reflects no significant effect and “-“ reflects an 
impairment or decrease.
Executive 
Cluster < 0.5 g∙L-1 0.5 - 0.7 g∙L-1 > 0.7 g∙L-1
(-) (=) (+) (-) (=) (+) (-) (=) (+)
Inhibition 32 65 3 56 41 3 64 29 7
Working Memory 18 82 0 39 61 0 75 25 0
Attention
Cluster < 0.5 g∙L-1 0.5 - 0.7 g∙L-1 > 0.7 g∙L-1
(-) (=) (+) (-) (=) (+) (-) (=) (+)
Divided Attention 58 33 8 67 33 0 79 21 0
Focused/Selective Attention 7 86 7 62 38 0 74 26 0
Reaction Time 23 77 0 51 49 0 73 27 0
Motor          
Cluster < 0.5 g∙L-1 0.5 - 0.7 g∙L-1 > 0.7 g∙L-1
(-) (=) (+) (-) (=) (+) (-) (=) (+)
Visuo-Motor Control 43 57 0 85 15 0 89 11 0
Subjective Experience          
Cluster < 0.5 g∙L-1 0.5 - 0.7 g∙L-1 > 0.7 g∙L-1
(-) (=) (+) (-) (=) (+) (-) (=) (+)
Scale Alertness 19 78 4 53 42 5 41 53 6
Scale Calmness 20 80 0 21 75 4 31 69 0
Scale Craving 50 50 0 58 42 0 (38) (63) (0)
Scale Drug Effect 0 41 59 0 7 93 0 9 91
Scale High 0 36 64 0 0 100 (0) (0) (100)
Scale Mood 7 71 21 0 64 36 8 58 33
Perception
Cluster < 0.5 g∙L-1 0.5 - 0.7 g∙L-1 > 0.7 g∙L-1
(-) (=) (+) (-) (=) (+) (-) (=) (+)
Visual Perception - - - 36 64 0 60 40 0
Neurophysiologic 
Cluster < 0.5 g∙L-1 0.5 - 0.7 g∙L-1 > 0.7 g∙L-1
(-) (=) (+) (-) (=) (+) (-) (=) (+)
Evoked Potential 50 25 25 54 23 23 (50) (13) (38)
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abstract
background Alcohol effects or drug-alcohol interactions are preferably 
studied at constant blood levels. To achieve pseudo-steady state levels, 
various methods are used, which usually produce adequate averages but 
variable individual concentration profiles. In this study two modes of alcohol 
administration were compared: a ‘two-step prekinetic procedure’ and a 
‘clamping method’.
methods The two-step prekinetic procedure started with determination 
of individual pharmacokinetic parameters, during a prestudy occasion. 
Individual infusion regimens were calculated afterwards, based on a pseudo-
steady state breath alcohol concentration (brac) of 0.65 g·l-1 and applied 
during a separate occasion. For the clamping procedure, a spreadsheet-based 
paradigm was developed using brac guided adjustments of infusion rates, to 
maintain stable brac levels of 0.6 g·l-1.
results The mean brac during clamping (0.61 g·l-1 (95% ci: 0.58 - 0.63 
g·l-1)) did not differ from its intended level of 0.6 g·l-1 (1.0% on average). In 
contrast, the mean brac during the prekinetic procedure was significantly 
lower than the 0.65 g·l-1 set-point (0.59 g·l-1 (95% ci: 0.54 - 0.63 g·l-1)), 
and deviated from this target by 9.7% on average. The clamping method 
also showed less variation between subjects (cv: 6.2%), compared to the 
prekinetic procedure (cv: 14.6%).
conclusions Although the two methods differ considerably in their 
approach, clamping of brac resulted in more accurate alcohol levels than 
infusion based on pk-modelling and does not require an extra prestudy 
occasion. The novel alcohol clamping paradigm can be of value in future 
studies of alcohol interactions or the pharmacodynamics of acute alcohol 
administration.
introduction
Alcohol, or ethanol is widely used in social settings and causes dose-
dependent central nervous system (cns) depression (Little, 1991). Its 
metabolising systems show a large ethnic (Eng et al., 2007; Reed et al., 
1976) and interindividual variability, and there are many potential drug 
interactions. Alcohol intake can inhibit drug oxidation by competing 
with metabolising enzyme systems. On the other hand, chronic use of 
alcohol induces liver microsomal enzyme activity, which can lead to lower 
plasma levels of susceptible drugs when given concomitantly. Besides this 
pharmacokinetic interplay, alcohol consumption can also interact with 
drugs or substances on a pharmacodynamic level (Sellers and Holloway, 
1978). Hence, research for possible interactions between alcohol and other 
pharmacological compounds is often necessary when developing a safe drug 
therapy. Interactions with alcohol are particularly important for psychoactive 
drugs, since such compounds are often metabolised by the liver and they may 
affect the cns-effects of alcohol or vice versa. At the same time, alcohol abuse 
occurs with many psychiatric disorders (Kushner et al., 2000; Soyka et al., 
1993) and alcohol consumption is an accepted and frequent habit in Western 
society. Therefore, alcohol interaction studies are performed in many early 
drug development programs of psychoactive agents.
In determining the effects of alcohol or assessing alcohol-drug inter-
actions, it is helpful if alcohol plasma concentration can be maintained at 
pseudo-steady state levels. Most of the effects of alcohol are concentration- 
and time-dependent (Hiltunen et al., 2000; Vogel-Sprott, 1979), and in-
ter pretation of the results can be complex if plasma levels change over 
time. Nonetheless, many studies of alcohol effects or drug interactions are 
not performed at pseudo-steady state levels, or under other conditions in 
which these complexities are regulated. In many cases, alcohol exposure is 
merely controlled by adaptation of the dose to weight, and sometimes to 
gender or other demographic variables (Wilkinson, 1980). Measurements 
of the alcohol effects are usually performed at fixed time intervals after 
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intake. Often, breath alcohol levels are measured, but efforts to maintain 
constant levels are rare (Wilkinson, 1980). A major reason for this lack of 
methodological stringency is the complexity and variability of alcohol’s 
pharmacokinetic characteristics.
To achieve pseudo-steady state alcohol plasma concentrations, various 
methods have been reported in the literature. One method described by 
Hartmann et al. (Hartmann et al., 1988), used a two-step infusion rate 
protocol with a prestudy day. The pharmacokinetic profiles for alcohol 
were established after intravenous administration of a fixed alcohol dose 
on a prestudy day, and the individual parameters were used to calculate the 
infusion regimens needed to achieve a certain plasma concentration profile. 
On the actual study day, plasma samples were taken for determination of 
alcohol concentration, during the first hour of infusion. The results were 
available within the next hour and were used to adapt the infusion rate. In 
practice however, Hartmann et al. showed that these adaptations decreased 
the stability of the plasma alcohol concentrations (Hartmann et al., 1988). 
Therefore, the method was performed without these adjustments during 
several studies in our centre (van Steveninck et al., 1993; van Steveninck et al., 
1996). This technique produced a reliable average concentration profile with 
occasional over- or undershoots.
To avoid major fluctuations altogether and produce a more stable steady 
state serum level of alcohol with lower variability, it would be necessary to 
adapt the infusion rate to the plasma alcohol concentration instantaneously. 
O’Connor et al. (O’Connor et al., 1998) developed an algorithm that uses 
breath alcohol concentration (brac) to guide infusion rate adjustments for 
a steady alcohol plasma concentration. Their initial method started with an 
oral loading dose, adapted to body weight. After one hour, an alcohol infusion 
was initiated and brac samples were taken with ten minutes intervals. An 
experienced technician adapted the infusion rate to the brac-changes. The 
authors were able to keep alcohol plasma concentrations within 10% of the 
desired steady state, thus reducing variance introduced by changing alcohol 
plasma levels. Ramchandani et al. (Ramchandani et al., 1999), replaced the 
oral loading dose with a preprogrammed intravenous infusion rate profile. 
Using a physiology-based pharmacokinetic model, a steady brac within 5% 
window of the target concentration could be achieved. 
Despite its apparent advantages, the alcohol brac clamping method 
has not gained wide application. This might be related to the perceived 
complexity of the procedure, which in addition to an intravenous route 
of administration seems to require specific expertise and frequent brac-
measurements for adaptations of the infusion rate. In addition, although 
it seems clear that the alcohol clamp will improve the stability of alcohol 
levels, it has not yet been established how this compares to other procedures, 
such as two-step prekinetic methods. We describe a new method, based on 
O’Connor’s principles in comparison to the adapted two-step infusion rate 
method, which had been used previously (van Steveninck et al., 1993; van 
Steveninck et al., 1996).
methods
All of the studies described below were approved by the Medical Ethics 
Review Board of Leiden University Medical Centre. Both oral and written 
informed consent were obtained from all participating subjects after protocol 
approval. All studies were performed in compliance with the law on clinical 
trials of the Netherlands (wmo).
‘Two-step prekinetic procedure’
The alcohol data obtained from eight healthy male and eight healthy female 
volunteers participating in a drug-alcohol interaction study (chdr0111 – 
data on file) were used to evaluate the feasibility of the adapted two-step 
prekinetic procedure as described by Hartmann (Hartmann et al., 1988). 
Here, we only report alcohol data from the treatment arm that consisted of 
alcohol administration alone. On the prestudy day, an infusion of 50 grams of 
alcohol was administered for one hour (500 mL of 100 g∙l-1 alcohol solution 
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in 5% glucose). Breath alcohol concentrations were obtained at t = 0, 30, 55, 
75, 90, 120, 180, 240, 300 and 360 minutes. A hand-held Alco-Sensor iv meter 
was used for brac assessments during the study. To avoid an ‘overshoot’ in 
the alcohol level, the infusion of alcohol was terminated whenever the level of 
1.00 g·l-1 was reached.
individual infusion regimens
 
For each subject, individual pharmacokinetic parameters were determined 
as follows. Previously, a nonlinear mixed effects population pharmaco- 
kinetic model had been built, based on the data from an earlier chdr study 
with a similar design (van Steveninck et al., 1996), using nonlinear mixed 
effect modelling with nonmem version v software (Beal S.L. et al., 2006). 
A two-compartment model was used with Michaelis-Menten elimination 
from the central compartment. v1, v2, vmax , km and Q (inter-compartmental 
clearance) were estimated. Exponential models for inter-individial variabilty 
were used but inter-individual variability for km was fixed to zero to avoid 
numerical problems. An additive residual error model was used to avoid over-
estimating the importance of low alcohol measurements. Parameters were 
calculated using first-order conditional estimation (foce). These population 
parameters were used as priors in a Bayesian non-linear regression analysis of 
the brac-levels of the prestudy day, to generate pharmacokinetic parameters. 
Next, individual infusion regimens were simulated using the Bayes estimates. 
The regimen that approached and stayed at 0.65 g·l-1 was applied to the 
subsequent alcohol infusion occasions.
This infusion regimen consisted of a constant intravenous administration 
over one hour (loading phase), followed by a lower constant rate infusion 
over three hours (maintenance phase). Breath alcohol levels were obtained 
at t = 0, 60, 100, 150, 180, 210 and 300 minutes after the start of the loading 
phase. Contrary to Hartmann’s original procedure, no further adjustments in 
infusion rate were made during the infusion period.
‘Alcohol clamping procedure’
The O’Connor method (O’Connor et al., 1998) is based upon the theory 
that for substances with marked saturable elimination in the relevant 
concentration range (like alcohol), an approximately linear relationship 
exists between the applied infusion rate and the resulting change in alcohol 
concentration. When alcohol elimination is fully saturated, it is excreted at 
a constant (g/min) rate, independent of concentration. Therefore, when 
the input (g/min) is changed, this will result in a proportional change in 
alcohol concentration. The change in alcohol level required to achieve the 
target concentration can then be used to back-extrapolate the infusion rate 
that corresponds with, and should hence lead to this necessary change. The 
original brac clamping algorithm (O’Connor et al., 1998) consisted of an oral 
loading dose and brac samples, with possible infusion rate adaptations every 
ten minutes. It was anticipated that an intravenous loading infusion would 
reduce variability and shorten the time required to reach pseudo-steady state. 
Additionally, an increase in sampling interval to 30 minutes (after steady 
state was reached) would improve the feasibility of other pharmacodynamic 
or functional assessments, as a ten minute interval may interfere with the 
required measurements. Simulations were performed for a large range of 
scenarios using alcohol population parameters determined from previous 
chdr studies (88128, chdr0111, chdr0210 – data on file). These parameters 
are shown in table 1. The same population model was used as for the two-step 
prekinetic procedure, but the increase in information from using data from 
two extra studies, resulted in the possibility to estimate correlations between 
population parameters and inter-individual variability for km as well.
These simulations indicated that the original O’Connor (O’Connor et al., 
1998) procedure would result in infusion rate suggestions that would be too 
large, and that the increase to a 30 minute measurement interval would result 
in alcohol increases that would be difficult to recover from (even by shutting 
down the alcohol infusion for the next 30 minutes). As a result, an adapted 
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regime was empirically determined consisting of a time dependent reduction 
of the suggested O’Connor infusion rate. This regime is fully described in the 
Appendix and was implemented in a simple user-friendly Microsoft Excel® 
spreadsheet (available from the authors on request). During the procedure, 
online adjustments in infusion rates are made using the brac samples as a 
guideline to achieve a pseudo-steady state alcohol serum level of 0.6 g·l-1. 
This target level was expected to result in saturated alcohol elimination, since 
km was estimated at 0.0452 g∙l-1. At more than 10 times this concentration 
(during clamping at 0.6 g∙l-1), elimination will be saturated, hence complying 
with the prerequisite for the clamping technique. This new infusion paradigm 
was tested for its feasibility in a subsequent study.
Clamping study
Six healthy male and six healthy female volunteers were recruited for this 
alcohol clamping study, where alcohol was infused for five hours. brac 
samples were taken at baseline and every five minutes for the first 30 minutes 
after the start of the infusion, every ten minutes for the next 30 minutes and 
then every half hour until the end of the study. Again, the hand-held Alco-
Sensor iv meter was used for brac sampling. Since product specifications 
for this apparatus state that sampling intervals shorter than five minutes 
cause fatigue of the brac sensor, two different measurement devices were 
alternated during the clamping study.
The clamping study was performed in a randomised, double-blind and 
placebo-controlled fashion. The intravenous alcohol infusion (alcohol 10% 
w/v solution in glucose 5% or placebo (glucose 5%)) took place for five hours 
in total. An infusion assistant, who was not a member of the study team, 
was made responsible for the brac measurements and the execution of the 
clamp, to maintain blinding during the study. During the whole study day, 
volunteers performed a battery of both cognitive and psychomotor cns 
tests between sampling time points. The results of these pharmacodynamic 
assessments will be described elsewhere. 
spreadsheet-based procedure
 
In advance of a study occasion, the study statistician prepared individual 
computer spreadsheets, according to a randomisation schedule. For alcohol 
occasions, this spreadsheet contained a blank ‘measurement column’, in 
which the measured brac-values were entered by the infusion assistant. 
Based on these results, the spreadsheet calculated the new infusion rate. 
For placebo occasions, the spreadsheet contained a separate column with 
‘sham’ brac-values, determined from kinetic simulations. At each protocol 
time, the infusion assistant entered the corresponding ‘sham’ value into the 
measurement column. This value was used by the spreadsheet to calculate 
a new ‘sham’ infusion rate, which was subsequently applied. In this way, 
operations during the alcohol clamping and sham procedures were exactly 
similar for the subject.
 
Alco-Sensor iv Intoximeter
Two Alco-Sensor iv Intoximeters (Honac, Apeldoorn, the Netherlands) were 
used for brac measurements during the studies. The Alco-Sensor utilizes an 
electrochemical sensor (fuel cell) to quantify alcohol in the provided sample. 
Prior to the study, the relialibility of the brac devices was confirmed in a 
validation study. Twelve subsequent samples of a 1.08 g∙l-1 calibration gas 
(taken at t = 0, 10, 20, 35, 55, 115, 175, 235, 295, 355, 415 and 475 min.) resulted in 
a mean value of 1.07 g∙l-1 (95% ci: 1.06, 1.08 g∙l-1) for the first apparatus and 
a mean value of 1.08 g∙l-1 (95% ci: 1.07, 1.09 g∙l-1) for the second apparatus. 
An important error in the measurement of alcohol levels during the clamping 
study could be exhaustion of the brac sensor. Since, exhaustion of the sensor, 
which was most likely during the ascending limb of the brac curve (where 
frequent brac measurements are required) could result in incorrect alcohol 
values, two brac devices were alternated. The instruments were calibrated 
prior to the start of the studies.
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Subject characteristics
Subjects participating in the two-step prekinetic study were on average 27 
years of age (range 18 - 53 years old), had an average weight of 77 kg (range 
53 - 95 kg) and an average height of 175 cm (range 155 - 187 cm). Subjects 
participating in the alcohol clamping study were on average 22 years old 
(range 18 - 39 years old), had an average weight of 74 kg (range 56 - 89 kg) 
and an average height of 173 cm (range 161 - 195 cm). All subjects participating 
in the previous alcohol studies (88128, chdr0111, chdr0210 – data on file) 
used to construct the pharmacokinetic model were on average 24 years of age 
(range 18 – 53 years old), had an average weight of 77 kg (range 53 - 97 kg) and 
an average height of 180 cm (range 155 – 194 cm). All subjects were occasional 
users of alcohol.
Safety
To prevent local pain in the beginning of the alcohol infusion, an additional 
diluting glucose 5% infusion (100 mL·hr-1) was given to all participants, 
during the first ten minutes after the start of the alcohol infusion over the 
same infusion line. No further specific safety measurements were planned for 
both the alcohol clamping procedure and the two-step prekinetic procedure. 
During both studies, alcohol was infused to a level of 0.6 g·l-1, just above the 
legal limit of 0.5 g·l-1 for adult motor vehicle drivers in the Netherlands.
results
Subjects
During the prestudy day of the two-step prekinetic procedure, the infusion 
of one of the subjects was stopped 38 minutes after the start of the alcohol 
infusion, because brac exceeded 1.0 g·l-1 and concomitant nausea and 
inebriation occurred. The available data from this subject were used for the 
analyses, and for the determination of well-tolerated infusion regimens for 
the ‘pseudo-steady state’ part of the two-step procedure. 
In the clamping study, one subject dropped out after the first occasion for 
personal reasons. This subject was replaced by another volunteer receiving 
the same order of alcohol/placebo administration. Another subject repeated 
his first occasion because he had hardly slept the night before the study 
occasion, despite instructions to maintain a regular diurnal rhythm during 
the study period. Both repeated occasions were used for the pharmacokinetic 
analysis. All other subjects completed the studies according to protocol.
Two-step prekinetic procedure
The average brac-profiles over time for both steps of the two-step prekinetic 
procedure are presented in figure 1. A large variability in brac values was 
observed after the fixed intravenous alcohol dose in the prekinetic occasion. 
Individual peak brac levels ranged from 0.71 g∙l-1 to 1.71 g∙l-1. During the 
loading phase of the pseudo-steady state occasions, the maximum initial 
overshoot reached up to 0.93 g∙l-1, which is an excursion of almost 50% above 
the target value. A slight, but clear declining trend in average brac level could 
be observed during the maintenance phase. During this period brac values 
ranged from 0.56 to 0.63 g∙l-1. A ‘plateau phase’ could be observed between 
100 and 210 minutes post-dose. During this part, brac values were 9.7% below 
the desired concentration on average. 
Alcohol clamping procedure
The average brac profiles of subjects participating in the alcohol clamping 
study are presented in figure 2. The 0.6 g∙l-1 pseudo-steady state level 
was reached within 25 minutes after the start of the alcohol infusion. The 
intravenous loading regimen did not produce an overshoot as could be 
observed from the figure. A pseudo-steady state phase can be observed 
between 25 and 300 minutes. During this period, brac values ranged from 
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0.55 to 0.65 g∙l-1. On average, the clamping procedure slightly exceeded its 
target level by 1.0% during the plateau phase. The graph also shows that the 
stability of the clamp was not affected by the simultaneous performance of 
the pharmacodynamic test battery.
The applied infusion rates during clamping may serve as an indirect 
parameter for alcohol clearance. This parameter can be used to compare 
alcohol metabolism between certain subgroups. Differences in alcohol 
metabolism between sex and race or changes in alcohol pharmacokinetics 
due to drug-alcohol interactions can be assessed and quantified, using 
infusion rates as a marker. In this study the mean individual infusion rates 
during the plateau phase were somewhat higher for males than for females 
(143.5 mL·hr -1 (sd: 36.1) and 108.3 mL·hr-1 (sd: 23.7) respectively), but the 
difference did not reach significance in this small group (p = 0.08).
Comparison of the alcohol clamping procedure  
and the two-step prekinetic procedure
To compare the two different infusion regimens the mean brac level during 
the relevant steady state interval and the coefficient of variation were calculat-
ed. During the two-step prekinetic procedure (target level 0.65 g·l-1) a mean 
brac of 0.59 g·l-1 (95% ci: 0.54 - 0.63 g·l-1) was found. The mean brac of the 
novel alcohol clamping procedure (target level 0.60 g·l-1) was 0.61 g·l-1 (95% 
ci: 0.58 - 0.63 g·l-1). The calculated coefficient of variation of the clamping 
method (6.2%) was more than twice as low as the two-step prekinetic proce-
dure (14.6%). Thus, the novel clamping paradigm resulted in more accurate 
pseudo-steady state levels of alcohol compared to the mean brac during the 
two-step prekinetic procedure, with two-fold lower variability.
Adverse events
No serious adverse reactions occurred during either study. The most 
frequently reported adverse events included inebriation, a painful arm at the 
start of the infusion, sleepiness and headache (see table 2). These symptoms 
were all transient and mild in severity.
discussion 
The two-step prekinetic procedure resulted in a substantial overshoot prior 
to the maintenance phase, and a declining plateau phase entirely located 
below the desired target level. Some fluctuations were expected since online 
corrections were not implemented in this method. Despite these inaccuracies, 
the adapted paradigm was able to maintain serum levels of alcohol that were 
on average relatively stable. The clamping method did not require prior 
determination of individual disposition parameters and was able to keep 
constant alcohol levels over an extended period of time. Online adjusted 
brac levels could easily be targeted to a preset target level and showed very 
little interindividual variability. The higher variability obtained with the two-
step prekinetic procedure might in part be attributable to the interoccasion 
variability related with the study design of the two-step procedure. In this 
respect, the design of the alcohol clamp study appeared to be superior to the 
two-step design of the prekinetic procedure. 
A less obvious, but  potentially important advantage of the clamping 
method is that if a drug modifies alcohol kinetics, the brac guided 
method will instantly adapt. This will improve the safety and tolerability 
of drug-alcohol interaction studies. Using applied infusion rates and brac 
assessments, alcohol kinetics can still be determined; but a much simpler 
comparison of alcohol metabolism can be obtained from the total amounts 
of infused alcohol that were needed to maintain pseudo-steady state brac-
levels.
Contrary to O’Connor’s originally described procedure, the clamping 
study presented here used an intravenously administered loading dose. 
Although it was not investigated in this study, it is likely that intravenous 
loading will cause less variability than oral loading because between subject 
variability in absorption is removed. Two other practical advantages of the 
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new alcohol clamping method compared to the one originally proposed 
by O’Connor are its user-friendliness and the incorporation of wider inter-
sampling periods. By converting the paradigm (see Appendix) electronically 
into an easy-to-handle spreadsheet, the procedure can be executed by anyone 
able to modify an infusion pump and use a breath alcohol meter, after a short 
introduction. Furthermore, reducing the number of brac samples increased 
the time between two sequential brac sampling moments. This allows 
for the performance of other measurements, which makes the clamp more 
suitable for pharmacodynamic alcohol effect or interaction studies. This 
study showed that a battery of pharmacodynamic cns measurements could 
be integrated in the course of the clamp without affecting the stability of the 
target level.
Since the clamping method is based on empirical principles it is not 
necessarily state of the art. Systematic procedures like target-controlled 
infusions or physiology-based pharmacokinetic methods may result in 
more accurate alcohol concentrations over time. The procedure described 
by Ramchandani, based on precalculation of infusion rates, probably 
approaches this more closely (Ramchandani et al., 1999). However, these 
state of the art approaches are rarely implemented in practice, because of the 
perceived complexity during execution. The clamping procedure presented 
here, is a simple to implement procedure that allows everyone to use it with 
good results.
Future studies should focus on further optimisation of the alcohol 
clamp. Both over- and undershoots that appear particularly during the 
transition from the ascending (loading) limb to the plateau (maintenance) 
phase of the brac curve can be minimised by individualisation of the initial 
infusion rates during the first ten minutes. The initial fixed infusion rates 
for the first ten minutes, could for example be replaced by infusion rates 
that are based on individual demographic characteristics (e.g. gender, age, 
height and weight). More research is needed to find out if the clamping 
method is also able to produce stable brac levels for longer periods 
than the five hours used in this study, or at different target brac levels. 
In conclusion, the novel alcohol clamping paradigm was an accurate, user-
friendly method, with low variability, able to maintain constant alcohol levels 
for hours. The current paradigm shows an opportunity to perform intensive 
pharmacodynamic or functional assessments during the execution of the 
clamp, which could be of great value for future studies of alcohol.
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figure 1 results of the ‘two-step procedure’
Left: Average brac-profile of the participating subjects during the prekinetic 
occasion and their sd’s. Minimum and maximum values are also presented. 
The straight vertical line marks the end of the one-hour infusion period. Right: 
Average brac-profile of the participating subjects during the pseudo-steady state 
experiment and their sd’s. Minimum and maximum values are also presented. 
The area between the two straight vertical lines at t=0 and t=60 minutes marks 
the ‘loading phase’. The area between the two straight vertical lines at t=60 and 
t=240 minutes marks the ‘maintenance phase’.
figure 2 aver age brac-profile of the participating 
volunteers during alcohol clamping procedure with  
their sd’s 
Minimum and maximum values are also presented. The vertical lines mark 
the start and the stop of the infusion. 
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table 1 nonmem alcohol population par ameters 
Mean: population average, iicv: inter-individual coeffcient of variation.  
These population parameters are based on 68 subjects and 6052 brac samples.
mean iicv between subject correlations
Vc Vp Km Vmax
Vc (L) 13.6 51%
Vp (L) 36.0 36% -0.13
Km (g·L-1) 0.0452 46% -0.56 -0.49
Vmax (g·L-1·min-1) 0.0117 49% -0.90 0.34 0.51
Q (L·min-1) 1.22 25% -0.35 0.81 -0.50 0.50
SD residual error (g·L-1) 0.035
    
table 2 distribution of adverse events during both 
evaluated methods
The numbers represent the occurrence of the symptoms as a percentage of the total 
number of adverse events per study.
‘Clamping method’ ‘Two-step prekinetic procedure’
alcohol placebo alcohol placebo
“inebriation” 22% 3% 26% 3%
“painful infusion” 22% 3% 8% 0%
“sleepiness” 16% 3% 20% 16%
“headache” 8% 3% 8% 9%
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r efer ences
Alcohol was infused for a total of five hours with a 
set point of 0.6 g·l-1.
brac measurement were obtained at 5, 10, 15, 20, 
25, 30, 40, 50, 60, 90, 120, 150, 180, 210, 240, 270, 300, 
330, 360, 390, 420 and 480 minutes postdose.
Infusion rate between 0 and 5 minutes was fixed 
at 72 g·hr-1. 
Infusion rate between 5 and 10 minutes was fixed 
at 60 g·hr-1.
Infusion rates were modified at 10, 15, 20, 25, 30, 40, 
50, 60, 90, 120, 150, 180, 210, 240 and 270 minutes.
Regression equations of applied infusion rate vs. 
resulting change in alcohol concentration were 
calculated for all available pairs of data (i.e. starting 
with the measurement at 5 minutes) and updated 
with each new data point, up to 270 minutes.
If a negative infusion rate is suggested by  
the regression equation (e.g. to correct for  
an overshoot), then the infusion rate was set  
at 1.0 g·hr-1 (the lowest possible rate on the  
infusion apparatus).
At times (especially at early sampling points)  
it is possible for the regression equation to arrive 
at a negative slope. This means that the equation 
suggests that in order to increase the concentration, 
less alcohol needs to be infused. This anomaly was 
corrected by replacing the regression equation in 
this case by a population average equation, 
determined using a large number of simulated 
regression equations. The population average 
equation was: new_rate = (required_rate_of_ 
change + 0.013) / 0.06.
In order to correct for the suggested infusion rates, 









rate was reduced by 25%).
If, after all these adjustments, rates were still too 
high, the following  maximum time-dependent  
rates were applied:
•	 from	10	to	30	minutes	(not	incl.)	the	maximum	
allowed rate was 144 g·hr-1,
•	 from	30	to	60	minutes	(not	incl.)	the	maximum	
allowed rate was 72 g·hr-1,
•	 from	60	minutes	onwards	the	maximum	allowed	
rate was 36 g·hr-1.
The average total amount of infused alcohol is 
approximately 75 grams when a pseudo-steady 
state of 0.6 g∙l-1 is achieved for five hours. 
This corresponds to the consumption of less 
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ethanol clamping in healthy volunteers
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abstract
background In determining the acute effects of alcohol, it is helpful 
if alcohol concentrations are maintained at stable levels, to facilitate the 
interpretation of the results. Recently, an alcohol clamping method was 
developed that resulted in stable alcohol concentrations for hours. In this 
study, a range of central nervous system (cns) effects were tested under 
pseudo-steady state conditions.
methods To achieve a pseudo-steady state of 0.6 g·l-1, breath alcohol 
concentrations (brac) were frequently measured, and fed back into a 
spreadsheet-based program to guide intravenous dosing. cns-effects were 
frequently measured throughout the clamp.
results The clamping paradigm resulted in a pseudo-steady state brac of 
0.61 g·l-1 (cv: 6.2%). A plateau was maintained from 25 - 300 min. and caused 
significant effects on smooth pursuit eye movements (-9.7% (95% ci: -12.4, 
-7.1)), adaptive tracking (-3.4% (95% ci: -4.5, -2.2)), vas alertness (-13 mm 
(95% ci: -20, -6)), vas alcohol effects (16 mm (95% ci: 7, 25)) and body sway 
(21.3% (95% ci: 1.8, 45)). Some effects (like smooth pursuit eye movements) 
closely followed the relatively stable alcohol concentrations, whereas others 
(such as body sway and vas alcohol effects) fluctuated during the plateau-
phase.
conclusions Most cns-effects of alcohol showed a trend to change over 
time, despite stable concentrations. Other variables remained stable under 
pseudo-steady state conditions. The intravenous clamping method provides 
careful control over brac levels and allows frequent repetition of different 
cns-measurements. These features make this technique eminently suitable to 
study the complex pharmacodynamic effects of acute alcohol administration.
introduction 
To determine the effects of alcohol or to assess alcohol-drug interactions, 
it is helpful to maintain alcohol plasma concentration at reasonably steady 
state levels, since most of the effects of alcohol are concentration dependent. 
Nonetheless, few studies of alcohol effects or drug interactions are actually 
performed under (pseudo) steady state conditions. In many cases, alcohol 
exposure is controlled by adaptation of the dose to weight, and sometimes 
to sex or other demographic variables (Wilkinson, 1980). Measurements of 
the alcohol effects are usually performed at fixed time intervals after intake. 
Often, breath alcohol levels are measured, but plasma levels vary after admin-
istration and efforts to maintain constant levels are rare (Wilkinson, 1980).
Based on the principles described by O’Connor et al. (O’Connor et al., 
1998), we recently developed a method, which is able to maintain constant 
levels of alcohol for hours by clamping the breath alcohol concentration 
(brac). This new clamping procedure demonstrated a stable and reliable 
pseudo-steady state alcohol concentration profile for five hours, with low 
variability. The procedure is described elsewhere in more detail (Zoethout 
et al., 2008). The pharmacodynamic results that were obtained during this 
procedure are reported here.
Alcohol has many measurable cns-effects in healthy subjects. Numerous 
test methods have been developed to study these parameters like alertness, 
oculomotor function, (visio-)motor control, attention and subjective effects 
(de Visser et al., 2001; Heishman et al., 1997; Shamsi et al., 2001). All of these 
cns-domains are covered in the ‘Neurocart’ test battery that has been devel-
oped at the Centre for Human Drug Research (chdr) to examine different 
kinds of cns-active drugs (de Haas et al., 2007; van Steveninck et al., 1993; van 
Steveninck et al., 1996). In the current exploratory study, these methods were 
used to determine the pharmacodynamic cns-effects of alcohol at a pseudo-
steady state level of 0.6 g∙l-1 for five hours, and to investigate whether this 
intensive battery of cns-measurements could be performed during clamp-
ing, without affecting its concomitant execution or vice versa.
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The study was a randomised, double-blind, placebo-controlled, two-way 
cross-over study in 12 healthy volunteers, with a minimum washout period 
of two days.
Subjects 
Six healthy female and six healthy male volunteers, between 18 and 39 years 
of age gave oral and written informed consent after approval of the study 
protocol by the Medical Ethics Review Board of the Leiden University 
Medical Centre (lumc). Before inclusion, subjects were screened by medical 
history and physical examination and participated in a pharmacodynamic 
training session. All 12 subjects were found eligible to participate and entered 
the study. Subjects were familiar with the effects of alcohol and were instructed 
not to use more than two alcohol consumptions a day, for at least two days 
prior to the study occasions. Twelve hours prior to each study start, the use 
of alcohol was prohibited. The oral use of alcohol and xanthine containing 
beverages was not allowed on study days. On the evening following each test 
day, driving and the handling of machines were not permitted.
General Procedure
All subjects reported at the research unit at 08:00 in the morning of each 
test day. After a short introduction, eeg- and eye-electrodes were mounted. 
Around 09:00 a standard breakfast was provided. The alcohol or placebo 
infusion started between 09:30 and 10:00. Alcohol breath samples and 
pharmacodynamic measurements were obtained at regular time points. 
A standardised lunch was given around 3.5 hours after starting the infusion. 
The administration of alcohol or placebo ended five hours after the start of 
the infusion. All subjects were taken home by taxi at the end of the study day. 
The second study occasion was performed in an identical way.
Study Treatments
An ethanol solution (10% w/v in 5% glucose) was prepared and was infused 
on study days. Infusion was based on an alcohol breath clamping paradigm to 
achieve a target level of 0.6 g∙l-1 (Zoethout et al., 2008). Glucose 5% was used 
as a placebo, employing a sham-procedure including adaptations of placebo 
infusion rates based on a simulated spreadsheet. The infusion rates between 
0 and 5 minutes and between 5 and 10 minutes were fixed at 72 g∙hr-1 and 60 
g∙hr-1, respectively. Hereafter, rates were modified at 10, 15, 20, 25, 30, 40, 50, 
60, 90, 120, 150, 180, 210, 240 and 270 minutes, according to the obtained brac 
samples, which were measured at the same timepoints. During study days, a 
parallel glucose infusion (glucose 5%) was administered to all subjects during 
the first ten minutes post-start, to prevent pain or discomfort in the infusion 




During the intravenous infusion procedure, online adjustments in infusion 
rates were made using brac samples as a guideline to maintain a pseudo-
steady state alcohol level of 0.6 g·l-1, according to a recently introduced 
infusion paradigm, which was adapted from a method originally described by 
O’Connor (O’Connor et al., 1998). The O’Connor method is based upon the 
theory that for substances with marked saturable elimination in the relevant 
concentration range (like alcohol), an approximately linear relationship 
exists between the applied infusion rate and the resulting change in alcohol 
concentration. When alcohol elimination is fully saturated, it is excreted at a 
constant (g·min-1) rate, independent of concentration. Therefore, when the 
input (g·min-1) is changed, this will result in a proportional change in alcohol 
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concentration. The change in alcohol level required to achieve the target 
concentration can then be used to back-extrapolate the infusion rate that 
corresponds with, and should hence lead to this necessary change. Although 
accurate results were obtained by O’Connor, an increase in sampling interval 
to 30 minutes (after steady state was reached) would improve the feasibility 
of other pharmacodynamic or functional assessments, as a ten minute 
interval (used by O’Connor) may interfere with the required measurements. 
However, simulations indicated that the original O’Connor procedure 
would result in infusion rate suggestions that would be too large, and that 
the increase to a 30 minute measurement interval would result in alcohol 
increases that would be difficult to recover from (even by shutting down the 
alcohol infusion for the next 30 minutes). As a result, an adapted, spreadsheet-
based regime was empirically determined consisting of a time dependent 
reduction of the suggested O’Connor infusion rate. This new brac clamping 
method is described in detail elsewhere (Zoethout et al., 2008). In the current 
study, it was tested for its feasibility to perform an intensive battery of cns 
measurements concomitantly. 
alcohol concentrations Both breath alcohol concentrations and 
plasma alcohol levels were obtained for pharmacokinetic analysis during each 
study day at t = 0, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 150, 180, 210, 240, 270, 
300, 330, 360, 390, 420, 450 and 480 minutes. 
breath alcohol concentrations (brac) Online adaptation of 
the brac was based on measurements with a hand-held Alco-Sensor iv 
meter (Honac, Apeldoorn, the Netherlands), which had a lower limit of 
quantification (llq ) of 0.01 g∙l-1. The brac was entered into a spreadsheet, 
which calculated the corresponding infusion rate to maintain the brac at 
0.6 g∙l-1. Because sampling intervals shorter than five minutes (occurring 
during the initial part of the infusion) cause the brac meter to show fatigue, 
two different measurement devices were alternated. A pilot study was 
performed prior to the start of the study, in which no fatigue was observed 
during alternation of both brac devices according to the sampling scheme 
of the study. A research assistant, who was not involved in any other activity 
was made responsible for the brac measurements and the execution of the 
clamp (or the sham procedure (during placebo administration)), to maintain 
blinding of the study participant and the research team members during the 
investigation. The brac devices were calibrated prior to the start of the study.
blood alcohol concentrations (bac) Blood samples were col-
lected in 8.5 ml sst® Gel and Clot Activator tubes (Becton and Dickinson) 
and were allowed to clot for at least 30 minutes (max. 60 minutes) at room 
temperature. Subsequently, samples were centrifuged at 2800G for ten min-
utes at 4°c. Tubes were then stored refrigerated until alcohol concentrations 
were determined within 24 hours after collection, in the Central Laboratory 
for Clinical Chemistry of the lumc. An enzymatic assay using a Modular P 
analyzer (Roche, Switzerland) was employed, where ethyl alcohol and nad 
were converted to acetaldehyde and nadh by alcohol dehydrogenase. nadh 
formed during the reaction was measured photometrically as a rate of change 
in absorbance, which is directly proportional to the ethyl alcohol concentra-
tion. The analyzer’s llq was 0.1 g∙l-1.
cns-pharmacodynamics
The ‘Neurocart’ is a battery of sensitive tests for a wide range of cns-domains 
that has been developed at chdr to examine different kinds of cns-active 
drugs (de Haas et al., 2007; van Steveninck et al., 1993; van Steveninck et al., 
1996). The following tests were performed twice at baseline, and repeated 
hourly during the plateau and washout phases in a quiet room with ambient 
illumination, in the following order:
body sway Body sway was measured with an apparatus similar to the 
Wright ataxiameter (Wright, 1971). The body sway meter allows measurement 
of body movements in a single plane, providing a measure of postural 
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stability. During sway measurements, subjects were instructed to keep their 
eyes closed for two minutes. Body sway measurements were obtained twice 
pre-dose and at t = 5, 15, 25, 40, 50, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 
360, 390, 420, 450 and 480 minutes.
symbol-digit substitution test (sdst) The symbol-digit (sdst) 
and digit-symbol substitution tests (dsst) have frequently been used in 
human psychopharmacology for establishing the effects of a wide range of 
psychotropic drugs on cns-functioning (Magliozzi et al., 1989; Jalava et al., 
1995). During sdst measurements, selected symbols appear in random 
order on a computer screen. Subjects were instructed to reproduce the digits 
associated with the symbols by using a symbol-digit code. The numbers 
of attempted and correct responses were recorded to assess attention and 
executive functions, for a period of 90 seconds. sdst measurements were 
obtained twice pre-dose and at t = 60, 120, 180, 240, 300, 360, 420 and 480 
minutes.
visual analogue scales (vas) Visual analogue scales, as originally 
described by Norris (Norris, 1971) have been used previously to quantify 
subjective effects of a variety of sedative agents (van Steveninck et al., 1991; 
van Steveninck et al., 1996; van Steveninck et al., 1993; van Steveninck et al., 
1999). In the current study alertness, mood and calmness were derived from 
a vas previously described by Bond and Lader (Bond and lader, 1974). These 
factors were used to quantify subjective drug effects. The specific subjective 
effects of alcohol were assessed by a vas alcohol effects, asking the subject to 
indicate ‘how large is the effect of alcohol that you feel?’ All scales consist of 
10 cm line segments. Subjects mark a point on the line that best represents 
their subjective state corresponding to the condition tested. The result is a 
distance calculated from the mark on the line. The vas measurements were 
obtained twice pre-dose and at t = 60, 120, 180, 240, 300, 360, 420 and 480 
minutes.
 
adaptive tracking The adaptive tracking test was performed as 
originally described by Borland and Nicholson (Borland and Nicholson, 
1984), using customised equipment and software (Hobbs, 2000, 
Hertfordshire, uk). Adaptive tracking is a pursuit tracking task that has proved 
to be useful for measurement of cns-effects of alcohol, various psychoactive 
drugs and sleep deprivation (van Steveninck et al., 1991; van Steveninck et al., 
1999). Each test was preceded by a run-in period. Performance was scored 
after a fixed period of five minutes and reflected visuo-motor control and 
vigilance. The average performance scores were used in the analysis. Adaptive 
tracking measurements were obtained twice pre-dose and at t = 60, 120, 180, 
240, 300, 360, 420 and 480 minutes.
saccadic eye movements Saccadic eye movements were recorded 
using a microcomputer-based system, customised ced software for data 
sampling and analysis (Cambridge Electronics Design, Cambridge, uk), 
Nihon Kohden equipment for stimulus display, signal collection and 
amplification (Nihon Kohden Corporation, Tokyo, Japan), and disposable 
surface electrodes for registration of the electro-oculographic signals 
(Medicotest n-oo-s, Olstykke, Denmark). Average values of latency 
(reaction time), saccadic peak velocity and inaccuracy (difference between 
stimulus angle and corresponding saccade in percentages) were calculated 
for all artefact-free saccades. Saccadic peak velocity has been validated as 
one of the most sensitive parameters for sedation (de Haas et al., 2007; 
van Steveninck et al., 1996; van Steveninck et al., 1993; van Steveninck et al., 
1991; van Steveninck et al., 1999). Saccadic eye movements were performed 
twice pre-dose and at t = 60, 120, 180, 240, 300, 360, 420 and 480 minutes. 
 
smooth pursuit eye movements For smooth pursuit eye movements, 
the target moves sinusoidally at frequencies ranging from 0.3 to 1.1 Hz, by 
steps of 0.1 Hz. The amplitude of target displacement corresponds to 22.5 
degrees eyeball rotation to both sides. Four cycles were recorded for each 
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stimulus frequency. The time in which the eyes were in smooth pursuit of 
the target was calculated for each frequency and expressed as a percentage of 
stimulus duration. The average percentage of smooth pursuit for all stimulus 
frequencies was used as a parameter. This parameter can be used as an 
accurate biomarker for oculomotor function and attention (Lehtinen et al., 
1982). The method has been validated earlier (van Steveninck et al., 1989; van 
Steveninck, 1993) based on the work of Bittencourt et al. (Bittencourt et al., 
1983) and the original description of Baloh et al. (Baloh et al., 1975). Smooth 
pursuit eye movements were performed twice pre-dose and at t = 10, 20, 
30, 40, 50, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 390, 420 and 480 
minutes.
electroencephalography (eeg) Pharmaco-electroencephalography 
was measured to provide non-specific measures of cns-functions (Cohen et 
al., 1985). eeg signals were obtained from leads Fz - Cz and Pz - Oz. The signals 
were amplified using a Nihon Kohden ab-621g bioelectric amplifier (Nihon 
Kohden Corporation, Tokyo, Japan) with a time constant of 0.3 seconds 
and a low pass filter at 100 Hz. For the fast Fourier analysis, data collection 
and analysis were performed using customised ced software (Cambridge 
Electronics Design, Cambridge, uk). Per session eight consecutive blocks 
of eight seconds were recorded. The signal was ad-converted using a ced 
1401 laboratory interface (Cambridge Electronics Design, Cambridge, uk). 
Data blocks containing artefacts were identified by visual inspection and 
these were excluded from the analysis. Fast Fourier transform analysis was 
performed to obtain the sum of amplitudes in the delta (0.5 - 3.5 Hz), theta 
(3.5 - 7.5 Hz), alpha (7.5 - 11.5 Hz) and beta (11.5 - 30 Hz) frequency ranges. 
The duration of eeg measurements was two minutes per session. eeg 
measurements were obtained twice pre-dose and at t = 60, 120, 180, 240, 300, 
360, 420 and 480 minutes.
 
Statistical analysis
The pharmacodynamic endpoints were analysed by mixed model analyses 
of variance (using sas proc mixed) with subject, subject by treatment 
and subject by time as random effects, with treatment, occasion, time and 
treatment by time as fixed effects, and the average baseline value was included 
as covariate. Time and treatment by time effects were only included for 
graphical representation of the baseline corrected data; the contrast between 
alcohol and placebo was calculated within the statistical mixed model. All 
statistical analyses were performed using sas version 8.2 (sas Institute Inc., 
Cary, nc., usa).
The different elements in our mixed model were implemented to explain 
part of the variation and to estimate the correct residual variation to test the 
fixed effect variation against. The only tested factor of interest though, was 
the treatment effect; all other factors were only used to attribute the correct 
amount of variation to the treatment and to calculate the right residual term 
to test the treatment effect against. The statistical hypothesis tested in this 
study was ‘there is no difference between alcohol and placebo’.
results
Subjects
Subjects participating in the study were on average 22 years old (range: 18 - 39 
years old), had an average weight of 76 kg (range: 56 - 89 kg) and an average 
height of 173 cm (range: 161 - 195 cm). 
One subject dropped out after the first occasion, because of personal rea-
sons. This subject was replaced by another healthy volunteer, who received 
the same order of treatments. Another subject repeated the first occasion, be-
cause this subject turned out not to have slept the night before the occasion, 
despite instructions to maintain a regular diurnal rhythm during the study 
period. All other subjects completed the study according to the protocol.
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Safety
No serious adverse reactions occurred during the study. Frequently reported 
adverse events after alcohol treatment included inebriation, a painful arm at 
the start of the infusion, sleepiness and headache. These symptoms were all 
transient and mild in severity.
Alcohol concentrations
The average brac and bac profiles are presented in figure 1. A pseudo-
steady state level of approximately 0.6 g∙l-1 for both the brac and the bac 
measurements can be observed from the figure. This level was reached 
within approximately 25 minutes after the start of the alcohol infusion and 
was maintained until the end of the infusion at 300 minutes. The intravenous 
loading regimen did not produce an overshoot. The mean brac level during 
the pseudo-steady state phase (i.e. from 25 to 300 minutes) was found to 
be 0.606 g∙l-1 (sd: 0.038 g∙l-1, range: 0.54 - 0.67 g∙l-1), with a coefficient of 
variance (cv) of 6.2%. The mean bac level during this period was 0.628 g∙l-1 
(sd: 0.042 g∙l-1, range: 0.56 - 0.69 g∙L-1) with a cv of 6.7%. The brac curve 
slightly but consistently exceeded the bac curve on the ascending limb of 
the concentration-time figure. In contrast, during the pseudo-steady state 
phase and the descending limb, all parts of the bac curve exceeded the brac 
curve. However the difference was too small in view of the variability to reach 
statistical significance (p = 0.18). Rejection of the null hypothesis would 
have provided support for the possibility that brac and bac results are not 
necessarily identical at the same sampling timepoint.
The applied infusion rates during clamping may serve as an indirect 
parameter for alcohol clearance. This parameter can be used to compare 
alcohol metabolism between certain subgroups. Differences in alcohol 
metabolism between sex and race or changes in alcohol pharmacokinetics 
due to drug-alcohol interactions can be assessed and quantified, using 
infusion rates as a marker. In this study the mean individual infusion rates 
needed to maintain a stable brac during the plateau phase were somewhat 
higher for males than for females (143.5 mL∙hr-1 (sd: 36.1) and 108.3 mL∙hr-1 
(sd: 23.7) respectively), but the difference between men and women did not 
reach significance in this small group (p = 0.08).
cns-pharmacodynamics
Pharmacodynamic test results are summarised in table 1. 
visual analogue scales (vas) Figure 2 shows a significant average 
reduction of 13 mm (95% ci: -20, -6) on the vas alertness after the 
administration of alcohol, compared to placebo. The vas alcohol effects 
increased significantly after alcohol treatment compared to placebo (16 mm 
(95% ci: 7, 25)), as can be observed from figure 3. Both the vas alertness and 
the vas alcohol effects showed variations in effect over time, despite stable 
alcohol levels. vas mood and vas calmness were not significantly affected by 
alcohol.
body sway The body sway results were log-transformed prior to the 
analysis to meet the anova requirements. The results are presented in figure 
4. A significant mean increase in body sway of 21.3% (95% ci: 1.8%, 45%) was 
observed after alcohol treatment compared to placebo. The effects of alcohol 
on body sway appeared to vary despite pseudo-steady state brac levels.
adaptive tracking Alcohol reduced adaptive tracking scores 
significantly by 3.4% (95% ci: -4.5%, -2.2%) compared to placebo. These 
results are presented in figure 5. Tracking scores seemed to fluctuate during 
the plateau phase. The effect of alcohol on adaptive tracking showed a profile 
that was reminiscent of an inverted body sway profile.
smooth pursuit eye movements Alcohol produced a significant 
reduction in percentage smooth pursuit of 9.7% (95% ci: -12.4%, -7.1%) 
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compared to placebo (figure 6). Throughout the plateau phase, average 
smooth pursuit reductions fluctuated between -5.4% and -12.6%, but these 
reductions in smooth pursuit performance remained relatively stable 
throughout the clamp.
saccadic eye movements Saccadic peak velocity seemed to decrease 
somewhat under alcohol treatment, but no significant effects were observed 
on any of the saccadic eye movement outcome parameters.
electroencephalography (eeg) No significant alcohol effects on the 
electroencephalography measurements were observed.
symbol-digit substitution test (sdst) The symbol-digit substitu-
tion test was not significantly affected by alcohol.
Time- and concentration-related changes in cns-effects
Most cns-effects of alcohol (like body sway and vas alcohol effects) 
showed some variations despite stable concentrations, indicating that 
the concentration dependence of these effects varies with time. Other 
parameters (such as smooth pursuit eye movements) remained stable under 
pseudo-steady state conditions.  Since this study was not primarily designed 
as such, no detailed analyses of concentration-effect relationships were 
performed. Formal pharmacokinetic/pharmacodynamic (pk/pd) analyses 
would have required more frequent pharmacodynamic measurements 
during the ascending part of the concentration-time curve, and/or more 
fluctuations at different alcohol levels. With these limitations, these changes 
were examined post hoc in an exploratory fashion, by plotting average alcohol 
levels against the various concomitant average cns-effects to describe pk/
pd relations. The average blood alcohol levels at the times of cns-testing 
were calculated by linear interpolation from adjacent measurements. Figure 
7-10 show the relationships between the average blood alcohol levels and the 
different cns-measurements. The shapes of these time-effect-curves confirm 
the observation that most cns-effects did not remain as stable as the alcohol 
levels during the plateau phase of the alcohol clamp.
discussion 
The alcohol breath clamping method, which is described elsewhere in more 
detail (Zoethout et al., 2008), produced an accurate and stable alcohol serum 
concentration of 0.6 g∙l-1 over a five hour period. The procedure resulted in 
constant alcohol levels, and did not produce any relevant concentration over- 
or undershoot in any individual.  Although the exact cause remains unknown, 
brac curve deviations from the bac curve were observed in this study. This 
phenomenon has already been reported in literature ( Jones and Andersson, 
2003) and is explained by intra- and inter-individual differences in e.g. body 
temperature (Fox and Hayward, 1987; Fox and Hayward, 1989) and breathing 
technique ( Jones, 1982; Mulder and Neuteboom, 1987). These factors change 
the course of the brac profile, leaving the bac profile unaffected. Moreover, 
ethanol is able to induce changes in these physiological factors that may affect 
the brac curve even more. However, we would like to stress that the differ-
ences between the breath and serum estimates were only relatively small.
Authors like Jones ( Jones, 1997) and Ramchandani (Ramchandani et 
al., 2001) clearly describe the effect of food on alcohol metabolic rates. They 
argue that the feeding state influences hepatic blood flow and that this may 
consequently alter hepatic (alcohol) elimination capacity. Although this is a 
widely accepted phenomenon, we do not think that the meal given around 
3.5 hours after the start of the alcohol infusion can explain the declining trend 
in alcohol levels, which can be observed after approximately 150 minutes 
(figure 1). First of all, in our study the apparent clearance, estimated from the 
infusion rates during the plateau phase was not clearly affected by the light, 
standardized meal that we provided to our subjects. But, even if this meal 
would have influenced alcohol metabolic rates, we sincerely doubt whether 
this would have affected the shape of the concentration curve shown in figure 1. 
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The pharmacokinetic feedback mechanism incorporated in the infusion 
paradigm automatically corrects for any change in the system (e.g. a change 
in alcohol metabolism rate) to keep alcohol serum concentrations close to 
their intended target level. In our opinion, any apparent change in alcohol 
metabolic rate would not have affected the concentration curve as presented 
here.
The alcohol clamp resulted in significant changes in body sway, visual 
analogue scales, adaptive tracking and smooth pursuit eye movements. 
These results correspond to literature findings. Effects on postural stability, 
subjective assessments, (visuo-)motor control and oculomotor coordination 
or attention are frequently observed after alcohol administration (van 
Steveninck et al., 1993; van Steveninck et al., 1996). Some of these effects 
fluctuated significantly during the plateau phase, despite relatively constant 
alcohol levels. The causes for these fluctuations are not immediately apparent, 
but there are several possibilities. First, subtle brac/bac-changes during the 
clamp could have resulted in exaggerated response fluctuations. Second, the 
rapid increase of alcohol levels during the loading phase could have caused 
some delay in the development of cns-responses. Third, acute tolerance to 
the effects of alcohol may have ensued during the plateau phase. And fourth, 
some parameters may have exhibited effect thresholds. The different time 
profiles for the various effects indicate that these processes vary between 
cns-effects, and combinations of these processes are also possible. In all, 
this could produce quite complicated relationships between concentrations 
and effects, which cannot be easily investigated with this relatively simple 
clamp, where one alcohol level was achieved rapidly with a loading phase 
that allowed for only a few cns-measurements when alcohol levels changed. 
Consequently, the range of concentrations and concomitant measurements 
was too limited for detailed pk/pd-analyses, which would be necessary to 
dissect the complex concentration-effect relationships that were observed.
With these limitations to a more detailed interpretation, it seems that 
various processes underlie the different time-effect profiles. The body sway 
profile (figure 4) showed a rather sudden increase after pseudo steady state 
levels were reached, followed by an equally fast decrease at the end of the 
plateau phase was. This curve might be explained by a slow development of 
the responses (hysteresis) combined with an acute tolerance to the effects 
of alcohol (proteresis). The initial slow development of the body sway 
impairments could also be due to a threshold effect, but the measurements 
during the loading phase were not frequent enough to allow this conclusion. 
Similar to the body sway responses, tracking performance, vas alertness 
and vas alcohol effects decreased significantly throughout the course of 
the clamp. This may have been due to acute tolerance, or to an exaggerated 
response to a slight decrease in brac brac-levels, which graphically seemed 
to diminish slightly towards the end of the plateau phase of the clamp (figure 
1). Again, the number of assessments over time was not frequent enough to 
allow a distinction between hysteresis, proteresis or threshold effects as an 
explanation for the course of the effects over time for these measurements. 
Other effects like smooth pursuit eye movements remained more constant.
Apparently, time-related changes in alcohol sensitivity differ between 
the various cns-systems that are affected by alcohol. The literature shows 
several attempts to investigate these phenomena. Acute changes in the effects 
of alcohol over time (acute tolerance) have been demonstrated in many 
single-dose studies, but this phenomenon has been questioned for alcohol 
at steady state (Kaplan et al., 1985). Other research showed indications for 
acute tolerance to stable alcohol levels in a small subject sample (Hiltunen 
et al., 2000), but the obtained average alcohol level was less constant than 
the pseudo-steady state concentrations presented here. A few groups were 
able to generate accurate and stable alcohol levels, by clamping the brac 
according to the original O’Connor procedure (O’Connor et al., 1998), 
and reported acute tolerance to constant alcohol levels, particularly for 
subjective measurements (Morzorati et al., 2002; Ramchandani et al., 2002; 
Ramchandani et al., 1999b). However, these findings were based on only two 
measurements throughout the steady state periods. The results presented 
here show acute changes in cns-effects of alcohol at pseudo-steady 
state on multiple functional cns-domains and were based on intensive 
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pharmacodynamic sampling. The causes and practical implications of 
these observations could not be established from this single-level clamping 
experiment. Most pharmacodynamic measurements were obtained at 
relatively stable alcohol concentrations, and hardly any during the increasing 
part of the clamp. Alcohol clamping experiments at several different levels 
or different rates of increase of alcohol concentrations should be performed 
to examine the concentration- and time-effect relationships of alcohol on 
different functional domains. In principle, the alcohol clamp presented here 
could also be used to maintain several different alcohol levels.
Neither the symbol digit substitution test nor the visual analogue scales 
for mood and calmness or the electroencephalography measurements were 
affected by the stable clamp level. Alcohol decreased saccadic peak velocity, 
but not significantly. Other  research did show effects of alcohol on saccadic 
eye movements (Nutt et al., 2007) and electroencephalography (Ehlers et al., 
1999) at higher doses. The clear effects on the visual analogue scale for alcohol 
effects indicate that subjective parameters seem more sensitive to a stable 
alcohol level than objective measurements that reflect alertness indirectly. 
In this respect, the effects of alcohol, which is an indirect gabaa-agonist 
(Santhakumar et al., 2007) differ considerably from those of benzodiazepines, 
for which saccadic peak velocity and eeg beta power are particularly sensitive 
(de Visser et al., 2003).
Although significant cns-changes on multiple domains were observed 
in this study, the artificial pseudo-steady state condition does not resemble 
alcohol consumption in real life. Fluctuations in alcohol levels that occur 
during social drinking, may result in different cns-effects compared to the 
effects at pseudo-steady state, at similar brac levels. Moreover, in contrast to 
the changing pharmacodynamic effects under an experimental pseudo-steady 
condition, acute tolerance in a social drinking situation may be counteracted 
by increases in the oral intake of alcohol, to maintain the desired effect level.
The alcohol clamp has distinct advantages to study the acute effects 
of alcohol. The pseudo-steady state levels with very little inter- and intra-
variability allow the separation of concentration- and time-dependent 
changes in alcohol effects. In the current study, the results show indications 
for a delayed development of the effects of alcohol, followed by an acute 
reduction of the effects relative to the plasma concentrations. Under less 
well controlled circumstances, such observations are often difficult to make 
because of fluctuating alcohol concentrations, although successful efforts 
have been made to by-pass this problem (Martin and Moss, 1993; O’Connor 
et al., 1998; Ramchandani et al., 1999a).
The present study demonstrated that the responsiveness to constant 
alcohol levels changes over time. Concentration-effect modelling would be 
needed to examine these phenomena in more detail, but this would require 
frequent measurements at different levels of alcohol. This could be achieved 
with step-wise increases and decreases of target alcohol levels that can also be 
attained with the alcohol clamp. Such studies are needed to help understand 
the functional and medico-legal implications of alcohol’s concentration-
effect relationships, which apparently are diverse and time-dependent. A time 
component in the risk assessment of blood alcohol concentrations might be 
necessary.
In summary, significant cns-effects were observed during a pseudo-
steady state alcohol serum concentration of 0.6 g∙l-1 for five hours. The 
course of alcohol effects differed among cns-measurements. Indications 
for both hysteresis and acute tolerance were found, but these findings were 
not equally distributed among the performed cns-tests and could not 
completely be confirmed. Some of the questions rising from the current 
exploratory study may be answered by future research (e.g. clamping at 
multiple alcohol levels during one session to facilitate pk-pd modeling, or 
acute tolerance development during pseudo-steady state conditions). Our 
clamping paradigm has not only shown to be a practical and accurate way 
to maintain stable serum levels of alcohol, it has also proved to be a suitable 
method to study the pharmacodynamic cns-effects of constant alcohol 
serum concentrations concomitantly. The clamping procedure might be a 
useful tool in future alcohol interaction studies or in studies investigating the 
complex pharmacodynamic effects of alcohol.
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figure 1 serum and breath alcohol concentr ation 
profiles with their sd’s as error bars
Alcohol was infused between t=0 and t=300 min. The plateau-phase is marked  
by the two vertical lines. The set-point is marked by the horizontal line.
figure 2 ls means gr aph of vas alertness (mm):  
change from baseline with 95% ci error bars
The plateau-phase is marked by the two vertical lines.





































































figure 3 ls means gr aph of vas alcohol effects  
(mm): change from baseline with 95% ci error bars
The plateau-phase is marked by the two vertical lines.
figure 4 ls means gr aph of body sway (mm):  
% change from baseline with 95% ci error bars
The plateau-phase is marked by the two vertical lines.
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figure 5 ls means gr aph of tr acking (%):  
change from baseline with 95% ci error bars
The plateau-phase is marked by the two vertical lines.
figure 6 ls means gr aph of smooth pursuit
Change from baseline with 95% ci error bars. The plateau-phase is marked  
by the two vertical lines.

























































figure 7 explor atory pk/pd relationship between 
aver age serum alcohol and the mean effects on body sway
figure 8 explor atory pk/pd relationship between 
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figure 9 explor atory pk/pd relationship between 
aver age serum alcohol and the mean effects on vas 
alcohol effects
figure 10 explor atory pk/pd relationship between 
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table 1 summary of pharmacodynamic effects of alcohol 
compared to placebo













Saccadic peak velocity 
(deg/s)
433.4 455.4 -22.1 0.2006 ( -58, 13.8)
Saccadic latency (s) 0.228 0.221 0.006 0.2660 (-.01, .019)
Saccadic inaccuracy (%) 9.9 7.4 2.5 0.3272 (-3.0,  8.1)
Smooth pursuit (%) 46.0 55.7 -9.7 <.0001 ( -12.4, -7.1)
SDST number correct 78 81 -3 0.6159 ( -16,   10)
SDST number incorrect 1.2 0.9 0.3 0.0883 (-0.1,  0.6)
Body Sway (mm) 318 263 21.3% 0.0347 (1.8%,  45%)
Tracking (%) 24.3 27.7 -3.4 0.0004 (-4.5, -2.2)
SD of Tracking (%) 3.8 4.1 -0.2 0.3364 (-0.7,  0.3)
vas alertness (mm) 71 84 -13 0.0022 ( -20,   -6)
vas mood (mm) 84 85 -1 0.3396 (  -5,    2)
vas calmness (mm) 83 86 -3 0.1197 (  -6,    1)
vas alcohol effects  (mm) 24 8 16 0.0029 (   7,   25)
eeg Alpha FzCz (μV) 3.203 3.032 5.6% 0.1572 ( -3%,  15%)
eeg Alpha PzOz (μV) 5.668 5.618 0.9% 0.8501 ( -9%,  12%)
eeg Beta FzCz (μV) 1.745 1.673 4.3% 0.3085 ( -5%,  14%)
eeg Beta PzOz (μV) 2.087 2.145 -2.7% 0.5180 (-11%, 6.7%)
eeg Delta FzCz (μV) 2.404 2.479 -3.0% 0.4986 (-12%, 7.1%)
eeg Delta PzOz (μV) 2.354 2.200 7.0% 0.1029 ( -2%,  16%)
eeg Theta FzCz (μV) 2.996 2.819 6.3% 0.1941 ( -4%,  17%)
eeg Theta PzOz (μV) 3.129 2.946 6.2% 0.3679 ( -8%,  23%)
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A comparison of the central nervous system 
effects of alcohol at pseudo-steady state in 
Caucasian and expatriate Japanese healthy 
male volunteers
Manuscript submitted for publication (Alcohol)
 
R.W.M. Zoethout, M.L. de Kam, A. Dahan, A.F. Cohen,J.M.A. van Gerven
applications of alcohol clamping in early drug development
– 102 –




In general, Japanese and Caucasians differ in their response to alcohol. To 
investigate these differences the alcohol clamping method can be used. This 
strictly controlled infusion regimen provides a reliable tool to study contrasts 
in central nervous system (cns) effects and/or alcohol disposition. In this 
study twelve Japanese and twelve Caucasian healthy volunteers received two 
concentrations of intravenous alcohol or placebo using the alcohol clamp. 
Infusion rates during the steady state phase were used to compare alcohol 
clearance between the subgroups. Central nervous system (cns) effects were 
frequently measured throughout the clamp. On average, significantly lower 
amounts of alcohol were needed to maintain similar stable concentrations 
in the Japanese group However, these differences disappeared when values 
were corrected for lean body mass. The most pronounced pharmacodynamic 
differences between the groups were observed on body sway and on the visual 
analogue scale (vas) for subjective alcohol effects, mainly at the highest dose 
level. The alcohol clamp seems a useful method to compare differences in 
alcohol metabolism between groups. Some cns-effects of alcohol differed 
clearly between Japanese and Caucasians, but others did not, even though 
alcohol levels were stable and similar between the two groups.
introduction 
Japanese people are more sensitive to alcohol compared to Caucasians 
(Shibuya et al., 1989). This is at least partly related to genetic differences 
in pharmacokinetics, since a high proportion of Japanese have a relative 
deficiency for alcohol dehydrogenase (adh) and/or aldehyde dehydro- 
genase (aldh) causing higher blood levels of alcohol and/or acetaldehyde 
(Chan, 1986). Differences in body size and in lifestyle (food, use of medi- 
cation) may further influence the kinetics of alcohol (Duranceaux et al., 
2008). Repeated exposure to alcohol may also induce tolerance to its effects 
(Bennett et al., 1993), and avoidance could therefore contribute to increased 
sensitivity. It is less clear however, whether Japanese and Caucasian subjects 
differ in their sensitivity to the various central nervous system (cns) effects 
of alcohol. 
To determine the effects of alcohol or to assess alcohol-drug interactions, 
it is helpful to maintain alcohol plasma concentration at reasonably steady 
state levels, since most of the effects of alcohol are concentration- and time-
dependent. In an earlier study, stable breath alcohol concentrations (brac) 
were maintained for hours, using a breath alcohol clamping paradigm 
in a Caucasian population, with different body postures and metabolic 
profiles (Zoethout et al., 2008). Since this clamping method is based on 
the feedback of individual alcohol concentrations, it is likely that the clamp 
will also be able to overcome major differences in alcohol kinetics between 
certain ethnic subgroups, with potentially distinct metabolic activities or 
body compositions. In this way, alcohol elimination rates can be compared 
relatively easily. Moreover, ethnic differences in pharmacodynamic effects of 
alcohol can be accurately compared using the alcohol clamp, since alcohol 
levels are kept at comparable levels. 
To investigate differences in cns drug effects a transportable cns 
measurement battery used for on site assessment of drug effects was used. 
This has been used in numerous studies with different kinds of cns drugs 
at the Centre for Human Drug Research (chdr) (de Haas et al., 2006; de 
Visser et al., 2001; van der Post et al., 2004), including alcohol (Zoethout 
et al., 2009). The Neurocart consists of a series of measurements that were 
chosen for their frequent repeatability, low variability, and their sensitivity to 
a wide range of drug-induced cns-effects. Elements of the Neurocart have 
previously also been used in a comparative study of the effects of nitrazepam 
in Caucasians and Japanese (van Gerven et al., 1998).
In the current study, the pharmacokinetic and cns-pharmacodynamic 
effects of two levels of alcohol were examined and compared between healthy 
Japanese and Caucasian volunteers, using the multimodal cns-test battery 
and an intravenous alcohol clamp.
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This was a randomised, double-blind, placebo-controlled, three-way cross-
over study with a washout period of two weeks, in which the effects of two 
levels of alcohol and placebo were examined in healthy Caucasian and 
Japanese male volunteers.
Subjects
Twelve healthy Caucasian male subjects and twelve healthy Japanese males 
(expatriates living in the Netherlands), aged 18-40 years, gave their oral and 
written informed consent after approval of the study protocol by the Medical 
Ethics Review Board of the Leiden University Medical Centre (lumc). 
Before inclusion, subjects were screened for general health by medical history 
and physical examination and participated in a pharmacodynamic training 
session. Subjects who used more than four units of alcohol per day on average 
were excluded from study participation. 
All subjects were familiar with the effects of alcohol and were instructed 
not to use more than two alcohol consumptions a day, for at least two days 
prior to the study occasions. Twelve hours prior to each study start, the use of 
alcohol was prohibited. 
General procedure
Subjects reported at the chdr at 08:00hr in the morning of the test day in 
fasted condition, after which a short introduction was given. Two intravenous 
cannulae (one cannula for blood sampling and another for infusion of 
ethanol or placebo) were inserted and electroencephalography- (eeg) and 
eye-electrodes were mounted. Before the start of the infusion subjects were 
provided with a light breakfast. The alcohol infusion started between 09:30hr 
and 10:00hr and ended five hours later, followed by an infusion-free washout 
period of three hours. Blood alcohol samples, breath alcohol measurements 
and pharmacodynamic measurements were obtained at regular time 
intervals indicated below, until eight hours after the start of the infusion. A 
standardised lunch was given at around 3.5 hours post-dose. Subjects were 
taken home by taxi, after dinner. 
Alcohol clamping method 
Ethanol 10% w/v solution in 5% glucose (for the 0.6 g∙l-1 occasion), ethanol 
5% w/v solution in 5% glucose (for the 0.3 g∙l-1 occasion) and glucose 5% 
(placebo) were administered intravenously on three different occasions, 
according to the study design previously mentioned. Ethanol 5% and ethanol 
10% were used to achieve alcohol levels of 0.3 and 0.6 g∙l-1, respectively. 
Glucose 5% was used during placebo sessions. A parallel glucose infusion 
(glucose 5%) was administered to all subjects during the first ten minutes post-
start, to prevent pain or discomfort in the infusion arm that might be caused 
by the high-flow alcohol infusion during the loading phase. The infusion rates 
for the first and the second five minutes were determined individually for each 
subject (before the start of the infusion), based on demographic data (weight, 
height, age and gender) and on the target level (0.3 or 0.6 g∙l-1) to avoid 
overshoots, using Watson’s estimates of body water (Watson et al., 1981). After 
the loading phase, infusion rates during the plateau were adapted to brac 
changes to maintain one of the two predefined pseudo-steady state levels, 
according to a recently introduced spreadsheet-based infusion paradigm that 
was adapted from a method originally described by O’Connor (O’Connor 
et al., 1998). This method resulted in stable alcohol levels for hours and is 
described in more detail elsewhere (Zoethout et al., 2008). Infusion rates 
were adapted to brac changes, based on measurements obtained at 10, 15, 20, 
25, 30, 40, 50, 60, 90, 120, 150, 180, 210, 240, 270 and 300 min post-dose, when 
the infusion was stopped. Additional brac levels were determined at 330, 360, 
390, 420, 450 and 480 minutes. At the same times, samples for measurements 
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of blood alcohol concentrations were obtained, which were processed and 
analyzed according to methods described previously (Zoethout et al., 2009). 
Unfortunately, we were unable to set up reliable acetaldehyde measurements 
or to determine aldehyde dehydrogenase polymorphisms.
brac measurements were performed with a hand-held Alco-Sensor iv 
meter (Honac, Apeldoorn, the Netherlands), which had a lower limit of 
quantification (llq ) of 0.01 g∙l-1. The brac was entered into a spreadsheet, 
which calculated the infusion rate predicted to maintain or reach a brac-level 
at 0.6 g∙l-1 or at 0.3 g∙l-1. Because sampling intervals shorter than five minutes 
(as required during the initial part of the infusion) cause the brac meter to 
show fatigue, two different devices were alternated. A pilot study showed that 
no fatigue was observed during alternation of both brac devices according to 
the sampling scheme of the study. Both brac devices were calibrated prior to 
the start of the study. A research assistant, who was not involved in any other 
activity was made responsible for the brac measurements and the execution 
of the clamp (or the sham procedure during placebo administration), to 
maintain blinding of the study participant and the research team members 
throughout the study. 
cns-pharmacodynamics
The following tests were performed twice at baseline, and repeated hourly 
during the plateau and washout phases in a quiet room with ambient 
illumination, in the following order:
body sway The body sway meter allows the determination of body 
movements in a single plane, providing a measure of postural stability. Body 
sway was measured with an apparatus similar to the Wright ataxia meter 
(Wright, 1971). With a string attached to the waist, all body movements over 
a period of two minutes were integrated and expressed as millimeter (mm) 
sway on a digital display. Measurements were performed with closed eyes.
visual analogue scales (vas) Visual analogue scales as originally 
described by Norris (Norris, 1971) have been used previously to quantify 
subjective effects of a variety of sedative agents (van Steveninck et al., 1996; 
van Steveninck et al., 1991; van Steveninck et al., 1999; van Steveninck et al., 
1993). From these measurements, three factors were derived as described 
by Bond and Lader (Bond and lader, 1974), corresponding to alertness, 
mood and calmness. The Bond and Lader vas have been extensively used at 
chdr and were performed electronically and according to chdr standard 
operating procedures. In addition, to this vas-list a separate 100 mm-line 
was added, asking the subject to indicate ‘how large is the effect of alcohol 
that you feel?’ (vas alcohol effects). Both Japanese and Dutch versions were 
available and all subjects completed the scales in their own native language. 
The Japanese version was tested and validated prior to the start of the study, 
to avoid semantic issues.
adaptive tracking Adaptive tracking is a pursuit tracking task. A circle 
moves randomly on a computer screen. The subject must try to keep a dot 
inside the moving circle by operating a joystick. If this effort is successful, 
the speed of the moving circle increases. Conversely, the velocity is reduced 
if the subject cannot maintain the dot inside the circle. Performance was 
scored after a fixed period. Each test is preceded by a run-in period. After 
4 to 6 practice sessions, learning effects are limited. The adaptive tracking 
test is more sensitive to impairment of eye-hand coordination and vigilance 
by drugs than compensatory pursuit tasks or other pursuit tracking tasks, 
such as the pursuit rotor. The adaptive tracking test has proved to be useful 
for measurement of cns effects of alcohol, various psychoactive drugs and 
sleep deprivation (van Steveninck et al., 1991; van Steveninck et al., 1999). The 
adaptive tracking test was performed as originally described by Borland and 
Nicholson (Borland and Nicholson, 1984), using customised equipment and 
software (Hobbs, 2000, Hertfordshire, uk). The average performance and the 
standard deviation of scores over a 3.5 minutes period were used for analysis.
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saccadic eye movements Saccadic peak velocity is one of the most sen-
sitive parameters for sedation (van Steveninck et al., 1996; van Steveninck et 
al., 1991; van Steveninck et al., 1999; van Steveninck et al., 1993). Recording 
and analysis of saccadic eye movements was conducted with a microcom-
puter-based system for sampling and analysis of eye movements. The equip-
ment used for stimulus display, signal collection and amplification was from 
Nihon Kohden (Nihon Kohden Corporation, Tokyo, Japan). Disposable 
silver-silver chloride electrodes (Medicotest n-oo-s, Olstykke, Denmark) 
were applied on the forehead and beside the lateral canthi of both eyes of the 
subject for registration of the electro-oculographic signals. Skin resistance 
was reduced to less than 5 kOhm before application of the electrodes. Head 
movements were restrained using a fixed head support. The target consisted 
of an array of light emitting diodes on a bar, fixed at 50 cm in front of the head 
support. Saccadic eye movements were recorded for stimulus amplitudes of 
approximately 15 degrees to either side. Fifteen saccades were recorded with 
interstimulus intervals varying randomly between 3 and 6 seconds. Average 
values of latency (reaction time), saccadic peak velocity and inaccuracy of all 
artefact-free saccades were used as parameters. Saccadic inaccuracy was cal-
culated as the absolute value of the difference between the stimulus angle and 
the corresponding saccade, expressed as a percentage of the stimulus angle.
smooth pursuit eye movements The same system as used for 
saccadic eye movements was also used for measurement of smooth pursuit. 
For smooth pursuit eye movements, the target moved sinusoidally at 
frequencies ranging from 0.3 to 1.1 Hz, by steps of 0.1 Hz. The amplitude of 
target displacement corresponded to 20 degrees eyeball rotation to both 
sides. Four cycles were recorded for each stimulus frequency. The time in 
which the eyes were in smooth pursuit of the target was calculated for each 
frequency and expressed as a percentage of stimulus duration. The average 
percentage of smooth pursuit for all stimulus frequencies was used as 
parameter. Prior studies show that this parameter can be used as an accurate 
biomarker for oculomotor function and attention (Lehtinen et al., 1982). The 
method has been validated earlier (van Steveninck et al., 1989) based on the 
work of Bittencourt et al. (Bittencourt et al., 1983) and the original description 
of Baloh et al. (Baloh et al., 1975).
pharmaco-electroencephalography (pheeg) pheeg was used to 
monitor any drug effects, which can be interpreted as evidence of penetra-
tion and activity in the brain (van Steveninck et al., 1993; Cohen et al., 1985). 
Electroencephalography (eeg) provides non-specific measures of cns func-
tions. eeg recordings were obtained at times specified in the study flow chart. 
eeg recordings were made using gold electrodes, fixed with ec2 paste (As-
tromed) at Fz, Cz, Pz and Oz, with the same common ground electrode as for 
the eye movement registration (international 10/20 system). The electrode 
resistances were kept below 5 kOhm. eeg signals were obtained from leads 
Fz-Cz and Pz-Oz and a separate channel to record eye movements (for ar-
tefacts). The signal was amplified by use of a Grass 15lt series Amplifier Sys-
tems with a time constant of 0.3 seconds and a low pass filter at 100 Hz. Data 
collection and analysis was performed using customized ced and Spike2 for 
Windows software (Cambridge Electronics Design, Cambridge, uk). Per ses-
sion eight consecutive blocks of eight seconds were recorded. The signal was 
ad-converted using a ced 1401 Power (Cambridge Electronics Design, Cam-
bridge, uk) and stored on hard disk for subsequent analysis. Data blocks con-
taining artefacts were identified by visual inspection and these were excluded 
from analysis. For each lead, fast Fourier transform analysis was performed 
to obtain the sum of amplitudes in the delta- (0.5-3.5 Hz), theta (3.5-7.5 Hz), 
alpha- (7.5-11.5 Hz) and beta- (11.5-30 Hz) frequency ranges. The duration of 
eeg measurements was 64 seconds per session.
Statistical analysis
The pharmacodynamic endpoints were analyzed by a mixed model analyses 
of variance (using sas proc mixed) with treatment, group, period, time, 
treatment by time, treatment by group and treatment by time by group as 
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fixed effects and  subject, subject by treatment and subject by time as random 
effects and the average baseline value was included as covariate. Body sway 
and eeg values were log-transformed prior to analysis to correct for the 
expected log-normal distribution of the data. Least square means (lsm) were 
obtained and were used to compare the effects of alcohol on the different 
pharmacodynamic parameters. All calculations were performed using sas 
for windows v9.1.2 (sas Institute, Inc., Cary, nc, usa).
results
Subjects
Twelve healthy Caucasian subjects were included in the study and completed 
the study per protocol. Eleven Japanese subjects completed the study 
per protocol. One Japanese subject had to unexpectedly return to Japan 
for personal reasons, and hence did not complete his third occasion. The 
complete data of eleven Japanese subjects and the two completed occasions 
of the Japanese dropout were included in the analysis. 
Caucasian subjects participating in the study were on average 26 years old 
(range: 18 - 39 years old), had a weight of 85 kg (range: 63 - 103 kg) and an 
average height of 186 cm (range: 178 - 197 cm). On average, they used 1.75 units 
(range 1 - 3 units) of alcohol per day. Japanese subjects were on average 28 
years old (range: 20 - 34 years old), weighed 67 kg (range: 56 - 94 kg) and 
had a height of 174 cm (range: 164 - 182 cm). The Japanese habitually used 
somewhat less alcohol than the Caucasians (1.33 units (range 0-4) per day), 
but the difference was not significant (p=0.283).
Adverse events
No serious adverse reactions occurred during the study. Signs of poor alcohol 
tolerability or intoxication (i.e. nausea and vomiting, rashes and heavy 
perspiration) only occurred in the Japanese subpopulation and were more 
frequently observed at the highest ethanol level (0.6 g∙l-1). All symptoms 
were transient and mild to moderate in severity. An overview of all the 
adverse events observed after alcohol treatment is presented in table 2.
Alcohol concentrations
Average brac profiles of both Caucasian and Japanese volunteers for both 
target levels are shown in figure 1. Pseudo-steady state alcohol concentrations 
were obtained for both ethnic subgroups at both target levels. The set-points 
were achieved within approximately 30 minutes after the start of the infusion. 
Following a minor overshoot, pseudo-steady state levels can be observed 
throughout the infusion from 30 – 300 minutes. After the alcohol infusion 
was stopped, brac levels returned to baseline. No clinically meaningful 
differences between the brac profiles of the two groups were observed, at 
both the 0.3 g∙l-1 level (0.003 g∙l-1 (95% ci: -0.01, 0.01)) and the 0.6 g∙l-1 level 
(0.012 g∙l-1 (95% ci: -0.01, 0.03)).
Alcohol disposition
During the loading phase, alcohol infusion rates were based on 
anthropometric estimates of body water (Watson et al., 1981). They were 
hence closely correlated with age, height and weight and on average lower 
in the Japanese subjects than in the larger Caucasians. The total amount of 
alcohol infused during the steady state plateau phase may serve as an indirect 
parameter for alcohol clearance, which is expected to be also related to 
metabolic differences. The mean infusion rates required to maintain both 
set-points per subgroup are presented in figure 2. For both levels, lower rates 
are required to maintain pseudo-steady state concentrations in Japanese 
compared to Caucasians (since the Japanese curves are entirely located 
below the Caucasian curves). Japanese required 35.9 g of alcohol on average 
to maintain the 0.3 set-point for 5 hours, compared to 46.8 g in Caucasians 
(p < 0.00008). However, when these values were corrected for lean body 
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mass, according to a formula described by Hallynck (Hallynck et al., 1981), 
this difference was no longer significant (p = 0.14). Japanese required 50.1 g of 
alcohol to maintain the 0.6 set-point for 5 hours, which differed significantly 
from the larger amount of 62.5 g needed in Caucasians (p = 0.0011). This 
difference was also abolished after correction for lean body mass (p = 0.73).
cns pharmacodynamics
visual analogue scales (vas) The vas results are graphically 
presented in figure 3 and 4. The only significant effect in the Caucasian 
subgroup was a significant increase of vas alcohol effects at the highest dose 
level (i.e. 11.9 mm (95% ci: 0.6, 23.2) compared to placebo). For the Japanese 
volunteers, both a reduction in alertness during clamping at 0.6 g∙l-1 (10.7 
mm (95% ci: -15.9, -5.4)) and an increase in subjective alcohol effects on both 
alcohol levels were found (13.9 mm (95% ci: 2.4, 25.4) at 0.3 g∙l-1 and 43.0 
mm (95% ci: 31.4, 54.6) during the 0.6 g∙l-1 session). Despite similar brac 
levels of 0.6 g∙l-1, Japanese volunteers rated their alertness on average 5.9 mm 
(95% ci: -11.2, -0.6) lower than Caucasian volunteers. Also, Japanese subjects 
rated themselves 30.6 mm (95% ci: 17.0, 44.2) ‘more drunk’ compared to the 
Caucasians.
body sway The body sway results are presented in figure 5. Neither 
treatment caused significant effects on the body sway in the Caucasian 
group. However, in the Japanese group, body sway measurements increased 
46.5% (95% confidence interval (ci): 25.7, 70.7) during clamping at 0.6 g∙l-
1 compared to placebo. No significant differences from placebo or between 
ethnic groups were observed during the 0.3 g∙l-1 level. The difference between 
Caucasian and Japanese subjects was significant at the 0.6 g∙l-1 level. Japanese 
had 51.2% (95% ci: 17.7, 94.2) higher scores than Caucasians
adaptive tracking The results of the adaptive tracking task are 
presented in figure 6. Reduced scores were only found under high alcohol 
doses for both populations (-2.7% (95% ci: -4.4, -1.0) and -3.1% (95% ci: -4.9, 
-1.4) for the Caucasians and the Japanese, respectively). There were no ethnic 
differences.
saccadic eye movements The only significant effect in the Caucasian 
group was found during clamping at 0.6 g∙l-1. At this level, peak velocity was 
decreased by 20.9 deg/s (95% ci: -33.7, -8.2) compared to placebo (figure 7). 
In the Japanese group, neither alcohol level showed effects on saccadic eye 
movements. There were no significant differences between the two groups.
smooth pursuit eye movements In Caucasians, smooth pursuit 
decreased after the low alcohol dose compared to placebo (-3.9% (95% ci: 
-7.5, -0.2)), and even more during clamping at the higher level (-11.1 (95% 
ci: -14.8, -7.5)). The Japanese volunteers were only significantly impaired 
at the higher alcohol level (-6.0% (95% ci: -9.8, -2.3)). Furthermore, 
at the low alcohol dose, the Caucasian volunteers were on average 
5.0% (95% ci: -9.8, -0.3) more impaired on this test compared to the 
Japanese volunteers. No differences between the groups were observed 
at the higher clamp level. All these effects are presented in figure 8. 
pharmaco-eeg The only (minor) eeg-effect found in the Caucasian 
group was a decrease in eeg delta (Fz-Cz) of 10.3% (95% ci: -19.2, -0.5) at the 
0.6 level, compared to placebo. Some other eeg-changes were found in Japa-
nese, which showed an increase in eeg beta (Fz-Cz) at the 0.3 level (12.3% 
(95% ci: 2.2, 23.5)) and an increase in eeg theta (Pz-Oz) at the 0.6 level (13.1% 
(95% ci: 2.5, 24.8), compared to placebo. This eeg theta increase in Japanese 
was 19.8% (95% ci: 0.1, 43.5) larger than in Caucasians. No other eeg-effects 
were found. Pharmacodynamic test results are summarized in table 1. 
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Our study indicated that Japanese were more sensitive to the subjective 
effects of alcohol compared to Caucasians, who seemed to be subjectively 
more resilient. Somewhat unexpectedly, strictly regulated alcohol levels did 
not cause much more pronounced objective impairments in Japanese than 
in Caucasians. There were some differences between the two populations 
in eeg changes (where a bit more slowing in Japanese was found) and in 
smooth pursuit (which were somewhat more impaired in Caucasians), but 
these effects do not signify major ethnic differences. The adaptive tracking 
effects were in fact quite consistent. Apart from the much larger subjective 
effects of alcohol, the Japanese only showed a considerably larger impairment 
of body sway at the 0.6 g∙l-1 level. 
These pharmacodynamic differences between Japanese and Caucasians 
cannot be explained by differences in concentration, since comparable 
alcohol levels were obtained. The small disparity in habitual alcohol exposure 
(on average 1.33 vs 1.75 units per day, respectively) is also an inadequate 
explanation for the variations in sensitivity. The fact that subjective effects 
were more pronounced in Japanese could be related to cultural differences, 
for instance in the acceptability of alcohol effects or the expression of feelings 
of inebriation; or even to linguistic differences in the interpretation of visual 
analogue scales (van Gerven et al., 1998). It is also important to realize that 
lifestyle differences (food, repeated exposure to alcohol) between indigenous 
and expatriate Japanese are known to influence the kinetics of alcohol 
(Duranceaux et al., 2008).
Acetaldehyde may also have played a role, particularly for differences in 
body sway effects. Many of the observed side-effects in Japanese (headache, 
dizziness, nausea, vomiting) were compatible with higher serum concentra-
tions of acetaldehyde in this population (Eriksson, 2001). Accumulating acet-
aldehyde levels may not only have accounted for the observed adverse events, 
but may also have directly caused some of the cns-differences, notably on 
postural imbalance. This would also explain the gradual increase of postural 
instability during the plateau phase of the ethanol clamp (figure 5). Contrary 
to the fairly stable elevations of most other pharmacodynamic parameters 
that roughly followed the brac timeprofile, average body sway increased 
from 515 mm one hour after the start of the infusion to 727 mm two hours 
later (figure 5). A delayed development of postural imbalance was also found 
in a previous alcohol clamping study in Caucasian subjects (Zoethout et al., 
2009). Clearly, determination of the concentration profiles of alcohol and ac-
etaldehyde and their relationships to the different pharmacodynamic param-
eters is needed to show which effects are related to alcohol and which to the 
metabolite or both. Unfortunately, we were unable to measure acetaldehyde 
concentrations or aldehyde-dehydrogenase polymorphisms in this study. 
However, table 2 suggests that approximately 25% of the Japanese population 
suffered from high acetaldehyde levels.
Our findings show that the subjective alcohol scale was a very sensitive 
tool to detect alcohol effects in both Caucasians and Japanese subjects. This is 
confirmed by earlier literature findings (Zoethout et al., 2010). The vas alco-
hol effects seemed to be even more responsive in Japanese, because effects on 
this scale were not only found at the highest alcohol level (like with the Cau-
casians), but also with the lowest dose. In Japanese, the subjective alcohol ef-
fect scale was the only measurement that was affected by both alcohol levels.
There were clear ethnic distinctions between the postural and subjective 
effects of alcohol, but it is perhaps more surprising that we found only a few 
other and relatively small pharmacodynamic differences between the two 
groups. In Caucasians, only smooth pursuit eye movements were affected by 
both alcohol levels. Smooth pursuit performance was reduced at doses that 
did not result in any subjective effects, and this test can therefore be consid-
ered as the most sensitive test to detect alcohol effects in Caucasians in this 
setup. In Japanese, smooth pursuit performance was only significantly affect-
ed by the highest alcohol dose.
Postural stability was not significantly influenced by ethanol in the Cau-
casian volunteers. This differs from other research groups that demonstrated 
effects of ethanol on body sway at comparable doses ( Jones, 1993; Martin 
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et al., 1981; Lukas et al., 1989; Zoethout et al., 2009; Zoethout et al., 2010). In 
contrast, body sway did show pronounced effects in Japanese, but mainly at 
the highest dose level. Body sway was somewhat less sensitive to alcohol than 
subjective alcohol scales in Japanese or smooth pursuit performance in Cau-
casians, which both showed significant effects at the 0.3 g∙l-1 level. Adaptive 
tracking showed a similar sensitivity i.e. only to the higher alcohol level in 
both ethnic groups. This finding is in accordance with prior research.
In the Caucasian group, we found no reductions of vas alertness but 
significant decreases of saccadic eye movements. Subjective scores of 
alertness and (even more so) saccadic eye movements are both described as 
sensitive biomarkers for the sedative effects of benzodiazepines (de Visser 
et al., 2003). Nonetheless, ethanol (as an indirect non-competitive agonist 
at the gaba a-receptor (Santhakumar et al., 2007)) only affected the eye 
movements in this study. In Caucasians, saccadic eye movements thus seem 
more sensitive to ethanol level than subjective measurements of alertness. In 
contrast, the (non-significant) impairment in saccadic eye movements in the 
Japanese group was confirmed by effects on the vas alertness.
In Japanese some small eeg effects were observed (i.e. an increase in eeg 
Theta) that were in line with the sedative effects observed with other tests. 
However eeg does not seem to be a very specific biomarker for the effects of 
other sedative drugs (e.g. neuroleptics (de Visser et al., 2001) or cannabinoids 
(Zuurman et al., 2009)). The only eeg effect in Caucasians was a decrease in 
delta waves.
Besides these pharmacodynamic effects and differences, this study shows 
that constant alcohol concentrations could be maintained for several hours at 
two different levels in both Japanese and Caucasian healthy male volunteers, 
using the alcohol clamping paradigm. The alcohol clamping method allows 
frequent measurements of cns-effects concomitantly and serves as an ideal 
procedure to compare different (ethnic) groups in their alcohol clearance 
abilities as well as in their individual cns responses to stable levels of alcohol.
In summary, we found considerable subjective differences in the effects 
of alcohol between Japanese and Caucasians, at levels that were stable and 
similar between the two groups. Japanese also developed significantly more 
postural instability than Caucasian healthy volunteers. We hypothesize that 
acetaldehyde might play a role in these differences. Other pharmacodynamic 
measurements like adaptive tracking and eye movements did not differ 
quite as much between the two groups, which could be an indication that 
some cns-functions are influenced more by alcohol itself than by its major 
metabolite. More research is required to confirm this hypothesis.
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figure 1  breath alcohol concentr ation profiles 
With standard deviations (sd) as error bars. Square: ethanol 0.3 g·l-1;   
triangle: ethanol 0.6 g·l-1; open symbols: Caucasians; closed symbols: Japanese. 
figure 2  mean infusion r ates per subgroup per dose level
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figure 3  least square means of vas alcohol effects  
Change from baseline with 95% confidence intervals (ci) as error bars.  
Circle: placebo; square: ethanol 0.3 g·l-1; triangle: ethanol 0.6 g·l-1;  
open symbols: Caucasians; closed symbols: Japanese.
figure 4  least square means of vas alertness
Change from baseline with 95% confidence intervals (ci) as error bars.  
Circle: placebo; square: ethanol 0.3 g·l-1; triangle: ethanol 0.6 g·l-1;  
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figure 5 least square means of body sway 
Change from baseline with 95% confidence intervals (ci) as error bars. 
Circle: placebo; square: ethanol 0.3 g·l-1; triangle: ethanol 0.6 g·l-1;  
open symbols: Caucasians; closed symbols: Japanese.
figure 6 least square means of adaptive tr acking  
Change from baseline with 95% confidence intervals (ci) as error bars.
Circle: placebo; square: ethanol 0.3 g·l-1; triangle: ethanol 0.6 g·l-1;  
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figure 7 least square means of saccadic peak velocity  
in degrees per second
Change from baseline with 95% confidence intervals (ci) as error bars.  
Circle: placebo; square: ethanol 0.3 g·l-1; triangle: ethanol 0.6 g·l-1;  
open symbols: Caucasians; closed symbols: Japanese.
figure 8 least square means of smooth pursuit eye 
movements  
Change from baseline with 95% confidence intervals (ci) as error bars.
Circle: placebo; square: ethanol 0.3 g·l-1; triangle: ethanol 0.6 g·l-1;  
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table 2 adverse events after ethanol treatment
* Nausea and vomiting , rashes and heavy perspiration 
0.3 g∙L-1 Japanese Caucasians
Inebriation 7 (58%) 5 (42%)
Sleepiness 5 (42%) 4 (33%)
Dizziness 3 (25%) 2 (17%)
Headache 3 (25%) 0 (0%)
Poor alcohol tolerability* 1 (8%) 0 (0%)
0.6 g∙L-1 Japanese Caucasians
Inebriation 9 (75%) 6 (50%)
Painful infusion 5 (42%) 6 (50%)
Sleepiness 5 (42%) 3 (25%)
Dizziness 3 (25%) 3 (25%)
Poor alcohol tolerability* 3 (25%) 0 (0%)
Dry mouth 0 (0%) 3 (25%)
Headache 2 (17%) 0 (0%)
Feeling hot 2 (17%) 0 (0%)
table 1 contr asts between treatments and subgroups  
for each pharmacodynamic par ameter

























Body sway (%) 4.1 (-10.2, 20.7) 11.1 (-4.3, 29.0) 12.8 (-2.7, 30.9) 46.5 (25.7, 70.7) 24.3 (-2.7, 58.7) 51.2 (17.7, 94.2)
Saccadic Inaccuracy (%) -0.2 (-0.8, 0.3) -0.0 (-0.6, 0.5) 0.2 (-0.3,  0.8) -0.5 (-1.2, 0.1) 0.5 (-0.5, 1.4) -0.5 (-1.5, 0.4)
Saccadic Peak Velocity 
(deg/sec)
-9.3 (-22.1, 3.5) -20.9 (-33.7, -8.2) -1.6 (-14.4, 11.2) -10.7 (-24.0, 2.6) -9.6 (-28.8, 9.5) -7.2 (-27.3, 13.0)
Saccadic Reaction  
Time (msec)
0.9 (-5.9, 7.7) 2.2 (-4.6, 9.0) 7.7 (0.9, 14.5) 12.9 (5.7, 20.1) 1.0 (-12.3, 14.4) 4.9 (-8.6, 18.4)
Smooth pursuit (%)  -3.9 (-7.5, -0.2) -11.1 (-14.8,  -7.5) -3.2 (-6.9, 0.4) -6.0 (-9.8, -2.3) -5.0 (-9.8, -0.3) -0.6 (-5.4, 4.1)
Adaptive tracking (%) -1.3 (-3.0, 0.4) -2.7 (-4.4, -1.0) -1.39 (-3.1, 0.3) -3.1 (-4.9, -1.4) -1.2 (-3.9, 1.4) -1.6 (-4.3, 1.1)
vas Alcohol effects (mm)   8.6 (-2.7, 19.9)  11.9 (0.6, 23.2)  13.9 (2.4, 25.4)  43.0 (31.4, 54.6)   4.8 (-8.5, 18.1)  30.6 (17.0, 44.2)
vas Alertness (mm) -4.8 (-9.9, 0.3) -3.5 (-8.6, 1.7) -4.2 (-9.4, 0.9) -10.7 (-15.9, -5.4) 1.9 (-3.3, 7.1) -5.9 (-11.2, -0.6)
vas Calmness (mm)   1.5 (-5.7, 8.7) 3.1 (-4.1, 10.3) 6.4 (-0.9, 13.6) 1.1 (-6.2, 8.5) 6.2 (-0.9, 13.3) -0.7 (-7.9, 6.6)
vas Mood (mm)  -0.0 (-4.7, 4.7) 0.8 (-4.0, 5.5) 0.1(-4.6, 4.9) -3.5 (-8.3, 1.4) 1.0 (-3.5, 5.5) -3.3 (-7.9, 1.3)
eeg Alpha Fz-Cz (μV)  1.5 (-9.2, 13.5) 2.9 (-8.0, 15.1) -0.3 (-10.8, 11.6) 1.4 (-9.6, 13.8) -5.2 (-16.1, 7.2) -4.9 (-16.1, 7.8)
eeg Alpha Pz-Oz (μV) -1.3 (-11.9, 10.7) 2.8 (-8.3, 15.3) -6.4 (-16.4, 5.0) 3.0 (-8.7, 16.3) -7.6 (-33.7, 28.8) -2.4 (-30.1, 36.3)
eeg Beta Fz-Cz (μV)  1.4 (-7.7, 11.5) -2.4 (-11.2,  7.3) 12.3 (2.2, 23.5) 2.8 (-6.7, 13.3) 2.6 (-7.0, 13.1) -2.5 (-11.8,  7.8)
eeg Beta Pz-Oz (μV) -4.1 (-13.4,  6.3) -0.8 (-10.4, 10.0) -3.7 (-13.1, 6.7) 7.4 (-3.5, 19.5) 3.3 (-14.5, 24.9) 11.4 (-8.1, 34.9)
eeg Delta Fz-Cz (μV) -6.7 (-15.9, 3.5) -10.3 (-19.2, -0.5) 3.9 (-6.4, 15.4) -1.3 (-11.3, 9.9) 9.4 (-2.3, 22.4) 8.1 (-3.7, 21.4)
eeg Delta Pz-Oz (μV) -2.7 (-11.0,  6.3) -1.2 (-9.5, 8.0)  1.1 (-7.4, 10.5)  3.4 (-5.7, 13.4) 13.2 (-2.5, 31.3) 13.9 (-2.0, 32.4)
eeg Theta Fz-Cz (μV)  0.7 (-7.7, 9.9) -4.4 (-12.4,  4.3) 2.9 (-5.7,12.2) -4.0 (-12.3, 5.01) 0.6 (-9.5, 11.8) -1.1 (-11.3, 10.13)
eeg Theta Pz-Oz (μV)  1.1 (-8.0, 11.0)  3.6 (-5.7, 13.8)  4.0 (-5.3, 14.2) 13.1 (2.5, 24.8) 13.0 (-5.7, 35.4) 19.8 (0.1, 43.5)
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abstract 
A major challenge in central nervous system (cns) drug research is to de-
velop a generally applicable methodology for repeated measurements of 
drug effects on the entire cns, without task-related interactions and a priori 
models. For this reason, data-driven resting-state fmri methods are promis-
ing for pharmacological research. We aimed to investigate whether different 
psychoactive substances cause drug-specific effects in functional brain con-
nectivity during resting-state. In this double blind placebo-controlled (dou-
ble dummy) crossover study, seven resting-state fmri scans were obtained 
in 12 healthy young men in three different drug sessions (placebo, morphine 
and alcohol; randomized). Drugs were administered intravenously based on 
validated pharmacokinetic protocols to minimize the inter- and intra-subject 
variance in plasma drug concentrations. Dual-regression was used to estimate 
whole-brain resting-state connectivity in relation to eight well-characterized 
resting-state networks, for each data set. A mixed effects analysis of drug by 
time interactions revealed dissociable changes in both pharmacodynamics 
and functional connectivity resulting from alcohol and morphine. Post hoc 
analysis of regions of interest revealed adaptive network interactions in rela-
tion to pharmacokinetic and pharmacodynamic curves. Our results illustrate 
the applicability of resting-state functional brain connectivity in cns drug 
research. 
introduction 
One of the major challenges of central nervous system (cns) drug discovery 
is to develop a generally applicable methodology to demonstrate the effects 
of a compound on the brain across the different phases of drug development. 
An optimal methodology should be minimally invasive, repeatable and able 
to identify overlapping and distinguishable effects of different cns drugs 
with little reliance on a priori models for drug effects. 
The advances in functional neuroimaging, especially positron emission 
tomography (pet) and functional magnetic resonance imaging (fmri), 
have opened important frontiers for cns drug research. However, radiation 
dose restrictions in pet prevent repeated intra-subject measurements within 
short periods of time. This is a major limitation of pet because repeated 
measurements allow testing different drug compounds on the same individual 
and minimize the within-subject variances. More importantly, repeated 
neuroimaging acquisitions would allow the assessment of pharmacokinetic/
pharmacodynamic (pk/pd) relationships, which form the scientific basis of 
modern drug development.
Compared to pet, blood-oxygen-level-dependent (bold) fmri is non 
invasive, and benefits from high temporal and spatial resolution. Until recently, 
fmri was applicable in task-related designs, where pharmachologically 
induced changes in regional bold signal in response to a hypothesized cns 
function (e.g. pain alleviation) were investigated. For examples see (Honey 
and Bullmore, 2004). One of the major limitations of this approach was the 
difficulty in controlling for inter-subject variations in stimulus perception or 
performance in task-related experiments. In addition, fmri tasks had to be 
chosen to activate regions of interest based on a priori hypotheses about the 
site of drug effect (Breiter et al., 1997); or about the pk/pd profile (Stein et al., 
1998) – which in many cases are unknown. 
A recent breakthrough in neuroimaging has resulted from discovering 
the complex (but consistent and reliable) functional architecture of brain 
activity from the bold fluctuations (Biswal et al., 2010; Bullmore and Sporns, 
2009; Smith et al., 2009). Today, a growing body of evidence suggests that 
the ‘resting-state’ brain activity (i.e. spontaneous bold fluctuations in the 
absence of any specific stimuli) forms spatially correlated topographies, 
which represent functional connections that relate to, or even predict, 
emotional and cognitive behavioral outcomes (Fox et al., 2007; Seeley et al. 
2007) or clinical conditions (Greicius, 2008). These resting-state networks 
(rsns) represent distinct functional systems (e.g. motor, vision, attention, 
etc), that are reliable and reproducible (Beckmann et al. 2005; Biswal et al., 
2010; Damoiseaux et al., 2006; Zuo et al., 2009). Hence, if different drugs 
produce specific and detectable changes in the functional topography of 
these networks, then rsns may become a biomarker for cns drug research. 
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In this study we investigate whether different psychoactive drug compounds 
(alcohol and morphine) elicit distinguishable changes in functional topography 
of the resting-state brain networks. The rsn connectivity is determined in 
terms of similarity of temporal fluctuations in the whole brain in relation 
to eight networks of interest (noi). These nois represent the most reliably 
and reproducibly detectable rsns of functional significance (e.g. visual, 
somatosensory, motor, attention, working memory) (Beckmann et al., 2005; 
Damoiseaux et al., 2006). Drugs are administered under pk-controlled 
infusion protocols. Seven resting-state fmris (rs-fmri) and several pk and 
pd assessments are made at controlled intervals (figure 1). We report drug-
specific changes in the profile of rsn connectivity, and show their temporal 
relation to the profiles of drug concentrations and pharmacodynamic effects 
in areas where effects of morphine and alcohol are expected.
methods 
Experimental Design 
A schematic diagram of the study design and the analyses is provided in 
figure 1. This study is randomized, double blind (i.e. both examiner and 
the participant are unaware of which drugs are given), and double dummy 
placebo-controlled (i.e. placebo was used for each treatment, consisting of 
infusion of the vehicle for treatment A in parallel to the administration of active 
treatment B or vice versa, and two vehicle infusions in the placebo session). 
Alcohol and morphine are two of the most commonly used substances in 
addiction and pain studies with similar analgesic and euphoric effects but they 
also result in different autonomic responses. In humans, alcohol exerts a wide 
range of psychoactive effects by interacting with gabaergic, dopaminergic, 
serotonergic and even opiate neurotransmitter systems (Koob et al., 1998). 
In contrast, morphine targets specific receptors (μ-opioid), which in turn 
interact with many other neurotransmitter systems (Contet et al., 2004). This 
within-subject design aimed to test whether drug-specific effects on the rsn 
connectivity would be detectable and whether their profile corresponded to 
the pk and pd profiles we measured. However, both alcohol and morphine 
have dose-dependent effects on the regional cerebral blood flow (Blaha et al., 
2003; Wagner et al., 2001), and pharmacodynamic effects can significantly 
vary across individuals. Hence, we applied previously validated infusion 
regimens to achieve approximately steady state serum levels and controlled 
pharmacodynamic effects. The infusion protocols were based on validated 
pk models for each of these drugs (Sarton et al., 2000; Zoethout et al., 2009; 
Zoethout et al., 2008). This allowed 1) minimizing the between- and within 
subject variations in plasma drug concentration and 2) maintaining each of 
these drugs’ concentrations at a plateau level for 90 minutes (approximately 
60 minutes after the onset of experiment). 
Subjects
Twelve healthy male subjects (age range 18-40; bmi 18-26 kg/m2) were se-
lected to participate in the neuroimaging study. (See supplemental material 
for exclusion criteria.) The study was approved by the Medical Ethics Review 
Board of Leiden University Medical Centre. Both oral and written informed 
consents were obtained from all participating subjects. All studies were 
performed in compliance with the law on clinical trials of the Netherlands 
(wmo).  Each participant was scanned on three separate days, at least 7 days 
apart. Subjects fasted for at least four hours prior to the start of a study day. 
After arrival at the hospital a light standardized meal was provided. On each 
study day, negative scores on alcohol breath tests and a urinary drug screen 
for amphetamines, cocaine, morphine and ∆9-Tetrahydrocannabinol (thc) 
were required. Three intravenous cannulas (one for morphine or placebo 
administration, one for alcohol or placebo administration and one for blood 
sampling) were placed in veins of the arms. Before the start of drug or placebo 
administration, a baseline resting-state scan was made and two baseline mea-
surements of each visual analogue scale (vas) were taken. After the last scan, 
the intravenous cannulas were removed and a second meal was provided.
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Morphine Infusion Protocols
In order to reach stable serum levels of morphine (approximately 80 nmol/l) 
an initial bolus of 100 μg/kg/hour was infused during one minute; followed 
by a continuous infusion of 30 μg/kg/hour for 2.5 hours. Total volume of 
morphine infusion was approximately 14.5 mg. A prior morphine study using 
an identical infusion paradigm (Sarton et al., 2000) showed that this infusion 
regimen could be safely applied, without the occurrence of major side effects. 
This dose was also associated with significant pharmacodynamic cns effects. 
The total amount of morphine administered during one occasion using this 
dosage scheme, was approximately 14 mg for an average weighted male sub-
ject, infused over a time period of 2.5 hours. This is considered to be a safe 
and rational dose, since it is within the therapeutic range of morphine (i.e. 2.5 
mg - 15 mg in 4-5 ml in 4-5 minutes intravenously, for acute pain). To deter-
mine the plasma concentration of morphine, venous blood was collected in 
5 ml plain tubes (Becton and Dickinson). Blood samples were taken at 0, 15, 
30, 50, 60, 90, 120, 150, 180, 210 and 270 minutes after the start of the placebo 
or drug administration. All samples were centrifuged for 10 minutes at 2000 
G between 30 and 45 minutes after collection. Plasma samples were stored 
at -21° C. Plasma concentrations of morphine were determined using liquid 
chromatography with tandem mass spectrometry (Sarton et al., 2000).  
Alcohol Infusion Protocol
Alcohol concentrations were controlled based on an intravenous alcohol 
clamping paradigm using ethanol 10% in glucose 5% (O’Connor et al., 1998). 
We aimed to maintain alcohol levels at 600 mg/l, which barely exceeds the 
legal limits for driving in the Netherlands (approximately equivalent to two 
glasses of wine). The alcohol clamp has previously been well-tolerated at this 
serum level and produced statistically significant pharmacodynamic cns 
effects (Zoethout et al., 2009). Infusion rates required to maintain stable al-
cohol levels were computed by a non-blind staff member without any other 
involvement in the study, based on measurements of breath alcohol (brac) 
at 5-minute intervals between 0-30 minutes, at 10-minute intervals between 
minutes 30-60, and 30-minute intervals between minutes 60-300 after the 
start of the placebo or drug administration. The alcohol placebo condition 
consisted of a sham-procedure using a glucose 5% solution, including com-
puter-driven adaptations of infusion rates and brac measurements. 
Neuroimaging Acquisition and Processing Protocols
A 3t Achieva scanner (Philips Medical System, Best, The Netherlands) was 
used for image acquisition. For each subject we obtained 21 resting-state t2*-
weighted acquisitions (gradient echo epi with parameters set to a tr = 2180 
ms, te = 30 ms, flip angle = 80; 64x64x38 isotropic resolution 3,44 mm, 220 
frames, 8 minutes) and a t1-weighted high resolution scan for anatomical 
registration. During scanning, a pulse oximeter (invivo mri 4500, Siemens 
Healthcare, Germany) was used to monitor heart rate and oxygen saturation. 
A flexible pressure belt was used to record the respiratory signals. These rs-
fmri data were preprocessed using the standard procedure  including mo-
tion correction, brain extraction, Gaussian smoothing with a 5 mm fwhm, 
kernel, mean-based intensity normalization of all volumes by the same factor 
(i.e., 4d grand-mean), and high-pass temporal filtering (fwhm = 100 s). Af-
ter preprocessing, the functional scans were affine-registered to an mni152 
standard space (Montreal Neurological Institute, Montreal, qc, Canada). In 
all stages Functional Magnetic Resonance Imaging of the Brain (FmriB) Soft-
ware Library (fsl 4.0, Oxford, uk; www.fmrib.ox.ac.uk/fsl) was used.
Assessment of Drug Effects on rsn Connectivity
We defined rsn connectivity in terms of the similarity of the bold fluc-
tuations in each brain voxel in relation to characteristic fluctuation in eight 
predefined networks of interest (noi). These networks are obtained from a 
weighted mask of networks that are most reliably (and reproducibly) identi-
applications of alcohol clamping in early drug development
– 134 –
chapter 6 – the effects of alcohol and morphine on fmri
– 135 –
fied from a model-free analysis of the spatio-temporal structure of the resting-
state bold fluctuations (Beckmann et al., 2005). These template nois in-
clude over 80% of the total brain volume and comprise: medial and lateral vi-
sual systems (nois 1 and 2, respectively), auditory and somatosensory system 
(noi3), sensory motor system (noi4), the default mode network (noi5), 
executive salience network (noi6), and visual-spatial and working memory 
networks (nois 7 and 8, which represent almost mirrored networks). Each 
noi represents shared neurophysiological fluctuations of the anatomical lo-
cations it includes. 
To measure connectivity, we used the dual-regression method (Beckmann 
et al., 2009). Briefly, dual-regression is based on first extracting the temporal 
pattern of resting-state signal fluctuations within an rsn — for each 
resting fmri dataset; and next regressing these ‘fitted time courses’ against 
fluctuations in the entire brain. Dual- regression analysis generates statistical 
maps of z-scores that represent connectivity to the given noi. In other words, 
the higher the absolute value of the z-score, the stronger the connectivity to 
an noi. These statistical maps can then be used in voxel-wise mixed model 
analyses of complex experimental designs to obtain a statistical representation 
of where the drug interactions with any particular network connectivity are 
significant. The statistical sensitivity of the dual-regression method has been 
successfully demonstrated in a study that reported distinct differences in 
brain connectivity in young carriers of the apoe4 gene (Filippini et al., 2009). 
Here, dual-regression resulted in 252 statistical parametric maps of whole 
brain connectivity to each of nois (12 subjects x 7 rsfmris x 3 treatments x 
8nois). For each noi, the respective rsn connectivity maps were entered 
in a mixed-effect generalized linear model (glm) to identify which brain re-
gions and which networks were most significantly affected by the drug x time 
interactions. We used fixed factors treatment and time, and random factor 
subject. Particularly, we tested the difference between morphine-placebo and 
alcohol-placebo, while accounting for the variance across time (6 post-in-
jection time points vs. the first pre-infusion). The effects of morphine versus 
placebo; alcohol versus placebo, each of the time points 2 to 7 versus the pre-
drug time point, and an intercept for each subject were modeled as covariates. 
Pharmacologically induced variations in heart rate and respiration rate 
were expected. Previous studies have shown that both heart rate (Chang 
et al., 2009; Shmueli et al., 2007) and respiration (Birn et al., 2008; Chang 
and Glover, 2009b; Wise et al., 2004) fluctuations introduce variance in the 
resting-state bold signal. We controlled for global effects of respiration 
and heart rate by examining the linear association of average heart rate and 
average respiration rate with resting-state connectivity of each network. We 
also tested separate models, with and without respiration and heart rates as 
covariates to examine the robustness of detected effects to nuisance variables. 
Permutation-based statistical inference (Nichols and Holmes, 2002) 
(5000 permutation tests) was used. Statistical significance was set at p<0.05, 
after cluster-based correction for family wise errors (based on the null 
distribution of the max cluster size across the image) was performed. In all 
stages fsl 4.0 was used.
Pharmacodynamic Assessment
Computerised Visual Analogue Scales (vas) were used to measure subjective 
cns effects of drugs at baseline and repeated at 30, 60, 90, 120, 150, 180 and 
210 minutes after infusion started. The assessments were performed outside 
the scanner. The vas Bond and Lader (Bond and Lader, 1974) was used for 
the subjective assessment of the state of mind at that moment. Three factors 
corresponding to ‘alertness’, ‘mood’ and ‘calmness’ can be derived from 
the vas Bond and Lader. The vas Bond and Lader scores are expressed in 
millimeter (mm), in which 50 mm indicates a normal feeling.  
An adapted version of the vas Bowdle (Bowdle et al., 1998) was used for 
subjective assessment of psychedelic effects. From the vas Bowdle, three 
factors corresponding to ‘internal perception’ and ‘external perception’ (two 
modalities of psychedelic effects) and ‘feeling high’ can be derived. ‘External 
perception’ consist of the vas scores changing of body parts, changes of sur-
rounding, altered passing of time, difficulty controlling thought, changes in 
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color intensity and changes in sound intensity. It indicates a misperception of 
an external stimulus or a change in the awareness of the subject’s surround-
ings. ‘Internal perception’ reflects inner feelings that do not correspond with 
the reality, e.g. hearing of unrealistic voices or sounds, unrealistic thoughts, 
paranoid feelings and anxious feelings. ‘Feeling high’ is a separate item of the 
vas Bowdle. The minimum score for the vas Bowdle (absence of psyche-
delic effects) is 0 mm.  We also used vas nausea (Mearadji et al., 1998)  and 
vas alcohol effect (intoxication), each consisting of a single scale in which 
the extreme left side (0 mm) corresponds to ‘not nauseous/drunk at all’ and 
the extreme right side (100 mm) to ‘maximum nauseous/drunk’. 
Repeatedly measured pharmacodynamic and physiological data were 
compared with a mixed model analysis of variance with fixed factors 
treatment, period, time, and treatment by time and random factor subject, 
subject by treatment and subject by time and the average pre-value (average 
over all measurements at or before time=0) as covariate (sas for windows 
v9.1.2 ; sas Institute, Inc., Cary, nc, usa). Images were generated using 
Prism 5, GraphPad Software Inc., La Jolla, ca, usa). 
results 
Controlled Pharmacokinetic Profiles
To reduce inter- and intra-subject variability, we aimed to examine variations 
in resting-state connectivity under controlled pseudo-steady state plasma 
drug concentrations, using a target-controlled infusion regimen for mor-
phine and an intravenous clamp for alcohol. Figure 2 illustrates the concen-
trations over time for each subject. Sixty minutes after the start of the infusion 
at the onset of rs-fmri 2, the between-subject averaged (± sd) morphine 
level was 67.17± 10.22 (nmol/l), which remained in the same range in the fol-
lowing rs-fmris 3, 4 and 5 (68.63 ± 8.0; 66.88 ± 5.8; 68.04 ± 8.8, respectively). 
Average alcohol concentrations were also stable, with low between-subject 
variability at rs-fmri 2, 3, 4 and 5 (0.60 ± 0.05, 0.60 ± 0.056; 0.58 ± 0.069 and 
0.63 ± 0.038 (g/l), respectively.)
Pharmacodynamic Effects of Morphine and Alcohol 
Figure 3 and table 1 summarize the pharmacodynamic effects. Morphine 
significantly reduced the respiration and heart rates and increased calmness 
and sensation of nausea compared to placebo. Alcohol significantly increased 
the heart rate and feelings of intoxication. Other effects did not reach 
statistical significance.
Effects of Physiological Factors on rsn connectivity
Figure 4 shows overlaid F-stat maps for each network, at p < 0.05 (cluster cor-
rected). Simple regression shows significant correlation between respiration 
rate and connectivity patterns of noi4, noi5, noi6 and noi7. In contrast, 
heart rate correlated with connectivity of several areas including the cerebel-
lum, the brainstem and the amygdala in relation to noi3. Overlapping heart 
rate modulation of connectivity of a region close to major arteries (and ex-
tending to the amygdala) in relation to noi 4, noi5, noi6 and noi8 was also 
present. However, when effects of treatment by time were modeled in the 
glm, the patterns of correlation between physiological factors and connec-
tivity were diminished. Including respiration and heart rate, the topography 
of morphine effects were changed, but alcohol effects were unchanged (figure 
4). With the exception of the default mode network, it seems drug effects on 
resting-state connectivity were independent of global physiological varia-
tions of heart rate and respiratory depression (due to morphine).
Interactions of Morphine and Alcohol with rsn 
Connectivity  
Considering the location of regions where including physiological effects in 
the statistical model resulted in significant differences (white matter and a 
zone peripheral to the default mode network in relation to respiration), we 
expect these effect are non-neuronal and related to global cerebrovascular re-
sponses, potentially resulting from a hypercapnic condition due to respiratory 
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depression (Pattinson et al., 2007), or physiological noise (Birn et al., 2008). 
Therefore, for the purpose of this study, we have reported drug by time inter-
actions while including these variables in the glm, to avoid such confounds.
Figure 5 illustrates statistical maps (F-test; cluster p-values <0.05, 
corrected) of areas where connectivity in relation to a given noi (in red) was 
significantly different due to morphine (green) and due to alcohol (blue) 
over time. Details in terms of cluster size, cluster p-value and the t-value of the 
peak of the cluster are provided in table 2. 
morphine Effects of morphine on rsn connectivity over time (compared 
to placebo) were significant and dissociable in different nois. The affected 
areas include prefrontal regions (subgenual acc, medial prefrontal and 
basolateral prefrontal regions), posterior parietal areas (precuneus, posterior 
cingulate), medial temporal regions (amygdala and the hippocampal), 
primary sensory, primary motor, basal ganglia and cerebellum. The most 
extensive effects of morphine were observed in noi4 (primary sensory 
motor network). Within the total areas affected (52.6 ml of brain volume) 
39% of the effect was in the bilateral somatosensory areas (inside noi4), but 
the rest of the effects were distal to noi4 (26% in the limbic system and basal 
ganglia, 16% in the primary motor, 13% in the cerebellum and 10% in the visual 
area). The next most extensive effects were in the executive salience network, 
noi6 (15.13 ml, 73% of which was prefrontal area that lies inside noi6). 
alcohol Compared to morphine, effects of alcohol on rsn connectivity 
were more limited. The most extensive effects of alcohol were observed 
in noi3 (15.15 ml of brain volume), where 62% of the change was in the 
posterior parietal cortex and the rest in the cerebellum and brainstem (which 
are outside noi3). Small changes in connectivity of dorsocaudal acc and 
precentral gyrus to noi4 were present as well (4.52 ml) and in a small area 
(2.46 ml) inside noi1.
overlap In nois 1, 2, 3, 5, 6, and 7, the intersection of the significant 
clusters of each drug’s effects did not reveal overlap, suggesting topographic 
differences in each drug effect on these functional networks. Only a small 
(42 voxels = 0.34 ml) overlap was observed in connectivity of the cerebellum 
to noi4 and in connectivity of the superior frontal gyrus to noi8 (52 voxels 
= 0.416 ml). 
Post hoc Examination of Selected roi Responses
The purpose of the post-hoc analysis is to demonstrate the range and profile 
of changes in connectivity in some exemplar rois in relation to pk and pd 
profiles. These rois were chosen from nois that were most prominently 
affected by alcohol (noi3) or morphine (noi4). 
In the sensorimotor network (noi4), where the negative hippocampal 
connectivity emerged (figure 6-a), the hippocampal connectivity in relation 
to noi4 was small in alcohol and placebo conditions (95% ci: -1.176 to -0.1104 
and -1.230 to 0.09146; respectively). By contrast, morphine infusion increased 
the absolute value of hippocampal connectivity to noi4 (95% ci: -4.309 
to -3.043). We note that connectivity is defined in terms of linear fitting of 
spontaneous fluctuations at any given region to the ‘specific’ fluctuations 
within the entire network (i.e. the weighted average time course of all voxels). 
Therefore, the negative z-score suggests a distinct inverse relationship in 
terms of simple oscillations also a phase shift of the fluctuations of the 
hippocampus with respect to the sensory-motor network. By contrast, the 
connection of the central gyrus to noi4, which was similar prior to both 
infusions, remained stable for alcohol and placebo (95% ci: 8.08 to10.45; and 
8.34 to 10.33, respectively) but became stronger after morphine infusion (95% 
ci: 11.79 to 13.20) (figure 6-b).
Figure 6-c illustrates that alcohol significantly increased the connectivity 
within noi1 within the first 90 minutes of infusion (95% ci: 0.36 to 2.22). 
By contrast, in the brainstem (figure 6-d) morphine and placebo showed an 
increase in negative connectivity to noi3 (95% ci: -0.97 to -2.26 and -0.53 to 
-2.37; respectively), whereas this probably adaptive effect was not present 
with alcohol (95% ci: -0.07 to 0.87). 
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discussion
Effects of morphine and alcohol on changes in the rsn connectivity were 
measured at several time points (together with the pd and pk profiles of each 
drug). We detected effects where the within-subject variation in pre-infusion 
connectivity in relation to a given noi was minimal, whereas the difference 
in rsn connectivity (in relation to placebo) increased over the next six time-
points—after plasma concentrations became stable and during the recovery 
phase. Drugs produced distinct cns and clinical responses in terms of pd 
effects, physiological responses, and resting-state connectivity. 
The question of the neurological substrates of resting-state bold fluctua-
tions is still an open one. The bold signal originates from changes in cerebral 
blood flow, cerebral metabolism and oxygen extraction. At the present state of 
knowledge, interpretations of bold resting-state connectivity are tentative; 
although evidence for electrical (Britz et al., 2010; Mantini et al., 2007) and ar-
terial perfusion (Chuang et al., 2008) bases of functional connectivity in some 
of the putative resting-state networks is already available. Notwithstanding a 
definite biological interpretation of connectivity, we detected effects in most 
brain regions where changes in receptor binding, cerebral blood flow, or func-
tion in response to these specific substances are previously reported. For in-
stance, pet studies with opiodergic radiotracers have shown that the acc, 
opercular/insular cortex, thalamus, amygdala and putamen (the medial parts 
of the pain system) have the highest, and the primary somatosensory, senso-
rimotor areas (the lateral parts of the pain system) (Baumgartner et al., 2006; 
Jones et al., 1991; Zubieta et al., 2001) and occipital areas (Sadzot et al., 1991) 
to have the lowest binding potentials. As table 2 shows, we have detected pre-
dominant morphine effects both in areas that, according to pet studies, have 
low opioid binding potentials (such as primary sensorimotor connectivity to 
noi4), and areas that have high opiodergic binding potentials (such as the 
acc connectivity to noi6). This observation precludes interpretation of the 
effects simply as an outcome of metabolic modulation at the site of receptor 
action. However, it is possible that the detected effects reflect interactions be-
tween these different regions in terms of functional adaptation. Future stud-
ies of combined rsfmri and opiodergic pet studies can shed a light on this 
central question. 
On the other hand, we have been able to demonstrate different connec-
tivity effects resulting from morphine and alcohol, which have different sites 
of action. Unlike morphine, cns effects of alcohol are primarily mediated 
via gabaa receptors, which are expressed across the brain, although differ-
ent parts of the brain have higher affinity for different subunits (Kumar et al., 
2009). Presently, there are no radiotracer studies to have illustrated alcohol-
induced variances in regional gabaa binding potentials in humans. The most 
direct in vivo evidence for the effect of alcohol on cerebral activation is ob-
served in terms of reduced global metabolism (de Wit et al., 1990; Volkow et 
al., 2008; Volkow et al., 2006; Wang et al., 2000), with more relative decreases 
in the occipital cortex (Schreckenberger et al., 2004; Volkow et al., 2008; Wang 
et al., 2000) and the cerebellum (Volkow et al., 2008; Wang et al., 2000), and 
relative increases in the brainstem, striatum and the acc (Schreckenberger 
et al., 2004). Also, a radiotracer study of a gaba a ligand ([11c],Ro 15-4513, 
which has preferred binding potential for ethanol (Hanchar et al., 2006)) in 
monkeys indicates that the acc, insula and the limbic system have the high-
est, and the occipital cortex and the cerebellum have the lowest binding po-
tential for [11c],Ro 15-4513 (Maeda et al., 2003). Here, we observed that al-
cohol affected the connectivity of the visual cortex (in relation to noi1), the 
cerebellum (in relation to noi3 and noi4), the acc (in relation to noi3 and 
noi4) and the brainstem (in relation to noi3). Surprisingly, the most exten-
sive effect of alcohol was in changing the connectivity of pcc (in relation to 
noi3). It is known that alcohol effects can vary with dosage (Blaha et al., 2003; 
de Wit et al., 1990; Gordon et al., 1995; Luksch et al., 2009; Sano et al., 1993), 
and they may depend on interindividual differences in regular alcohol con-
sumption. The lesser extent of detected alcohol effects in our study can be hy-
pothetically attributed to these sources of variance and future studies need to 
address the issue more closely.
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With the exception of a small overlap in the cerebellum (in relation to 
noi4) and the superior frontal gyrus (in relation to noi8), drug effects on 
connectivity were distinct. Similarly, overlap in pharmacodynamic effects 
was limited. Alcohol significantly increased a feeling of drunkenness and 
morphine significantly increased nauseous sensation. The cns effects 
expected to be common in both drugs such as calmness, alertness and 
mood were not significant for alcohol (although calmness was significantly 
increased by morphine). Of course, we cannot conclude that alcohol and 
morphine do not interact on common brain circuitry. In this experiment, the 
vas scores indicate little overlap in terms of subjective changes in mood and 
feelings induced by alcohol and morphine. However, alcohol (ethanol) was 
administered at relatively low levels (0.6 g/l), whereas morphine was given in 
a therapeutically relevant dose (14.5 mg) with considerable functional impact. 
It is likely that higher doses of alcohol intoxication that result in stronger 
cognitive and affective responses, will elicit more pronounced changes in 
local functional connectivity. Presently, without extensive psychometric tests 
the behavioral correlates of the observed cns effects cannot be discussed. 
More precise recordings of certain aspects of emotion and cognition would 
have enabled us to study the functional significance of rsn connectivity 
changes. In this experiment, we omitted cognitive testing between different 
resting-state measurements to avoid introducing performance-related 
confounds. In fact, our study underlines an important advantage of the 
resting-state pharma-fmri (rs-Phfmri). Significant changes were detected 
in regions that are expected to be associated with the cns effects of these 
drugs; without a priori models and performance- or task-related confounds.
It is crucial to note the effects of global physiological variations due to 
morphine and alcohol. Previous studies have well documented that respirato-
ry depression due to opiodergic drugs generates hypercapnic conditions that 
increases cerebral blood flow (MacIntosh et al., 2008), and causes focal bold 
signal reduction in response to hypercapnic condition in the sensorimotor 
brain regions (Pattinson et al., 2007). On the other hand, it has been shown 
that bold fluctuation correlating with respiration and heart rate can com-
promise delineation of the default mode network (Chang et al., 2009; Chang 
and Glover, 2009b). Nevertheless, the impact of physiological noise on bold 
is nearly global and including the timecourse of physiological fluctuations 
do not drastically change the results of connectivity estimation (Birn et al., 
2006; Chang and Glover, 2009a). We observed a significant respiratory de-
pression after morphine injection and an increase in heart rate due to alcohol. 
Our study does not address effect of physiological variables in dual regression 
outcome, but we have examined the effects of overall physiological variations 
(in terms of average respiration and average heart rates per each subjects per 
each session) on resting-state connectivity, and have shown that inclusion of 
physiological covariates in a repeated measures model does not change the 
main effects of the drug by time interaction. Interestingly, including respira-
tion and heart rate in the model removes emerging connections from white 
matter to noi4, and reduces the extent of morphine effect on connections 
to the noi5, the default mode network, whose fluctuations seem to overlap 
in frequency with spontaneous bold changes in the default mode network 
(Birn et al., 2006; Wise et al., 2004). It should be noted that our framework 
is based on examining connectivity to eight noi templates corresponding to 
the most consistently determined rsns. These template networks are initially 
obtained from independent component analyses (co). It has been suggested 
that the default-mode network obtained from ica might not be fully respi-
ration-proof (Birn et al., 2008). It is therefore striking that modeling a global 
measure of respiration change at the group level analysis would demonstrate 
an effect expected from more careful analysis of the respiration spectra (Birn 
et al., 2006; Wise et al., 2004). We cannot preclude the possibility that varia-
tion in the temporal physiological profiles have a stronger explanatory power 
on effects of some of these networks, such as noi4. Our aim in this study was 
to show that rs-fmri is a sensitive and applicable method for detecting drug 
effects in the brain. Future studies that aim to validate rs-fmri in relation to 
specific metabolic effects of especially opiodergic drugs should make precise 
recordings of variables such as end-tidal co₂ or arterial co₂ tension during 
the rs-fmri session and incorporate them in such analyses.
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It is worth mentioning that, without considering the time and the session 
effects in the model, we have detected significant associations between the 
heart rate and connectivity of several regions outside of noi3 in relation to 
this network, in addition to changes in connectivity of a region near major 
arteries (circle of Willis) that also extends to the amygdala, in relation 
to noi3, noi4, noi5, noi6 and noi8. By contrast, respiration changes 
affected connectivity to noi4, noi5, noi6 and noi7. An understanding of 
the neural or vascular substrates of physiological modulation is potentially 
crucial to interpretation of the neurological substrate of resting-state bold 
connectivity. Especially in pharmacological studies, the autonomic responses 
to the cns drug are central to the research and these questions should be 
carefully considered in the study design. For instance, heart rate modulated 
the connectivity of amygdala to noi4 (sensorimotor), noi5 (default mode 
network), noi6 (salience executive) and noi8 (right dorsomedial visual 
stream). This observation is striking, since amygdalar association with visual-
emotional (Critchley et al., 2005; van Marle et al., 2009) or executive-motor 
(Napadow et al., 2008) modulation of the heart rate is previously reported. 
Regardless of neurobiological interpretations, our findings illustrate that 
different nois vary in degree of susceptibility to physiological modulation; 
and highlight a need for considering different statistical models to ensure 
important results are not obscured.  
Our study overcomes some limitations in earlier pharmacological fmri 
studies, and poses challenging questions. We have successfully detected 
effects reported in previous studies of morphine and alcohol—without 
subjectively delineating an roi necessary for commonly used seed-based 
rs-fmri analysis (Anand et al., 2007; Hong et al., 2009; Kelly et al., 2009; 
Rack-Gomer et al., 2009). It may be argued that predefined nois limit the 
scope of observations by restricting the criterion of connectivity to temporal 
similarity with a given noi. However, these networks were chosen on the 
basis of previous studies that robustly reproduced them in entirely different 
population (Beckmann et al., 2005; Damoiseaux et al., 2006). By choosing 
these networks we avoided typical ambiguities associated with ica approach 
that depends on choosing the model order, or on subjective selection of 
similar or relevant components for further analysis. Nevertheless, we have 
detected significant changes in connectivity of regions such as the cerebellum 
and the hippocampus that are outside the reference nois. Therefore this 
method seems to be robust and less limiting than alternative ica or roi 
methods in detecting regions where the drug effects may not be expected. 
New approaches such as eigenvector centrality mapping (ecm) (Lohmann 
et al., 2010) might bring us closer to the goal of total model-free analyses, but 
such methods are computationally more costly than dual-regression using 
pre-defined noi templates, as we did. It would be interesting to compare 
results from ecm analysis and our proposed methodology.
An important advantage of resting-state connectivity, compared to other 
(more quantitative) neuroimaging methods is that it reveals the complexity 
of the temporal profile of drug effects in each region or interest. For instance, 
no significant connection is present between the hippocampus and the 
sensorimotor network (noi4) under placebo or alcohol conditions, but 
during morphine infusion, a significant negative connectivity emerges. At the 
same time, morphine diminishes the connection of the supplementary motor 
area to noi4 to zero. To date, the issue of negative connectivity remains a 
topic of debate (Murphy et al., 2009). Several hypothetical explanations are 
possible: It may be argued that global vascular effects of morphine (especially 
due to respiratory depression) would give rise to the observed negative 
connectivity demonstrated in the hippocampus. However, these particular 
emerging negative correlations are anatomically confined to bilateral 
hippocampus, and although we cannot comment on the neurophysiological 
basis of the effect, they are unlikely to be non-specific artifacts. Another 
possibility is that reduction of physiological noise (e.g. due to respiratory 
depression due to morphine) would enhance negative correlations (Fox et 
al., 2009). Alternatively, the negative connectivity in the hippocampus may 
correspond to a delayed, and perhaps adaptive function of this structure (Bast 
2007; Khalili-Mahani et al., 2010). We remind that these particular effects were 
not affected by inclusion of respiration and heart rate averages in the group-
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level statistical model. Such inter-regional and inter-network heterogeneity 
of effects raise questions about compensatory and adaptive mechanisms 
that interact with the drug (which reflects interactions of different brain 
regions with each other); and underlines the added advantage of resting-state 
connectivity analysis compared to other neuroimaging modalities.
In conclusion, we have shown that drug-class specific effects on dynamics 
of brain function at resting-state can be detected even without a priori 
models. An important advantage of the resting-state Pharma-fmri is that 
it is not confounded by differences in alertness or test strategies and other 
factors that influence the performance and outcomes of task-induced fmri, 
and demonstrates effects even if no appropriate task is available. This study 
was designed to exhibit limited pharmacokinetic variability, and was hence 
unsuitable to investigate concentration-effect relationships, although the time 
profiles of the mri-effects roughly followed those of the clinical responses. 
This study demonstrates that rs-fmri could be useful for ‘finger-printing’ 
different drug actions within the same individual’s brain. Notwithstanding 
the exploratory nature of the present study, and the inability to characterize 
the neurophysiological substrates of resting-state bold fluctuations, many 
of our results correspond to findings from previous quantitative pet studies. 
Because rs-fmri is noninvasive, widely available and frequently repeatable, 
it may become an important biomarker for cns-drug development, able to 
distinguish detailed drug-induced response patterns in healthy subjects and 
patients.
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figure 1 schematic presentation of study design and data 
collection ( full colour version inside cover)
Each subjects participated in three randomized sessions. Both examiners and the 
subject were blind to which drug they received. The expected pharmacokinetic 
profiles for alcohol and morphine are plotted (1). The placebo infusion was 
conducted concurrently with the drug infusion. After preprocessing (2) dual 
regression on all data sets to estimate whole-brain connectivity in relation to the 
eight template rsns (3), followed by statistical testing (4).
figure 2 pharmacokinetic effects 
(a) Plasma morphine concentrations for each subject; (b) Breath alcohol 
readouts. The bars illustrate when the rs-fmri acquisition took place.
figure 3 pharmacodynamic effects over time (mean ± sem)
See table 1 for details of main effects.
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figure 4 overlaying maps of voxel-wise regression of 
respir ation (resp) and heart r ate (hr) with connectivity  
to the 8 template networks ( full colour version inside cover)
F-statistics; cluster corrected p<0.05 in glm, including treatment by time interactions.
figure 5 overlaying maps of drug by time inter actions  
with connectivity to the 8 template networks (full colour  
version inside cover) F-statistics voxel-wise p < 0.0001; cluster corrected p<0.05; 
average physiological rates included as covariates. The nois are represented in pale 
red, morphine effects in green and alcohol effects in blue. table 2 for the effects details. 
wm, working memory; dvs, dorsal visual stream.
figure 6 profile of change in resting-state connectivity 
in select roi’s (full colour version inside cover)
Statistical parametric maps (t-statistics, cluster corrected p<0.05) reflect the 
amplitude of drug-induced changes in functional connectivity (drug versus 
placebo over time). Morphine leads to increased negative connectivity of the 
hippocampus (a), and positive connectivity of the central gyri (b) in relation to 
the sensory-motor network (noi4). Alcohol enhances the intra-connectivity of the 
visual network (c) and disrupts adaptive connectivity of brainstem (d). In the roi 
diagrams, red corresponds to placebo, green to morphine and blue to alcohol.
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table 2 details of drug effects on functional 
connectivity 
(cluster corrected threshold, p <0.05)
Network Morphine Ethanol
 Location #voxels t x y z Location #voxels t x y z
noi1: Medial Visual Network 
relaying visual input through 
thalamus to primary visual area. 
Includes, Calcarine, inferior 




4.77 27 28 16 R visual 140
***
4.78 35 27 41
L cerebellum 101
**
4.8 64 30 15 L visual 100
**
5.57 52 26 46
R hippocampus 65
**
5.05 33 50 29 L parietal lobule 67
**





5.87 37 88 50
Precentral gyrus 26* 4.88 44 53 71
noi2: Lateral visual Network 
visual spatial attention. 
R occipital V5 91
**
5.52 23 26 40 R cuneus 56
**
4.9 22 33 21
L occipital V4 70
**
4.87 57 20 29 Precuneus 24* 4.45 46 32 43
L posterior 
insula
45* -5.24 65 51 45
R superior 
frontal
33* -4.83 38 88 51
noi3: Superior Temporal 
Network auditory, 
somatosensory and autonomic 
functions includes insular and 








5.3 45 50 59
R paracingulate 322
***




5.86 27 39 58
R cerebellum 96
**
-4.57 39 45 26 Left cerebellum 167
***





-5.31 54 42 13 Bi culmen 153
***









5.03 41 42 25
L amygdala 63
**
-4.6 54 62 25  brainstem 144
**
6.29 43 54 23




5.61 68 45 59
L frontal pole 46* -4.75 57 86 52 L precuneus 45* 4.92 47 35 41
L occipital 
superior
38* -4.77 56 26 62 R supramarginal 
gyrus
38* 5.44 18 45 59
R occipital 
superior
44* -4.37 37 26 58 L orbitofrontal 34* 5.16 70 76 32
R postcentral 53* -4.58 18 59 57 R anterior 
cingulate
22* 4.80 39 86 36
table 1 pharmacodynamic effects
Pharmacodynamic Effects
Least Square Means Contrasts








vas Alcohol effects 
(mm)
1.7 19.1 7.2 0.0096 17.4  
(6.7, 28.2)  
 p=0.0030
5.5  
(-5.1, 16.2)  
 p=0.2907
-11.9  




48.6 46.0 43.7 0.1843 -2.6  
(-8.0, 2.8)  
 p=0.3236
-5.0  
(-10.3, 0.4)  
 p=0.0696
-2.3  




53.4 58.2 60.6 0.0428 4.7  
(-1.5, 11.0)  
 p=0.1323
7.2  
(1.6, 12.7)  
 p=0.0136
2.5  
(-3.3, 8.2)  
 p=0.3855
vas Mood (mm) 51.7 52.8 54.4 0.5171 1.1  
(-4.1, 6.2)  
 p=0.6623
2.8  
(-2.2, 7.8)  
 p=0.2618
1.7  
(-3.4, 6.7)  
 p=0.4982
vas Nausea (mm) 3.7 3.0 18.6 0.0320 -0.6  
(-13.5, 12.2)  
 p=0.9179
14.9  
(2.1, 27.8)  
 p=0.0247
15.6  
























vas feeling high 
log(mm)
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 noi6: Prefrontal Network 
Includes medial and inferior 
prefrontal cortices. Regions 
in this network are implicated 
in executive control, attention 
and pain. Includes medial and 
inferior prefrontal cortices. 
Regions in this network are 






-6.47 45 85 41      
L frontal pole 392*** -6.31 61 94 36      





-5.7 39 49 69      
L insula 115
**
-6.13 63 71 33
Bi thalamus 101** -5.42 45 62 42      
R lingual 63** -5.32 46 18 32      
R inferior 
parietal lob
50* -4.82 21 39 51      
L orbitofrontal 42* -5.43 54 71 27
L primary 
motor
40* -5.49 50 49 70
L lingual 36* -4.99 52 30 36
noi7: Left Dorsal Visual 
Stream Network Includes Broca 
rea 44, frontal pole, dorsolateral 
prefrontal cortex and parietal 
lobule. Working memory, visual 
spatial processing and language
L superior 
frontal
31* 4.83  46 91  45      
R frontal pole 81** -5.56 25 86 48      
R middle frontal 55** -4.8 32 73 63
noi8: Right Dorsal Visual 
Stream Network Includes 
homologous regions as noi7, 
plus right paracingulate gyrus, 
left posterior cingulated and left 






























-4.83 21 46 63




-5.5 28 67 63
R thalamus 35* -4.71 40 53 42
Cluster significance: * p < 0.05;  ** p<0.01; *** p<0.001
Voxel dimension is 2mm x 2mm x 2mm (voxel volume 0.008ml)
noi4: Sensory Motor Network 












 -5.74 27 40  23





-4.02  39 61  59




-4.79 19 47 49
L putamen -4.3 58 58 41 R precentral R 98** -5.3 49 65 56
L amygdala -6.27 37 61 27
R amygdala -6.02 52 61 28
L caudate -4.9 52 64 47      
Bi primary 
motor
1001 7.18 45 52 66
L cerebellum vi
851
-7.95 52 30 27      
Vermis -5.37 45 29 28      
L cerebellum vi -5.3 39 30 28      
R primary 
somatosensory
722 5.7 25 51 62
R putamen
668
-6.28 32 58 41      
R caudate -5.53 39 64 46      
L occipital 
fusiform
494 6.11 54 19 31      
R occipital 
fusiform
314 6.01 33 23 30      
L posterior 
insula
122 5.39 63 52 45
R posterior 
insula
84 5.12 23 56 44
thalamus 87 -4.64 45 52 41      
Brainstem 95 5.25 49 47 16      
Paracingulate 
gyrus
61 5.53 47 80 50      
noi5: Default Mode Network 
Includes rostral medial prefrontal 
and posterior medial parietal 
precuneal and pcc areas
L subgen acc 40* -5.27 47 76 31
L middle front 40* -4.81 61 76 59
Posterior 
cingulated
37* -4.53 45 40 48      
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chapter 7
The effects of tpa023, a gabaa α2,3 
subtype-selective partial agonist, on essential 
tremor in comparison with alcohol
Journal of Psychopharmacology 2012, Feb; 26(2), 282-91
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background Essential tremor (et) is a relatively frequent neurological 
disorder that responds in some patients to gaba a agonists (like benzodi-
azepines). Partial subtype selective gaba a-agonists may have an improved 
side effect profile compared to non-selective gaba a agonists. However, it is 
unknown which gaba a subtypes are involved in the therapeutic effects of 
benzodiazepines in et. 
methods The effects of 2 mg tpa023, a gaba a α2,3 selective partial agonist 
on et were compared to the effects of a stable alcohol level (0.6 g∙l-1) and 
placebo in nine et-patients. Tremor evaluation included laboratory acceler-
ometry and a performance-based scale. Additional measurements were per-
formed to evaluate other effects on the central nervous system (cns).
results Alcohol significantly diminished tremor symptoms in the postural 
and kinetic condition, as assessed by laboratory accelerometry, but the 
performance-based rating scale was unaffected. Tremor was also reduced 
after tpa023 treatment in the kinetic condition, albeit not significantly. 
Additionally, tpa023 decreased saccadic peak velocity, while alcohol 
decreased subjective feelings of alertness.
conclusions This study showed that alcohol reduced maximum tremor 
power, as assessed by laboratory accelerometry, unlike tpa023, which 
decreased tremor symptoms to some extent, but not significantly. This 
study showed that treatment with an α2,3 subunit selective gaba a partial 
agonist was less effective compared to a stable level of alcohol in reducing et-
symptoms. These results provide no support for a therapeutic role of tpa023 




Essential tremor (et) is one of the most common movement disorders 
(Pahwa and Lyons, 2003). The age- and gender-adjusted prevalence of et is 
estimated to be 3 to 4 per 1000, with an annual incidence of 23.7 per 100,000. 
Approximately 4% of adults in the age group above 40 years are affected by et 
(Zesiewicz et al., 2010). et has a 4-12 Hz frequency that predominantly affects 
the upper extremities, may also affect the head and voice, and rarely affects 
the legs. In contrast to resting tremor in Parkinson disease, essential tremor 
is characterised by postural and kinetic components (Elble, 2000). Although 
its cause is unknown the central oscillatory systems at the level of the inferior 
olivary nucleus of the medulla oblongata seem to play an important role in 
the pathophysiology of et (Deuschl and Elble, 2000). Current therapy 
for et includes beta blockers, phenobarbital (a primidone metabolite), 
benzodiazepines, and some antiepileptic agents. Treatment is symptomatic, 
effective in no more than roughly half of the patients, and often limited by 
side effects (Chen and Swope, 2003).
Preclinical and clinical studies suggest that a gabaergic pharmacologic 
agent could be effective in the treatment of et (Louis, 1999). Double-blind 
studies have demonstrated efficacy of alprazolam versus placebo in treating 
et (Gunal et al., 2000; Huber and Paulson, 1988). Different gaba a receptor 
subtypes have been identified, and pre-clinically linked to well-known effects 
of gaba a agonists like sedation (α1) (Rudolph et al., 1999), muscle relaxation 
(α2) (Rowlett et al., 2005), anxiolysis (α2,3) (Atack et al., 2005; Rudolph et 
al., 2001) and memory impairment (α5) (Collinson et al., 2002). Among 
these subtypes, the α2-receptor seems the most promising target for anti-
tremor activity, although the exact mechanism of the therapeutic activity of 
gaba agonists in essential tremor is unknown. tpa023 is being developed 
as a gaba a α2,3 selective partial agonist. Based on the selective properties of 
this compound, it is believed to be a muscle relaxant (and anxiolytic) without 
causing sedation and instability. Healthy volunteer studies have shown the 
selective effect profile in comparison with lorazepam (de Haas et al., 2007). 
Investigating the effects of this novel selective partial gabaa agonist on 
essential tremor might reveal new information about the pathophysiology of 
this disease, and possibly identify a new treatment modality. 
Alcohol, which is an indirect agonist of the gaba a-receptor 
(Santhakumar et al., 2007) relieves tremor symptoms in an estimated 50 to 
90% of et patients (Rajput et al., 1975; Deuschl, 1999) by reducing tremor 
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amplitude without affecting frequency (Koller and Biary, 1984). It most 
likely acts via a reduction of cerebellar over-activity, which results in reduced 
tremor amplitude, whereas the frequency is not altered (Koller and Biary, 
1984; Koller et al., 1994; Koller, 1991). In this study, alcohol was chosen as a 
positive control, using a novel clamping technique that was based on earlier 
publications (O’Connor et al., 1998). Ideally, a novel therapy for et would 
closely approach the tremor reducing effects of alcohol. Since the duration 
of action of tpa023 was estimated to be four hours, the clamping procedure 
took place during a similar period. To maximize the power of alcohol as a 
positive control, only patients who were familiar with the positive effects of 
alcohol on their symptoms were included in this project. 
In this exploratory study, the novel α2,3-selective gaba a partial agonist 
tpa023 was compared with intravenous alcohol and placebo for their effects on 
tremor symptoms. A battery of Central Nervous System (cns) function tests 
including body sway, eye movements, Visual Analogue Scales and adaptive 
tracking was also performed. The objectives were to distinguish between general 
cns pharmacodynamic effects of the gaba a α2,3-selective drugs and tremor-
specific effects in the accelerometry recordings, in a relatively small study. 
methods
Design
This exploratory study was performed in a double-blind, double-dummy, 
randomized, placebo-controlled, 3-period, crossover fashion in nine patients 
diagnosed with essential tremor, with at least a five-day washout period.
Subjects
Nine patients with essential tremor were recruited from the hospital database 
of the Leiden University Medical Centre, the Dutch patients’ association 
and by advertising in local newspapers. Subjects were informed about the 
contents of the study during an information visit. When they had decided 
to participate, subjects visited the research unit for a medical screening. 
After signing informed consent, they were medically screened to evaluate 
eligibility for study participation. A neurologist ( JvG) diagnosed essential 
tremor (et) of the hands and forearms according to the diagnostic criteria 
for ‘classic et’ defined by the consensus statement of the Movement Disorder 
Society (Deuschl et al., 1998), adapted from previous criteria established 
by the Tremor Research Investigation Group (trig) (Deuschl et al., 1995), 
as well as a more recent study indicating the importance of kinetic tremor 
(Brennan et al., 2002). An isolated head tremor was not allowed.
Only subjects who stated a positive effect of alcohol on their tremor 
symptoms were included in the study. Subjects had to refrain from alcohol 
48 hours prior to a treatment day and caffeine-containing products for at 
least 12 hours before treatment. Subjects were not allowed to use their own 
anti-tremor medications and had to abstain from grapefruit (juice) and St 
John’s Wort for at least 2 weeks before the start until completion of the study, 
because these substances have stimulating and inhibiting effects on cyp3a4, 
respectively. They were not allowed to drink more than six units of caffeine-
containing products or three units of alcohol per day or smoke more than five 
cigarettes per day during the total study period. On treatment days, the use 
of caffeine-containing products or smoking was not allowed. The study was 
approved by the Medical Ethics Review Board of Leiden University Medical 
Centre, and performed according to their standards.
Study treatments
Each patient received a single oral dose of tpa023 2 mg or matching placebo. 
Also on each study day, an alcohol (10% in 5% glucose) or sham placebo (5% 
glucose) clamping procedure was performed. Only the person who was 
responsible for the clamping method was unblinded for alcohol infusion due 
to measurement of the breath alcohol concentrations (brac). This person 
was not involved in any other part of the study.
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Alcohol was infused using a recently developed clamping method, in which 
the brac was used to guide intravenous dosing (Zoethout et al., 2008). An 
alcohol level of 0.6 g∙l-1 was chosen, because this was expected to cause a 
significant tremor reduction in the majority of patients. Previous studies 
have shown that mean blood alcohol levels of 0.35 and 0.50 g∙l-1 had tremor 
diminishing effects, but this was after a single oral dose (Zeuner et al., 2003). 
Levels of 0.6 g∙l-1 are routinely achieved during social drinking, without 
causing too many adverse effects.
In previous studies, the 0.6 g∙l-1 alcohol clamp was well-tolerated and pro-
duced statistically significant pharmacodynamic cns effects (Zoethout et al., 
2009). It was estimated that the duration of action of tpa023 would be ap-
proximately four hours (de Haas et al., 2007). To optimize the value of alcohol 
as a positive control, a clamping period of four hours was chosen for this study.
Safety
Adverse events, ecg, blood pressure and heart rate measurements were as-
sessed throughout the study. ecgs were assessed with a Cardiofax, equipped 
with ecaps12 analysis program (Nihon Kohden, Japan). Blood pressure 
and heart rate were measured with an automated blood pressure monitor 
(mpv1072, Nihon Kohden, Japan), showing an average value for two sequen-
tial (duplicate) measurements at each time point. All safety measurements 
were made after sitting in a semi-recumbent position for at least 5 minutes.
Alcohol concentrations
Breath alcohol (brac) samples were performed using the hand-held Alco-
Sensor iv meter (Honac, Apeldoorn, The Netherlands). To reduce fatiguing 
of the Alco-Sensor meter, a minimum interval of approximately 10 minutes 
was maintained between brac samplings, by alternating two different 
measurement devices. A recent study using the described alcohol clamping 
technique shows similar findings for breath alcohol and blood alcohol levels 
(Zoethout et al., 2008). Therefore, no pharmacokinetic blood samples were 
obtained for alcohol and only the breath alcohol samples were used for 
further pharmacokinetic analysis.
Pharmacodynamics 
tremor evaluation Tremor evaluations were performed at screening, 
predose (within 60 minutes prior to dosing) and 60, 150, 240, 330, 420 
minutes postdose on each study day. 
questionnaire/Evaluation scale The Tremor Disability Question-
naire was only performed at screening and was executed to assess the level of 
disability due to et according to the patients’ opinion. This is a 36-item, 10 
minute questionnaire that was designed in 1997 for the cadet study (Wendt 
et al., 2000). It has shown substantial test-retest reliability and was validated 
against multiple other endpoints, including a neurologist’s clinical ratings, 
the performance-based test of function, and quantitative computerized trem-
or analyses (Louis et al., 2000). The total score of this questionnaire ranges 
from 0 (no disability) to 100 (completely disabled).
Additionally, a Performance-Based Tremor Evaluation (pbte) was per-
formed (Louis et al., 1999). The test included the performance of 15 activities 
that were scored by a trained measurement assistant from 0 (no difficulty) to 
4 (unable to perform), and the total score was converted to a percentage rang-
ing from 0 (no disability) to 100 (maximally impaired) (Louis et al., 1999).
laboratory tremography Tremor was evaluated according the 
methodology of Gironell et al. (Gironell et al., 1999) using three miniature 
linear piezo-electric accelerometers (Nihon Kohden, mt-3t), which were 
attached to the distal end of a clamp, above the fingertips of the dominant 
arm. The accelerometers were placed at right angles to one another to enable 
three-dimensional analysis of movement (Gironell et al., 1999; Van Hilten 
et al., 1991). An emg recording of the flexor and extensor forearm muscles 
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was also obtained with silver-silver chloride electrodes applied 2cm apart at 
the belly of the muscles. The signals were amplified by use of a Grass 15lt 
(15a54/15a94), with a time constant of 1 second and a low pass filter at 100 
Hz. For the fast Fourier analysis, data collection and analysis were performed 
using customized ced software (Cambridge Electronics Design, Cambridge, 
uk). The upper limb tremor was recorded in three positions, each held for 
a 60-second interval: (1) at rest, with the arm hanging relaxed along the 
body, (2) postural, with the arm held in an outstretched, horizontal, prone 
position and (3) kinetic, moving the hand from a set point to the nose (back 
and forth). Tremor was quantified by a power spectrum analysis to determine 
the dominant frequency peak (Hz) and the magnitude of the accelerometer 
signal (absolute power of the dominant frequency peak in µv). 
cns measurements 
Pharmacodynamic measurements were performed predose (within 60 
minutes prior to dosing) and 30, 120, 210, 300, 390 and 480 minutes postdose. 
Subjects underwent pharmacodynamic tests individually in a quiet room 
with ambient illumination. All subjects were thoroughly trained and 
familiarized with the tests within 14 days preceding study start to minimize 
learning effects before proceeding to the study.
saccadic eye movements Saccadic eye movements were recorded us-
ing a micro-computer-based system for data recording (Cambridge Electron-
ics Design, Cambridge, uk), Nihon Kohden equipment for stimulus display, 
signal collection and amplification (Nihon Kohden Corporation, Tokyo, 
Japan), and disposable surface electrodes (Medicotest n-oo-s, Olstykke, 
Denmark) (van Steveninck et al., 1989). Average values of latency (= reaction 
time), peak saccadic velocity and inaccuracy (difference between stimulus 
angle and corresponding saccade in %) were calculated for all artefact free 
saccades. Saccadic peak velocity (spv) has been validated as the most sensi-
tive measure for the sedative effects of benzodiazepines (van Steveninck et 
al., 1991; van Steveninck et al., 1992; van Steveninck et al., 1999; de Visser et 
al., 2003) Previous healthy volunteer studies showed that tpa023 caused spv 
reductions, while alcohol did not (de Haas et al., 2007; Zoethout et al., 2009).
visual analogue scales Visual analogue scales as originally described 
by Norris (Norris, 1971) were previously used to quantify subjective effects 
of benzodiazepines (van Steveninck et al., 1991). From the set of sixteen 
scales three composite factors were derived as described by Bond and Lader 
(Bond and Lader, 1974), corresponding to alertness, mood and calmness. 
These factors were used to quantify subjective treatment effects. In contrast 
to tpa023, alcohol has previously shown to affect the vas alertness scale (de 
Haas et al., 2007; Zoethout et al., 2009). 
body sway Body sway was measured with an apparatus similar to the 
Wright ataxia meter (Wright, 1971), which integrates the amplitude of 
unidirectional body movement transferred through a string attached to 
the subject’s waist. Two-minute measurements were made in the antero-
posterior direction with eyes closed, with subjects standing comfortably on 
a firm surface with their feet slightly apart. In contrast to tpa023, alcohol 
has previously shown to increase postural instability (de Haas et al., 2007; 
Zoethout et al., 2009). 
adaptive tracking The adaptive tracking test was first performed by 
Borland and Nicholson (Borland and Nicholson, 1984), using customised 
equipment and software (Hobbs, 2000, Hertfordshire, uk). The average 
performance and the standard deviation of scores were used for analysis. 
Adaptive tracking is a pursuit-tracking task. A circle moves randomly 
about a screen. The subject must try to keep a dot inside the moving circle 
by operating a joystick. If this effort is successful, the speed of the moving 
circle increases. Conversely, the velocity is reduced if the test subject cannot 
maintain the dot inside the circle. Adaptive tracking was scored over a 
3-minute period. Each test was preceded by a run-in period. The adaptive 
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tracking test has proved to be useful for measurement of cns effects of 
alcohol (van Steveninck et al., 1996), various psychoactive drugs (Gorman et 
al., 1986), and sleep deprivation (van Steveninck et al., 1999).
Statistical analyses
The study was performed to explore the effects of tpa023 on et compared 
to an alcohol infusion. Because of the exploratory character of the study, no 
formal power calculation could be performed.
Most pd parameters were analyzed by mixed model analyses of variance 
(using sas proc mixed) with treatment, period, time and treatment by 
time as fixed effects, with subject, subject by time and subject by treatment 
as random effects, and with the baseline value as covariate, where baseline 
is defined as the average of the available values obtained prior to dosing. 
Treatment effects were reported as the contrasts specified below where the 
average of all post-dose measurements was calculated within the statistical 
model. Contrasts were reported along with 95% confidence intervals (95%ci) 
and analyses were two-sided with a significance level of 0.05. 
Body sway and tremor parameters were analyzed after log-transformation 
due to skewed response distribution. All other parameters were analyzed 
untransformed. Log-transformed parameters were back-transformed after 
analysis where the results may be interpreted as percentage change. All 
calculations were performed using sas v9.1.2 for Windows (sas Institute, 
Inc., Cary, nc, usa).
results
Subjects
Seventeen patients were medically screened after giving written informed 
consent. Seven patients did not qualify for the study mainly because 
their tremor was too mild to be quantified reliably with the laboratory 
tremography. Nine patients (two female, seven male) fulfilled the study 
criteria and completed the study. The remaining patient was standby to 
replace any discontinuations, but never participated in the study. Apart from 
their tremor, they were judged to be in good health on the basis of medical 
history, physical examination and routine laboratory data. Subjects were on 
average 47 years of age (range 18-80), had an average weight of 77 kg (range 
62-103 kg) and average height of 175 cm (range 159-189 cm). 
The mean (range) dominant tremor frequency at screening was 7.7 (95%ci 
5.4-9.4) Hz. Mean (standard deviation) scores on the Tremor Disability 
Questionnaire and Performance-Based Tremor Evaluation were 30 (18.2)% 
and 34 (30)% respectively. Two patients stopped their propranolol treatment 
two weeks before participation in this trial. The other patients did not use any 
treatment. 
Clinical observations
No serious adverse reactions occurred following any of the treatments. 
Frequently reported adverse events include headache, sleepiness, dizziness 
and a pain ful arm during infusion. Headache was the most common adverse 
event, occurring in five, one and two patient(s) after administration of 
alcohol, tpa023 and placebo, respectively. Dizziness and sleepiness occurred 
in four, two and one subject(s) after administration of alcohol, tpa023 and 
placebo, respectively. Five patients reported a painful arm just after the start of 




laboratory tremography During the postural condition of the 
measurement, alcohol infusion reduced maximum power of both the left-
right (-31.4% (-45.9, -13.0%)) and backward-forward (-37.6% (-60.4, -1.7%)) 
applications of alcohol clamping in early drug development
– 170 –
chapter 7 – effects of tpa023 and alcohol on essential tremor
– 171 –
tremor direction compared to placebo. For the kinetic condition, similar 
results were obtained (table 1). The maximum power of the left-right 
direction was reduced by 19.2% (-31.7, -4.3%) and that of the backward-
forward direction by 29.5% (-44.8, -9.9%) after alcohol infusion compared 
to placebo. These changes resulted in a decrease in average power in both 
conditions (figure 2). In the resting condition, no effects were seen in any 
tremor direction for any treatment. tpa023 did not affect tremor symptoms 
as effectively as a stable level of alcohol.
performance-based tremor evaluation Mean total tremor score 
decreased shortly after alcohol infusion had begun (figure 3). However, mean 
scores during placebo and tpa023 treatment also decreased. No differences 
compared to placebo were present after alcohol (-2.2 (-6.3, 1.9)) and tpa023 
(-1.0 (-5.1, 3.0)) treatment (table 1). 
relationship between laboratory tremography and pbte
Tremor amplitude and tremor rating scales are logarhithmically related and 
one can be estimated if the other parameter is known, using a set of formulas 
proposed by Elble (Elble et al., 2006). We used these formulas to investigate to 
what extent the pbte serves as a predictor for the effect on tremor amplitude. 
Based on the mean reduction in pbte, which was measured after alcohol 
treatment (compared to placebo) a 15% decrease in tremor amplitude was 
expected, while a 20% reduction was observed (for the kinetic condition). 
Additionally, the mean reduction in pbte scores, which was measured after 
tpa023 treatment in this study resulted in an estimated reduction in tremor 
amplitude of 7%, while a 6% reduction was observed in the kinetic condition.
central nervous system tests
saccadic eye movements tpa023 significantly decreased saccadic peak 
velocity (spv) with 45.4 deg/sec (-65.6, -25.1deg/sec) compared to placebo. 
tpa023 also increased inaccuracy with 1.0% (0.3, 1.6) but not latency. Alcohol 
did not show significant effects on eye movements (table 2).
 
body sway Neither treatment significantly affected body sway compared 
to placebo (table 2). 
adaptive tracking Adaptive tracking performance and sd of 
performance were not significantly affected compared to placebo (table 2).
visual analogue scales Alcohol decreased the vas alertness scale by 
8.0 mm (-13.2, -2.7mm) compared to placebo. vas mood and vas calmness 
were not affected significantly by alcohol or tpa023 treatment (table 2).
Pharmacokinetics
Mean breath alcohol concentrations increased in approximately 15 minutes to 
0.58 g/l and stabilized for 4 hours, after which the infusion was stopped and 
concentrations returned to baseline (figure 1). 
Post-hoc power calculation
In this exploratory study, the potential tremor reducing effects of tpa023 
were compared to the effects of alcohol that were identified in this study. 
A post-hoc power calculation revealed that a sample size of 139 et-patients 
would have been necessary to have 80% power to detect the same average 
difference between tpa023 and placebo (i.e. 0.068 μv) that was observed in 
nine et-patients during alcohol treatment.
discussion 
This placebo-controlled study explored the effects of a novel gaba a α2,3 
selective partial agonist in patients with essential tremor. Results showed that 
only alcohol, which was used as a positive control, reduced tremor power, as 
assessed by the laboratory tremography. 
Several studies have shown that alcohol is effective in reducing tremor 
amplitude in patients with essential tremor (Growdon et al., 1975; Zeuner 
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et al., 2003; Rajput et al., 1975; Koller and Biary, 1984). It is thought that 
alcohol acts within the central nervous system and not by affecting peripheral 
tremorogenic mechanisms (Growdon et al., 1975; Zeuner et al., 2003). 
Previous studies showed tremor reductions after a single oral intake of 
alcohol or an infusion bolus, causing mean blood alcohol levels of 0.35-0.55 
g∙l-1 (Zeuner et al., 2003). The current study was able to keep alcohol levels 
stable at 0.6 g∙l-1 for approximately four hours. Tremor power was reduced 
as long as the alcohol levels were stable and returned to baseline after the 
infusion was stopped. 
Allthough tremor reducing effects were observed after tpa023 treatment 
in the kinetic condition, these effects did not reach significance in this 
relatively small study. It is unlikely that this was due to doses that were too 
low. There were clear effects of tpa023 2 mg on saccadic eye movements in 
this study, and similar finding were obtained with the same dose in healthy 
volunteers (de Haas et al., 2007). The dose was predicted to be therapeutically 
active for the treatment of anxiety. A positron emission tomography study 
(Atack et al., 2010) demonstrated that the dose of tpa023 used in this study 
produces substantial and sustained occupancy (47 to 64% at ~2 hours and 34 
to 59% at ~7 hours postdosing). Although the required receptor occupancy 
for the postulated gabaergic effect in et is unknown, these levels are 
consistent with the occupancy associated with the minimum effective dose 
in animal models of anxiolysis (44 to 76%, 46% and 89%, for the elevated 
plus maze, fear-potentiated startle and conditioned suppression of drinking 
paradigms, respectively), indicating that they are likely to be centrally active 
(msd, data on file). In addition, the preliminary results of a fear-potentiated 
startle paradigm in healthy subjects support the anxiolytic efficacy of single 
dose tpa023 2.0 mg (msd, data on file). In the latter study, startle amplitude 
during threat conditions was significantly reduced when subjects received 
tpa023 2.0 mg compared to placebo (p<0.0035).  
To maximize the power of alcohol in detecting a treatment effect, only 
patients who were familiar with the positive effects of alcohol on their 
symptoms were included in this project. Patients could also have been 
selected on their (prior) responses to benzodiazepines or barbiturates. 
However, the clinical acceptability of such treatments was expected to be 
determined not only by the effect on et-symptoms but also by the individual 
tolerability to side effects. Moreover, benzodiazepine withdrawal can also 
induce tremor, which can be difficult to distinguish from recurrence of et-
symptoms. It was considered less problematic to use a positive alcohol 
response as a potential predictor of an effect of subtype-selective partial 
gaba a-agonist. Many patients report a positive effect of alcohol, but still 
do not routinely use alcohol to suppress their tremor. The half-life of alcohol 
is shorter than for most tremor-reducing medications. This diminishes the 
chance of tolerance and withdrawal after stopping alcohol. Since this drug 
also acts as an allosteric gaba a-agonist, subjective et-suppression with 
alcohol was also expected to increase the chance of finding effects with a 
subtype-selective gaba a-agonist.
For treatment of et and anxiety, similar clinical doses of benzodiazepines 
are used (Chouinard et al., 1982; Pahwa and Lyons, 2003). Early clinical 
studies also indicate that tpa023 has an anxiolytic effect (Atack et al., 2006). 
Therefore, the lack of effects of tpa023, which has a selective activity at 
the α2,3 subunit of the gaba a receptor, suggests that effects of gabaergic 
treatments of tremor are probably not mediated via the α2,3 subunit. 
However, we cannot rule out the possibility that the α2 and/or α3 subtypes 
are involved, but that tpa023 does not have enough intrinsic efficacy to 
produce clinical efficacy. It is uncertain which other gaba a-receptor 
subtypes are involved. The α5 subunit is mainly located in the hippocampus, 
and has been shown to be involved in memory processes (Wendt et al., 
2000). The α1 subunit is probably the best candidate, since it is the most 
widely distributed gaba a-receptor subtype (Benke et al., 2004). Recently, 
the α1 subunit knockout mouse has been introduced as an animal model 
for essential tremor as it exhibits postural and kinetic tremors that clearly 
reproduce the features of essential tremors ( Jankovic and Noebels, 2005; 
Kralic et al., 2005). This suggests that the expression of α1 subunits in the 
brains of patients with et may be abnormal. A pilot study in et patients, 
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however, could not demonstrate any relation between et and variants in the 
gene coding for this α1 subtype receptor (Deng et al., 2006). Another recent 
paper confirms this statement (Garcia-Martin et al., 2011). Nevertheless, 
other defects in the α1 subunit may still play a role in the pathophysiology of 
et. Since this receptor subtype is also involved in sedation, it may be difficult 
to find gabaergic tremor treatment that is completely devoid of this side 
effect, which is particularly cumbersome in elderly patients. 
It appeared that tremor power was largely reduced in all treatment groups 
in the first hour after treatment had started, as shown in figure 2. After this 
initial decrease, tremor remained stable during placebo treatment. This 
suggests that tremor was enhanced at baseline, e.g. by stress associated with 
the start of the study day (Whitney, 2006), or that there is a substantial initial 
placebo effect in treating et. The alcohol effects were still clearly present 
on top of these significant placebo effects. Nonetheless, a wash-in placebo 
infusion would be useful in future studies, to ensure a reduction to stable 
baseline tremor levels in this patient group.
Although clinical rating scales have proven their effectiveness in the 
assessment of et severity (Bain, 2000; Bain, 1998), the performance-
based tremor evaluation scale used in this study was not able to measure a 
statistically significant effect of alcohol on et, compared to placebo. The 
scoring of the test was performed by four trained persons, which might 
have caused too much inter-rater variability to detect a significant effect. 
Interestingly, the relationship between pbte and tremor amplitude in this 
relatively small study approximately complied with the logarhithmic criteria, 
which were proposed earlier (Elble et al., 2006).
In healthy volunteers, alcohol causes readily detectable increases in body 
sway and decreases in adaptive tracking (Zoethout et al., 2009), but this could 
not be found in our study. This could have been caused by two opposing 
effects of alcohol in this patient group. On the one hand, alcohol has positive 
effects on the tremor itself, counterbalancing the negative performance on 
this task caused by alcohol (Zoethout et al., 2009). Similar factors could play 
a role in the lack of effects on body sway. Previous studies have shown that 
patients with essential tremor had higher baseline ataxia scores compared 
to healthy controls, which diminished after alcohol ingestion (Klebe et 
al., 2005). As for general performance, the lack of a net effect of alcohol on 
body sway could be explained by a reduction of ataxia in et, combined with 
alcohol-induced postural instability. This might be a reason for the difference 
of alcohol effects between healthy volunteers and this patient group. 
The different effects of tpa023 in the current study and those observed in 
a previous study investigating the effects of tpa023 (de Haas et al., 2007) are 
approximately similar. tpa023 accounted for significant decreases in spv in 
both studies and vas alertness and body sway were not affected by tpa023 
treatment in both sessions. The only observed difference between the two 
studies is an increase in saccadic inaccuracy in the current study, which was 
not found in the previous study. The higher dose in the current study might 
be an explanation for this phenomenon.
This study has shown that treatment with an α2,3 subunit selective gaba a 
partial agonist was less effective compared to a stable level of alcohol in 
reducing et-symptoms. This suggests that the α2,3 subunit of the gaba a 
receptor is probably of less importance in the pathophysiology of essential 
tremor or in the beneficial effects of non-selective benzodiazepines and 
barbiturates. Additionally, the study has shown that the alcohol clamp is a 
reliable method for studies in patients with essential tremor. 
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figure 1 aver age gr aph of breath alcohol 
concentr ations (g/l) with sd error bars
Maximum and minimum values are shown with thin lines.
figure 2 gr aphs show changes from baseline of aver age 
maximum power of labor atory accelerometry in postur al 
and kinetic condition with 95%ci error bars
Closed circle is tpa023; square is alcohol; open circle is placebo.
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figure 3 gr aph shows change from baseline of aver age 
score on performance-based tremor evaluation scale with 
95%ci error bars
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table 2 least square means and pharmacodynamic  
differences relative to baseline for saccadic eye move-
ments, visual analogue scales, body sway and adaptive 
tr acking 
anova results are shown as contrasts, p-values and 95% ci.
cns 
Variable
ls means tpa023 - placebo Alcohol - placebo












413.6 443.0 459.0 -45.4 0.0002 -65.6, -25.1 -16.0 0.095 -35.3, 3.2
Latency (sec) 0.233 0.228 0.224 0.009 0.14 -0.003, 0.021 0.004 0.47 -0.008, 0.016
Inaccuracy 
(%)
7.5 6.5 6.6 1.0 0.0080 0.3, 1.6 -0.1 0.80 -0.8, 0.6
vas Alertness 
(mm)
61.6 56.2 64.2 -2.6 0.33 -8.1, 2.9 -8.0 0.0061 -13.2, -2.7
vas mood  
(mm)
73.8 73.2 73.9 -0.2 0.92 -3.9, 3.6 -0.7 0.68 -4.4, 3.0
vas Calmness 
(mm)














2.47 2.61 2.53 -0.06 0.71 -0.37, 0.26 0.09 0.54 -0.22, 0.40
table 1 least square means and treatment differences 
relative to baseline for different tremor variables





ls means tpa023 - placebo Alcohol - lacebo
tpa023 Alcohol Placebo difference P - 
value




Up-Down (uV) 0.192 0.149 0.151 26.8 0.19 -12.2, 83.1 -1.3 0.94 -31.7, 42.7
Left-Right (uV) 0.316 0.263 0.289 9.3 0.53 -18.8, 47.2 -8.8 0.53 -32.5, 23.3
Back-Forward (uV) 0.174 0.150 0.139 25.5 0.15 -8.8, 72.6 8.2 0.60 -21.5, 49.1
Average Maximum 
power (uV)
0.233 0.191 0.195 19.0 0.26 -13.4, 63.6 -2.3 0.88 -29.0, 34.5
Postural
Up-Down (uV) 0.623 0.390 0.588 6.0 0.77 -31.2, 63.3 -33.6 0.060 -56.8, 2.1
Left-Right (uV) 0.782 0.495 0.721 8.4 0.48 -15.0, 38.2 -31.4 0.0049 -45.9, -13.0
Back-Forward (uV) 0.482 0.317 0.508 -5.1 0.80 -39.7, 49.4 -37.6 0.043 -60.4, -1.7
Average Maximum 
power (uV)
0.652 0.410 0.620 5.2 0.75 -25.6, 48.7 -33.8 0.023 -53.1, -6.7
Kinetic
Up-Down (uV) 1.296 1.108 1.393 -6.9 0.58 -29.4, 22.7 -20.5 0.099 -39.9, 5.2
Left-Right (uV) 2.719 2.344 2.899 -6.2 0.41 -20.5, 10.6 -19.2 0.018 -31.7, -4.3
Back-Forward (uV) 1.112 0.866 1.228 -9.5 0.40 -29.6, 16.5 -29.5 0.0095 -44.8, -9.9
Average Maximum 
power (uV)
1.741 1.486 1.862 -6.5 0.48 - 23.6, 14.4 -20.2 0.036 -35.2, -1.7
Performance Based Tremor 
Evaluation score
15.1 13.9 16.1 -1.0 0.59 -5.1, 3.0 -2.2 0.26 -6.3, 1.9
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abstract
background Essential tremor (et) is a common movement disorder. 
Animal studies show that histaminergic modulation might affect the patho-
logical processes involved in the generation of et. Histamine-3 receptor in-
verse agonists (h3ria) have demonstrated attenuating effects on et in the 
harmaline rat model.
methods In this double-blind, three-way cross-over, single-dose, double-
dummy study the effects of 25 mg of a novel h3ria (mk-0249) and a stable 
alcohol level (0.6 g∙l-1) were compared to placebo, in 18 et-patients. Tremor 
was evaluated using laboratory tremorography, portable tremorography and 
a clinical rating scale. The Leeds Sleep Evaluation Questionnaire (lseq) and 
a choice reaction time (crt) test were performed to evaluate potential effects 
on sleep and attention, respectively.
results A steady state of alcohol significantly diminished tremor as 
assessed by laboratory tremorography, portable tremorography and clinical 
ratings compared to placebo. A high single mk-0249 dose was not effective in 
reducing tremor, but caused significant effects on the lseq and the crt-test.
conclusions These results suggest that treatment with a single dose 
of mk-0249 does not improve tremor in alcohol-responsive patients with 
et, whereas stable levels of alcohol as a positive control reproduced the 
commonly reported tremor diminishing effects of alcohol.
introduction 
Essential tremor (et) is one of the most common neurological disorders 
among adults, and is the most common tremor disorder  (Louis et al., 1998; 
Louis, 2001; Louis, 2005). In contrast with the resting tremor in Parkinson’s 
disease, et is provoked by postural and kinetic movements and has a domi-
nant frequency of 4-12 Hz (Pahwa and Lyons, 2003). The upper extremities 
are predominantly affected, but the head, the neck and the voice may also be 
involved, either separately or in combination. The prevalence of et is esti-
mated to be 4% within the general population (Pahwa and Lyons, 2003), and 
approximately 5% in the population above 65 years (Louis et al., 1998). 
Current pharmacological treatment, including beta blockers, benzodiaz-
epines and primidone, act symptomatically and have variable effectiveness 
(Chen and Swope, 2003). Moreover, the occurrence of side effects, like se-
dation, weight gain and cognitive impairment, limit their use. Estimations 
indicate that alcohol is effective in approximately 70% of et patients (Lou 
and Jankovic, 1991; Koller et al., 1994). This finding is confirmed by controlled 
studies where alcohol was administered acutely (Growdon et al., 1975; Koller 
and Biary, 1984). It most likely acts via a reduction of central over-activity, 
which results in reduced tremor amplitude, whereas the frequency remains 
unaffected (Koller and Biary, 1984; Koller, 1991). et can also be treated sur-
gically. Stereotactic thalamotomy and continuous deep-brain stimulation are 
promising techniques for patients with severe functional disability who are 
unresponsive to drug therapy (Koller, 1991; Louis, 2005). These two proce-
dures are equally effective, but thalamic stimulation has fewer adverse effects 
and results in a greater improvement in function (Schuurman et al., 2000).
Because little is known about the pathophysiology of et, the search for 
novel pharmacological treatment options has been challenging. Recent 
studies indicate that et might be attributed to a defect in the central 
oscillatory systems at the level of the inferior olivary nucleus of the medulla 
oblongata (Deuschl and Elble, 2000). Since histaminergic neurons project 
to the inferior olivary nucleus in the brainstem, the histaminergic system 
might play a role in the modulation of pathological processes involved in the 
generation of et. In addition, animal models for et show that modulating 
histaminergic tone in the central nervous systems (cns) neurons might be 
a fruitful strategy in the development of future pharmacological treatment 
(Merck Research Laboratories (mrl) – data not shown).
The histaminergic system is widely disseminated in the cns and regulates 
multiple functions including, arousal, satiety, attention and cognition. 
Histaminergic neurons originate in the tuberomammillary nucleus of the 
hypothalamus and project throughout the cns, including the inferior olivary 
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nucleus in the brainstem. Currently, four types of histamine receptors have 
been identified. Postsynaptically localized histamine subtype-1 (hi) and 
histamine subtype-2 (h2) receptors mediate the preponderance of cns 
effects, while the histamine subtype-3 (h3) receptors are localized on the 
presynaptic membrane as autoreceptors, and regulate the production and 
synaptic release of histamine as a part of a negative feedback mechanism. 
h3-receptors are mainly distributed in the cns and function to modulate 
histaminergic effects in the brain, making them a potential target for 
pharmacological manipulation. h3-receptors signal constitutively, which 
serves to tonically suppress histamine production at baseline. 
Recent preclinical findings indicate a potential role for the histaminergic 
system in the treatment of et. Rats treated with the β-carboline harmaline, 
a toxin from the Syrian Rue plant, develop an 8-12 Hz postural and kinetic 
tremor that is clinically similar to et (Martin et al., 2005). The toxin also 
activates and synchronizes firing in the olivocerebellar system (Martin et al., 
2005). Harmaline has been used to develop a rat model of et that responds 
in a dose dependent fashion to several of the currently available treatments 
for the disease, including propranolol, alcohol and benzodiazepines (Martin 
et al., 2005). An increase in brain histamine induced by single doses of 
histamine modulating agents at the h3-receptor reduced tremor significantly 
in a dose-dependent fashion in the harmaline rat model of et (mrl – data 
not published). Thus, histaminergic modulation might also contribute to the 
treatment of tremor seen in et. 
An increase in histamine concentration in the brain by pharmacological 
interference at the h3-receptor would avoid peripheral histamine effects. 
While a classical antagonist would only interfere with histamine-mediated 
negative feedback, h3-receptor inverse agonists have been demonstrated to 
decrease constitutive h3-receptor signalling, thus blocking tonic inhibition of 
histamine synthesis and release and further potentiating histaminergic effects 
(Arrang et al., 2007).
The primary objective of this study was to evaluate the effects of a single dose 
of mk-0249, a recently developed h3-receptor inverse agonist (shown in 
figure 1), on average maximum tremor power in et-patients. The chemical 
and biological characteristics of this class of h3-receptor inverse agonists 
have recently been published (Nagase et al., 2008). Since most et-patients 
experience attenuating effects of alcohol on their symptoms (Rajput et al., 
1975), the effects of mk-0249 on et were compared to a steady state level of 
alcohol as a positive control, versus placebo. The study design, methodologies 




Eighteen patients diagnosed with et, were included in the study. The effects 
of mk-0249 were investigated and compared to alcohol (as an active compar-
ator) and placebo in a randomized, double-blind fashion. Since ethanol was 
delivered as an intravenous infusion and mk-0249 was administered orally, a 
double-dummy design was adopted to maintain the double-blind character 
of the study. On each study day, patients received one of three different treat-
ment combinations: active ethanol with mk-0249 placebo, ethanol placebo 
(glucose 5% vehicle) with active mk-0249 and ethanol placebo with mk-0249 
placebo. The washout period between treatments was at least seven days.
Patients
Men and women of at least 18 years of age with documented et for at least 
six months were recruited from the databases of the Leiden University 
Medical Centre, University Medical Centre St. Radboud in Nijmegen 
and from a number of local surrounding hospitals. Patients were informed 
about the contents of the study during an information visit. Once having 
agreed to participate and having signed informed consent, patients visited 
the research unit for a medical screening, at which time they were medically 
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screened to evaluate eligibility for study participation. A neurologist ( J.G.) 
with experience in movement disorders clinically confirmed the diagnosis of 
et of the hands and forearms according to the diagnostic criteria for ‘classic 
et’ defined by the consensus statement of the Movement Disorder Society 
(Deuschl et al., 1998). This statement was adapted from previous criteria 
established by the Tremor Research Investigation Group (trig) (Deuschl 
et al., 1995) as well as from a more recent study indicating the importance 
of kinetic tremor (Brennan et al., 2002). An isolated head tremor was not 
allowed. Patients were also selected for having symptoms that, by history, 
were relieved with alcohol consumption.
Only patients who stated a positive effect of alcohol on their tremor 
symptoms were included to maximize the power of alcohol as a positive 
control. Patients had to refrain from alcohol 48 hours prior to a treatment day 
and from caffeine-containing products for at least 12 hours before treatment. 
They were not allowed to use their own (anti-tremor) medications and had to 
abstain from grapefruit (juice) and St. John’s Wort for at least 2 weeks before 
the start of the study until completion of the study. They were not allowed to 
drink more than six units of caffeine-containing products or three beverages 
of alcohol per day or smoke more than five cigarettes per day during the total 
study period. On treatment days, the use of caffeine-containing products 
or smoking was not allowed. The study was approved by the Medical 
Ethics Review Board of Leiden University Medical Centre, and performed 
according to their standards. The study was performed in compliance with 
the standards of Good Clinical Practice and the Declaration of Helsinki.
Study treatments
On study days, the effects of a single oral dose of 25 mg mk-0249 or an 
intravenous alcohol infusion (10% w/v in 5% glucose) were examined. This 
mk-0249 dose was the highest single dose that was previously administered 
to healthy elderly male and female subjects. Elsewhere, single doses of mk-
0249 up to 150 mg were safely administered to healthy young male volunteers. 
A yet unpublished positron emission tomography (pet) study in healthy 
young males suggests that the peak brain h3-receptor occupancy (after 
a single dose of 25 mg) would be approximately 90%, and be reached 
after approximately 6 hours. Given the long half life of this compound 
(approximately 14 hours), we would expect this level of receptor occupancy 
to be maintained during the entire observation period.
To diminish variability due to changing alcohol levels, alcohol was infused 
using a recently developed clamping method (Zoethout et al., 2008). Based 
on a procedure for clamping breath alcohol concentrations (brac) previously 
described by O’Connor et al. (O’Connor et al., 1998) a spreadsheet-based 
alcohol clamping paradigm was developed. Changes in brac were used to 
adapt the intravenous infusion rate of alcohol (10% w/v in 5% glucose). This 
resulted in stable alcohol levels with minimal variability (Zoethout et al., 
2008). The alcohol clamp has previously been well-tolerated and produced 
statistically significant pharmacodynamic cns effects (Zoethout et al., 2009).
An alcohol level of 0.6 g∙l-1 was chosen for this study, because this level is 
routinely achieved during social drinking, without causing too many adverse 
effects. Moreover, a prior study showed tremor reducing effects of alcohol 
at a mean level of 0.55 g∙l-1, after a single oral dose (Zeuner et al., 2003). 
Considering its pharmacokinetic profile, it was estimated that the action 
of mk-0249 would peak at about four hours and be sustained at high levels 
for at least seven hours. Consequently, to optimize the value of alcohol as 
a positive control, a level of 0.6 g∙l-1 was maintained for seven hours . The 
research assistant who was responsible for performing breath samples was 
unblinded to the alcohol infusion, but this person was not involved in any 
other assessments, to preserve the double-blind character of the study. 
This was a double-dummy study, so each active treatment was accompa-
nied by administration of placebo for the alternative treatment. Thus, a match-
ing placebo capsule for mk-0249 was given during the active alcohol occasion. 
On the day of administration of mk-0249 25 mg, a sham clamp was performed 
with glucose 5%, including preprogrammed pump rate changes and breath 
sampling (without revealing the results to the patient or the study team).
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It has been suggested that tremor symptoms could be enhanced before 
dosing, e.g. by stress associated with the start of the study (Whitney, 2006) 
To by-pass this problem a 90-minute, a single-blind saline infusion (0.9%) 
preceded the actual alcohol/placebo infusion. After this 90 min ‘run-in 
phase’, mk-0249 (or placebo) was administered orally at t = 0 min and at the 
same time we started the alcohol (or placebo) clamping procedure. The run-
in phase was single blind, and patients were told that the experiment started 
at t = - 90 min. The data collected between t = –90 min and t = 0 min were 
discarded.
Safety
Adverse events, ecg, blood pressure and heart rate measurements were 
assessed throughout the study. During study days, a parallel glucose infusion 
(glucose 5%) was administered to all patients during the first ten minutes 
post-start, to minimize pain and discomfort in the infusion arm, caused by 
the alcohol infusion.
Drug concentrations
Breath alcohol samples (brac) were performed using the hand-held Alco-
Sensor iv meter (Honac, Apeldoorn, the Netherlands). The pharmacokinetic 
profile of mk-0249 had already been extensively investigated, and it was 
therefore decided not to analyze the pharmacokinetic samples of mk-0249 
in this study.
Tremor evaluation
Tremor evaluations were performed at screening, predose (within 60 minutes 
prior to dosing) and at 60, 150, 240, 330, 420 and 510 minutes postdose on 
each study day.
laboratory tremorography Tremor evaluation was measured 
according to the methodology of Gironell et al. (Gironell et al., 1999). Tremor 
was evaluated with three miniature linear piezo-electric accelerometers 
(Nihon Kohden, mt-3t), which were attached to the distal end of the 
clamp, above the fingertips of the dominant arm. The accelerometers were 
placed at right angles to one another to enable three-dimensional analysis 
of movement (Van Hilten et al., 1991; Gironell et al., 1999). The upper limb 
tremor was recorded in three positions, each held for a 60-second interval: 
(1) at rest, with the arm hanging relaxed along the body, (2) postural, with 
the arm held in an outstretched, horizontal, prone position and (3) kinetic, 
moving the hand from an outstretched position to the nose, as accurately as 
possible. 
portable tremorography Tremor was also evaluated using a 
portable accelerometer (Dynaport MiniMod3) that consisted of three linear 
accelerometers placed in a perpendicular array, a data logger and a power 
source. The portable accelerometer is the size of a match-box, and was 
affixed to the fingertips of the dominant hand. The portable tremorography 
assessment was performed immediately following each laboratory 
tremorography assessment on the same hand, in exactly the same way.
performance-based clinical rating scale (crs) Clinical rating 
scales are often described as useful methods to assess tremor severity in 
et patients (Bain et al., 1993; Louis et al., 2000). A performance-based 
clinical rating scale (Louis et al., 1999) was used in this study to investigate 
the practical implications of alcohol and mk-0249 treatment on 15 simple, 
‘daily-life’ activities (e.g. carry a tray with two filled glasses, thread a needle 
or pour liquid from a milk carton into a glass). Performance on the crs was 
videotaped to permit post-hoc analysis by a blinded independent expert. 
Performance on each item was scored from 0 (no difficulty) to 4 (unable to 
perform). The total sum of activity scores was calculated.
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Additional measurements
choice reaction time (crt) test To investigate the possible effects 
of mk-0249 (and alcohol) on psychomotor function, a crt test was adminis-
tered. Choice reaction time was chosen for its known sensitivity to the seda-
tive effects of alcohol and other drugs (Grant et al., 2000), as well as to stimu-
lant effects of drugs like caffeine (Lieberman, 2007). During this test, either 
the word ‘left’ or the word ‘right’ was presented on a computer screen. All pa-
tients were instructed to press a corresponding button as quickly as possible. 
There were 32 trials for which each stimulus word was chosen randomly with 
equal probability. The duration of the interstimulus interval varied randomly. 
Both the amount of correct scores and the reaction time were assessed. crt 
was tested at screening, predose (within 60 minutes prior to dosing) and at 
60, 150, 240, 330, 420 and 510 minutes postdose on each study day.
leeds sleep evaluation questionnaire (lseq) Since mk-0249 
is thought to increase cns histamine levels, it is expected to be associated 
with alerting effects. Therefore the lseq was administered, to investigate 
the possible effects of mk-0249 on a wide scale of sleep parameters (Parrott 
and Hindmarch, 1980). The lseq is a standardized self-reporting instrument 
comprising ten 100 mm visual analogue scales that score the ease of getting 
to sleep, quality of sleep, ease of awakening from sleep and alertness and 
behavior following wakefulness (Parrott and Hindmarch, 1980). The lseq 
was administered at screening and pre dose on the morning of day 1 and at 
24 hours post dose. To maximize compliance, patients were contacted by 
telephone the next morning, 24 hours after dosing, to check whether the 
lseq was completed.
Statistical analyses
Changes in maximum kinetic tremor power (especially backward-forward 
movements), as assessed by laboratory accelerometry were of primary con-
cern. Given their pharmacologic profiles, tremor measurements between 240 
and 510 minutes post dose were specifically hypothesized to be affected to the 
largest extent by treatment. A mean treatment-induced reduction of 25% (or 
more) compared to average baseline tremor scores was considered clinically 
meaningful. With 18 patients, there was more than 99% power to detect such 
a difference between mk-0249 and placebo or between alcohol and placebo.
Because of their skewed response distribution all tremor parameters 
were analyzed after log-transformation. Log transformed changes from 
baseline for accelerometry tremor endpoints were analyzed with mixed 
effects models (using sas proc mixed). This resulted in least square 
means estimates for each treatment that indicate the change from baseline 
on the log scale. Subsequently, mean treatment effects were calculated as 
the contrasts between these least square means for placebo and either mk-
0249 or alcohol after back transformation from the log scale. The average of 
the measurements at 240, 330, 420 and 510 minutes was calculated within the 
statistical model. All results are presented on the original scale and reported 
as percent changes (all analyses were two-sided, with a significance level of 
0.05). Between treatment comparisons were made for lseq , crt and crs 
on the original scale. All calculations were performed using sas v9.1.2 for 
Windows (sas Institute, Inc., Cary, nc, usa).
results
Patients
Nineteen et-patients were found eligible for study participation. Apart 
from their tremor, they were judged to be in good health on the basis of 
medical history, physical examination and routine laboratory data. One 
patient dropped out after the first period because of the need to resume anti-
depressive medication. This patient was replaced by another patient, who 
received the same treatment randomization order. Eighteen patients (11 men, 
7 women) completed the study per protocol. Patients were on average 47 
years of age (range 19-81), had an average weight of 75 kg (range 61-98 kg) and 
an average height of 178 cm (range 161-191 cm).
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Alcohol concentrations
Figure 2 shows the mean graph of breath alcohol values for all 18 patients. The 
average target level of 0.60 g∙l-1 was achieved within 30 minutes. The steady 
state level was maintained until approximately 7 hours post-dose, after which 
alcohol infusion was stopped. Thereafter, brac returned to baseline.
Tremor evaluation
laboratory tremorography Baseline tremor scores are presented 
in table 1. Treatment effects on maximum tremor power obtained by 
laboratory tremorography are summarized in table 2. mk-0249 treatment had 
no significant effect on the laboratory tremorography in any direction. For 
the kinetic condition, the mean maximum power of the backward-forward 
direction (primary endpoint) was reduced by 34.9% (95% ci: -52.7%, -17.3%) 
and that of the left-right direction was reduced by 42.0% (95% ci: -59.9%, 
-24.5%) after alcohol infusion compared to placebo. Also, mean average 
maximum power was reduced by 33.4% (95%ci: -49.8%, -17.2%) compared 
to placebo (figure 3). During the postural condition of the laboratory 
tremorography, alcohol infusion significantly reduced mean maximum 
power of both left-right (-38.9% (95% ci: -67.2%, -11.6%)) and backward-
forward (-38.4% (95% ci: -66.1%, -11.9%)) tremor direction compared to 
placebo. The mean average maximum power was also significantly reduced 
after alcohol treatment (-37.0% (95% ci: -62.7%, -12.0%)) for the postural 
condition compared to placebo (figure 4). During the rest condition, alcohol 
infusion significantly reduced mean maximum power of both the up-down 
(-26.7% (95% ci: -53.8%, 0.0%)) and left-right condition (-46.1% (95% ci: 
-73.5%, -19.4%)) compared to placebo. Alcohol also reduced the mean average 
maximum power by 37.6% (95% ci: -62.5%, -13.4%) in the rest condition 
compared to placebo. Table 2 also shows additional contrasts (e.g. up-down 
for kinetic and postural and back-forward for rest) for which statistical 
significance was not noted.
portable tremorography Treatment effects on tremor power 
variables obtained by portable accelerometry are summarized in table 3. No 
effects of mk-0249 were observed in the rest, postural or kinetic condition 
during portable accelerometry measurements. Alcohol decreased mean 
maximum power in the up-down (-25.7% (95% ci: -42.9%, -8.8%), left-right 
(-27.8% (95% ci: -43.2%, -12.6%) as well as in the backward-forward (-32.7% 
(95% ci: -55.5%, -10.3%) directions compared to placebo, during the kinetic 
assessment. Mean average maximum power was also significantly reduced 
by 27.9% (95% ci: -44.2%, -11.8%) compared to placebo (figure 5). During 
postural measurements, alcohol reduced mean maximum tremor power 
in both the left-right and the backward-forward direction compared to 
placebo by 28.4% (95% ci: -56.6%, -1.1%) and 35.9% (95% ci: -69.4%, -3.8%) 
respectively. Mean average maximum power was also significantly reduced 
(-29.0% (95% ci: -58.2%, -0.8%) during postural assessments compared to 
placebo (figure 6). No significant changes were observed during the rest 
condition for any treatment, compared to placebo.
performance-based clinical rating scale The videotaped clinical 
rating scales were analysed by a blinded independent expert (e.d.l.). While 
all assessment time points were videotaped, performance scores obtained 
at t = 240 minutes were selected (the expected Tmax for mk-0249) for 
comparison between treatments. This analysis showed a significant effect of 
alcohol. Alcohol scores were on average 17% lower (95% ci: 3, 28%) compared 
to placebo, when both treatments were corrected for baseline values. There 
was no apparent effect of mk-0249.
clinical rating scale vs. tremorography
To estimate the predictive value of the experimental tremor registrations 
(tremorography) for clinical outcome, correlation coefficients of the clinical 
rating scale vs. tremorography were calculated at 240 minutes post dose. 
The Pearson correlation coefficient for the clinical rating scale vs. laboratory 
tremorography was 0.33 (p=0.018). The Pearson correlation coefficient for 
the clinical rating scale vs. portable tremorography was 0.38 (p=0.006).
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Additional measurements
choice reaction time (crt) During the crt test both reaction time 
(msec) and the number of correct responses were determined. Both alcohol 
and mk-0249 affected the reaction time significantly during this test. Alcohol 
infusion resulted in a mean increase of 43.2 msec (95% ci: 18.0, 68.5 msec) and 
mk-0249 resulted in a mean increase of 27.6 msec (95% ci: 1.8, 53.4 msec), as 
compared to placebo. The mean number of correct reactions after mk-0249 
treatment (31.49) improved slightly but statistically significantly compared to 
placebo treatment (31.23) by 0.26 trials (95% ci: 0.00, 0.52; p < 0.05). There 
was no apparent effect of alcohol on the number of correct responses. 
Leeds Sleep Evaluation Questionnaire (lseq)
There were no significant effects of alcohol on the lseq. On the night fol-
lowing administration, mk-0249 decreased the ‘speed of getting to sleep’ (i.e. 
getting to sleep more slowly than usual) by 12.4 mm (95% ci: -23.9, -0.9 mm) 
compared to baseline (pre-dose). mk-0249 also changed ‘restlessness dur-
ing sleep’ (i.e. more restless than usual) and the ‘periods of wakefulness’ (i.e. 
more periods of wakefulness than usual) with 30.4 mm (95% ci: -38.9, -21.8 
mm) and 30.2 mm (95% ci: -38.8, -21.6 mm) respectively. By comparison, in a 
study by Hindmarch et al. (Hindmarch et al., 2000), 150 mg caffeine increased 
the time to sleep onset and was associated with deterioration in the perceived 
quality of sleep compared with placebo. Mean changes in the 100 mm scale 
were 22 and 16 mm for time to sleep onset and quality of sleep, respectively.
Adverse events
All 19 subjects enrolled in the study were included in the assessment of 
safety and tolerability. Eighteen (18) of the 19 subjects enrolled, reported 
one or more clinical adverse experiences (ae). No laboratory adverse 
experiences were reported, no serious adverse experiences were reported, 
and no deaths occurred. If a subject reported the same ae more than once 
(per treatment period), this ae was counted only once. A total of 115 clinical 
adverse experiences were reported and 31 occurred while taking mk-0249. 
Of the 31 clinical adverse experiences reported while taking mk-0249, 25 
were considered to be related to study drug. The most common drug-related 
adverse experiences during active mk-0249 treatment were perspiration (5 
subjects), insomnia (4 subjects), and nausea (3 subjects). The most frequently 
reported adverse events after alcohol treatment were sleepiness (9 subjects), 
inebriation (7 subjects), a painful arm at the start of the infusion (7 subjects), 
dizziness (7 subjects) and headache (6 subjects). Headache was also reported 
by 6 subjects after placebo treatment. All symptoms were transient and mild 
in severity. One patient on placebo discontinued the study due to ‘moderate 
lightheadedness’, which was considered to be related to discontinuation of 
his own medication. 
discussion 
A stable level of alcohol (0.6 g∙l-1) for seven hours was associated with a 
reduction in average maximum tremor power by approximately 30%. The 
tremor diminishing effects of alcohol were not only observed using laboratory 
accelerometry, the pre-specified primary endpoint, but we also found that the 
portable tremorographer detected changes in tremor associated with alcohol 
treatment. Although it has only been tested under standard experimental 
conditions here, portable tremorography could be a promising technique for 
portable, standardized, ambulatory tremor registrations.
The present study confirms the commonly reported attenuating effects of 
alcohol on et that have been demonstrated earlier, in both database studies 
(Lou and Jankovic, 1991; Koller et al., 1994) and in controlled trials (Growdon 
et al., 1975; Koller and Biary, 1984). However, in contrast to most controlled 
trials in which the effect of alcohol on et is being studied, our results were 
obtained under tightly controlled, stable alcohol levels for a prolonged period 
of time. These fixed levels accounted for a stable condition that minimized the 
variability. The steady state level of alcohol clearly showed tremor relieving 
effects, confirming that the (partly experimental) methods and the design 
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of this study were sensitive enough to detect tremor reductions. The alcohol 
effects also set a benchmark for clinically significant tremor reductions, 
demonstrating that the effects of mk-0249 did not only fail to reach statistical 
significance, but also that they were much smaller than what is achieved with 
alcohol.
In contrast to resting tremor in Parkinson’s disease, essential tremor is 
characterized by postural and kinetic components (Elble, 2000), which were 
both affected by alcohol treatment in this study. Tremor symptoms at rest do 
occur in some et patients (Louis, 2006), and this finding may explain the 
effects of alcohol in the resting condition during laboratory accelerometry 
measurements. The effects of alcohol on et were maintained for most of 
the infusion period. Although acute tolerance to the effects of alcohol is 
frequently described (Martin and Moss, 1993; Hiltunen et al., 2000), no 
indications for acute changes in effects of alcohol on tremor power were 
observed in this study. 
Despite the promising results during the preclinical phase, single doses 
of mk-0249 (25 mg) did not reduce maximum tremor power on any of the 
tremor measurements in this study of alcohol-responsive et-patients. On 
average, most tremor measurements even seemed to deteriorate slightly with 
the h3-inverse agonist, although this was not statistically significant. The 
clear improvements with alcohol indicated that the power of the study and 
the sensitivity of the methods were sufficient to detect a clinically significant 
tremor reduction. Thus, a single dose of mk-0249 25 mg was not effective 
in reducing et symptoms and does therefore not seem to have a beneficial 
effect on human et. This was not due to a lack of brain penetration or cns 
activity, since clear cns effects were observed on the crt and the lseq after 
mk-0249 administration. Moreover, a comparable single dose of mk-0249 
was associated with alerting effects in a study of sleep-deprived healthy male 
volunteers (Iannone et al., 2010). It cannot be excluded that a more sustained 
exposure of mk-0249 would be needed for amelioration of tremor than would 
have been achieved with a single dose.
Interestingly, an analysis of linkage in a two-generation pedigree of patients 
with Tourette’s syndrome recently identified a rare functional mutation in 
the hdc gene encoding L-histidine decarboxylase, the rate-limiting enzyme 
in histamine biosynthesis. These findings pointed to a role for histaminergic 
neurotransmission in the mechanism and modulation of Tourette’s 
syndrome and tics (Ercan-Sencicek et al., 2010). This suggests that mk 0249 
may be beneficial for patients with Tourette’s syndrome and related features 
of compulsive behavior, but this hypothesis has not been tested.
Because neuronal histamine is one of the most important systems that 
stimulates and maintains wakefulness (Yanai and Tashiro, 2007), and because 
mk-0249 exerts its action through the histaminergic system, we expected that 
mk-0249 would be alerting. The significant effect on the lseq confirmed 
that mk-0249 had a pharmacodynamic effect in the cns in this population of 
patients. This effect was in agreement with the reported sleep-related adverse 
events. An h3-inverse agonist was also expected to increase attentiveness. 
mk-0249 caused a marginal increase in reaction time as measured by the 
crt-test, but was also associated with a statistically significant improvement 
in the number of correct scores. This could signify a shift in performance 
strategy from speed to accuracy. At the same time, it should be realized that 
the changes were very small in magnitude. These effects were however quite 
different from those of alcohol, which caused a significant delay in reaction 
time on the crt test and only little effect on the lseq.
There was a weak positive correlation between the clinical rating scale 
and the tremorography data. Hence, experimental tremor registrations used 
in this study were only slightly predictive for clinical outcome as measured 
by the clinical rating scale. However, both clinical ratings and portable 
tremorography improved after alcohol administration, albeit with somewhat 
less sensitivity than laboratory tremorography, showing convergent evidence 
for the effects of alcohol on et. These findings indicate the importance of 
performing clinical rating scales in addition to portable tremor registration 
methods, in studies focusing on tremor severity.
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A prior tremor study at our centre (chdr – data on file) showed large 
pharmacodynamic placebo effects during the first hour following the start 
of the study. Since tremor increases during anxiety or excitement (Whitney, 
2006), this placebo effect was attributed to stress at the start of the experiment. 
It was therefore decided to precede the actual clamping phase by a single-
blinded 90 min saline infusion period, to allow adaptation to the study 
circumstances before baseline values for each assessment were obtained. In 
contrast to the previous tremor study (chdr – data on file), no placebo effect 
was observed in the present study. An ‘adaptation period’ therefore seems to 
be a useful procedure in studies focusing on et measurements.
mk-0249 showed clear cns-effects that were compatible with its 
pharmacological action as a h3ria, but it did not reduce tremor in this 
study. In contrast to alcohol, most tremor measurements seemed to increase, 
although this never reached statistical significance. To the extent that the 
hypothesis could be tested with exposures from a single dose, these findings 
suggest that the histamine-3 receptor does not play an important role in the 
treatment of essential tremor. The harmaline rat model therefore does not 
seem a valuable predictor for the effects of histaminergic modulation on 
human et. Moreover, h3-inverse agonism as a target for treatment of human 
et seems of minor relevance. Clearly, more research is needed to investigate 
the role of histaminergic and other systems in the pathophysiology and 
possible treatment of this common movement disorder. This study shows 
that such studies are feasible and informative, using sensitive tremor 
detection methods in relatively small numbers of patients.
figure 1 chemical structure of mk-0249
figure 2 aver age gr aph of breath alcohol concentr ation 
(brac) with sd’s as error bars
figure 3 least square means gr aph of labor atory 
accelerometry in the kinetic condition
Average max power (change from baseline), with 95% ci error bars for mk-0249 
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figure 4 least square means gr aph of labor atory 
accelerometry in the postur al condition
Average max power (change from baseline), with 95% ci error bars for  mk-0249  
(up) and alcohol (down).
figure 5 least square means gr aph of portable 
accelerometry in the kinetic condition
Average maximum power (change from baseline), with 95% ci error bars  
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figure 6  least square means gr aph of portable 
accelerometry in the postur al condition
Average maximum power (change from baseline), with 95% ci error bars for   
mk-0249  (up) and alcohol (down).
table 1 baseline tremor values (in μv) with standard 
deviations between br ackets
Placebo mk-0249 Alcohol
Kinetic
Back-Forward 1.11 (0.73) 1.21 (1.15) 1.05 (0.77)
Average 1.88 (1.11) 1.92 (1.32) 1.89 (1.01)
Up-Down 1.81 (1.82) 1.84 (2.23) 1.72 (1.63)
Left-Right 2.70 (1.71) 2.72 (1.90) 2.91 (2.00)
Postural
Back-Forward 0.89 (1.35) 1.05 (2.13) 1.08 (1.86)
Average 1.21 (1.37) 1.16 (1.13) 1.22 (0.98)
Up-Down 1.61 (2.31) 1.35 (1.57) 1.44 (1.53)
Left-Right 1.11 (0.83) 1.07 (0.86) 1.14 (0.63)
Rest
Back-forward 0.15 (0.05) 0.17 (0.10) 0.20 (0.17)
Average 0.31 (0.19) 0.46 (0.50) 0.50 (0.38)
Up-Down 0.33 (0.34) 0.50 (0.68) 0.56 (0.77)
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table 2 least square means and treatment contr asts of 






ls Means 4-8½h 
(change from baseline)
mk-0249 vs. Placebo Alcohol vs. Placebo
Placebo mk-0249 Alcohol differ- 
ence
p-value 95% CI differ-
ence
p-value 95% CI
Kinetic Back-Forward (μV) 10.4% 20.1% -24.4% 9.7% 0.3771 -12.2% 31.7% -34.9% 0.0003 -52.7% -17.3%
Average (μV) 17.1% 19.0% -16.3% 1.9% 0.8440 -17.3% 21.0% -33.4% 0.0002 -49.8% -17.2%
Up-Down (μV) 10.7% 26.4% -10.0% 15.6% 0.3527 -18.1% 49.7% -20.8% 0.1474 -49.6% 7.7%
Left-Right (μV) 23.6% 19.6% -18.5% -4.0% 0.7058 -25.1% 17.1% -42.0% <.0001 -59.9% -24.5%
Postural Back-Forward (μV) -1.5% 27.9% -39.9% 29.4% 0.1284 -8.9% 68.6% -38.4% 0.0056 -66.1% -11.9%
Average (μV) 5.2% 22.4% -31.7% 17.2% 0.3000 -15.9% 50.6% -37.0% 0.0047 -62.7% -12.0%
Up-Down (μV) -0.4% 30.9% -22.3% 31.3% 0.1200 -8.5% 72.1% -21.9% 0.1558 -53.2% 8.7%
Left-Right (μV) 8.5% 16.6% -30.4% 8.0% 0.6452 -27.0% 43.3% -38.9% 0.0063 -67.2% -11.6%
Rest Back-Forward (μV) 1.1% 13.0% -11.4% 11.9% 0.2048 -6.7% 30.6% -12.6% 0.1309 -29.1% 3.9%
Average (μV) 19.9% 5.6% -17.7% -14.3% 0.2905 -41.6% 12.8% -37.6% 0.0033 -62.5% -13.4%
Up-Down (μV) 14.0% -5.6% -12.7% -19.6% 0.1588 -47.5% 8.0% -26.7% 0.0499 -53.8% 0.0%
Left-Right (μV) 33.3% 13.1% -12.8% -20.2% 0.1791 -50.4% 9.7% -46.1% 0.0012 -73.5% -19.4%
table 3 least square means and treatment contr asts of 






ls Means 4-8½h  
(change from baseline)
mk-0249 vs. Placebo Alcohol vs. Placebo
Placebo mk-0249 Alcohol difference p-value 95% CI difference p-value 95% CI
Kinetic Back-Forward (mG) 16.8% 26.8% -15.9% 10.0% 0.4640 -17.4% 37.5% -32.7% 0.0054 -55.5% -10.3%
Average (mG) 7.1% 15.9% -20.8% 8.8% 0.3620 -10.6% 28.3% -27.9% 0.0012 -44.2% -11.8%
Up-Down (mG) 1.4% 10.6% -24.3% 9.2% 0.3642 -11.1% 29.6% -25.7% 0.0039 -42.9% -8.8%
Left-Right (mG) 7.4% 16.0% -20.4% 8.6% 0.3474 -9.7% 27.0% -27.8% 0.0007 -43.2% -12.6%
Postural Back-Forward (mG) -0.4% 27.9% -36.3% 28.3% 0.2129 -16.9% 74.6% -35.9% 0.0294 -69.4% -3.8%
Average (mG) -8.3% 25.8% -37.3% 34.2% 0.0912 -5.7% 75.2% -29.0% 0.0443 -58.2% -0.8%
Up-Down (mG) -9.1% 16.1% -36.1% 25.2% 0.1833 -12.5% 63.8% -27.0% 0.0587 -55.9% 1.0%
Left-Right (mG) -9.6% 27.0% -37.9% 36.6% 0.0649 -2.4% 76.7% -28.4% 0.0415 -56.6% -1.1%
Rest Back-Forward (mG) 11.1% 3.7% -6.1% -7.4% 0.5310 -31.2% 16.3% -17.2% 0.1285 -39.8% 5.2%
Average (mG) -4.7% 3.5% -7.2% 8.2% 0.4163 -12.0% 28.5% -2.5% 0.7874 -21.2% 16.2%
Up-Down (mG) -13.8% 0.6% -9.4%  14.4% 0.1456 -5.2% 34.2% 4.4% 0.6257 -13.8% 22.7%
Left-Right (mG) -7.1% 4.9% -7.8%  12.0% 0.2939 -10.8% 34.9% -0.7% 0.9444 -21.5% 20.0%
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abstract
gsk598809 is a novel selective dopamine d₃ receptor antagonist, currently in 
development for treatment of substance abuse and addiction. In a blinded, 
randomized, placebo-controlled study, effects of single oral doses of 175 mg 
gsk598809 were evaluated in healthy volunteers. Pharmacokinetics, central 
nervous system (cns) effects and potential for interactions with alcohol were 
evaluated, using an alcohol infusion paradigm and analysis of eye movements, 
adaptive tracking, visual analogue scales, body sway, serum prolactin and 
verbal visual learning test. Adverse effects of gsk598809 included headache, 
dizziness and somnolence. Plasma concentration of gsk598809 was maximal 
2-3 hours postdose and decreased with a half life of roughly 20 hours. cns 
effects were limited to prolactin elevation and decreased adaptive tracking. 
Co-administration of gsk598809 and alcohol did not affect alcohol 
pharmacokinetics, but caused a 9% decrease of cmax and a 15% increase of 
auc of gsk598809. cns effects of co-administration were mainly additive, 
except a small supra-additive increase in saccadic reaction time and decrease 
in delayed word recall. In conclusion, gsk598809 causes elevation of serum 
prolactin and a small decrease in adaptive tracking performance. After co-
administration with alcohol, effects of gsk598809 are mainly additive and the 
combination is well tolerated in healthy volunteers.
introduction
A large body of evidence indicates that the mesolimbic dopaminergic 
pathway, which includes dopaminergic neurons in the ventral tegmental area 
projecting to the nucleus accumbens and other limbic forebrain structures, is 
one of the major neuronal circuits involved in the acute rewarding effects of 
drugs of abuse (Cami and Farre, 2003; Hyman and Malenka, 2001; Hyman, 
2005; Koob and Nestler, 1997; Koob et al., 1998). Although addictive drugs 
interact with many different neurotransmitter systems, most drugs ultimately 
cause an acute increase in synaptic dopamine in the nucleus accumbens and 
the mesolimbic dopaminergic system (Koob and Bloom, 1988; Nestler, 2005; 
Pierce and Kumaresan, 2006), as demonstrated by microdialysis studies in 
rats (Di Chiara and Imperato, 1988) and positron emission tomography (pet) 
studies in humans (Volkow et al., 1999; Volkow et al., 2003; Volkow et al., 2004; 
Volkow et al., 2007; Volkow et al., 2009). Several important observations have 
suggested that dopamine d₃ receptors may play a significant role in the effects 
of drugs of abuse and the pathophysiology of drug addiction (Heidbreder 
et al., 2005; Le Foll et al., 2005). First, dopamine d₃ receptors are located 
primarily in mesolimbic regions such as nucleus accumbens and ventral 
striatum (Gurevich and Joyce, 1999; Herroelen et al., 1994; Landwehrmeyer 
et al., 1993; Murray et al., 1994; Seeman et al., 2006). Second, studies in 
animal models have demonstrated that dopamine d₃ receptor activation 
may be involved in the reinforcing effects and self-administration of cocaine 
(Caine and Koob, 1993). Third, long term drug exposure appears to cause 
upregulation of dopamine d₃ receptors as demonstrated in postmortem 
studies of cocaine overdose fatalities (Segal et al., 1997; Staley and Mash, 
1996). Accordingly, it has been suggested that dopamine d₃ antagonism may 
be an effective strategy in pharmacotherapy of addiction (Heidbreder et al., 
2005; Joyce and Millan, 2005; Levant, 1997).
gsk598809 is a novel, potent and selective dopamine d₃ receptor 
antagonist (Searle et al., 2010), which is being developed as a novel treatment 
for substance dependence disorders. Functional assays showed that 
gsk598809 has greater than 100-fold selectivity for dopamine d₃ receptors 
over dopamine d₂, histamine h₁, muscarinic m₁, m₂, m₃, m₄, serotonin 5-ht₁a, 
5-ht₁b and 5-ht₁d receptors (data on file). Conditioned place preference 
(cpp) experiments in animal models indicated that gsk598809 significantly 
reduced nicotine- and cocaine-seeking behavior in a dose-dependent manner 
(data on file). In addition, gsk598809 significantly prevented relapse to 
nicotine-seeking behavior, although no effect was observed on reducing 
alcohol consumption in rats (data on file).
The present study was performed to evaluate the pharmacokinetics and 
central nervous system (cns) effects of single oral doses of gsk598809 in 
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healthy volunteers. Special emphasis was given to evaluating possible interac-
tions with alcohol, because the target population of patients will have alcohol 
dependence as primary disorder, or may abuse alcohol as comorbidity next 
to another substance abuse disorder. Pharmacokinetic interactions between 
alcohol and gsk598809 are theoretically possible, because a metabolite of 
gsk598809 shows in vitro to have a potential for inhibiting cyp2e1, which 
is one of the main enzymes involved in alcohol metabolism (Lieber, 1997). 
Also, pharmacodynamic interactions are theoretically possible as both com-
pounds are centrally active and influence the dopamine system. However, 
apart from these theoretical possibilities, there are no reasons to assume a 
priori that any specific pharmacodynamic interaction will occur between 
gsk598809 and alcohol. Currently, no validated human pharmacodynamic 
markers for dopamine d₃ antagonism are available. For exploratory purposes, 
we used a battery of quantitative central nervous system tests, sensitive to 
various compounds, including alcohol (Zoethout et al., 2009) and antipsy-
chotic drugs (dopamine d₂ receptor antagonists) (de Visser et al., 2001), was 
used to evaluate pharmacodynamic effects. An oral dose of 175 mg gsk598809 
was chosen because positron emission tomography using [11c]-(+)-phno 
in healthy volunteers has demonstrated that this dose can induce high occu-
pancy (near 100%) of dopamine d₃ receptors in the substantia nigra (Searle et 
al., 2010). Also, previous studies in healthy volunteers demonstrated that this 
dose is generally well tolerated (data on file).
methods
Study design
Twenty healthy volunteers, between 18 and 65 years of age and with a body 
mass index (bmi) between 18 and 30 kg/m2, were planned to participate in a 
blinded, randomized, placebo-controlled, double-dummy, four-period cross-
over study. The study was approved by the medical ethics review board of 
the Leiden University Medical Center and registered at the nih database of 
clinical trials (website http://clinicaltrials.gov) with identifier nct00887367 
and gsk id number 106591. Prior to medical screening, all volunteers gave 
written informed consent. All volunteers underwent training sessions for the 
pharmacodynamic tests in order to minimize possible learning effects.
Volunteers were assigned to a randomized treatment sequence (see figure 1), 
consisting of one period of oral administration of 175 mg of gsk598809 com-
bined with intravenous alcohol infusion (alcohol clamping, see below for fur-
ther details), one period of oral administration of 175 mg of gsk598809 com-
bined with intravenous placebo infusion, one period of oral placebo adminis-
tration combined with intravenous alcohol infusion, and one period with oral 
placebo administration combined with intravenous placebo infusion. This 
study design enables analysis of the following comparisons (see figure 1): 
1 Administration of 175 mg gsk598809 (n = 20) versus placebo (n = 20)
Intravenous alcohol infusion (n = 20) versus placebo (n = 20)
2 Co-administration of 175 mg gsk598809 and intravenous alcohol infusion 
(n = 20) versus placebo (n = 20)
3 Co-administration of 175 mg gsk598809 and intravenous alcohol infusion 
(n = 20) versus intravenous alcohol infusion alone (n = 20)
gsk598809 or matching placebo was administered orally 30 minutes after 
the start of the ethanol (or placebo) infusion. The alcohol (or placebo) 
infusion continued for 5 hours in total to cover the main part of the plasma 
concentration curve of gsk598809. Each study period consisted of five 
study days. The randomized treatment was administered in the morning of 
the first study day, followed by pharmacokinetic and pharmacodynamic 
measurements at regular time points. All periods were separated by a wash-
out time of at least five days.
Occasional (non-daily) smokers were eligible to participate in the study. 
Subjects were excluded from participation if they smoked on a daily basis. 
Also, subjects were excluded if they had an average daily intake of greater than 
2 units (in case of females) or 3 units (in case of males) or an average weekly 
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alcohol intake of greater than 14 units (in case of females) or 21 units (in case 
of males). One unit is equivalent to a half-pint (220 mL) of beer or 1 (25 mL) 
measure of spirits or 1 glass (125 mL) of wine. Subjects were instructed to 
abstain from smoking and alcoholic drinks on the day preceding all study 
periods and all subsequent study days. In addition, use of illicit drugs was not 
permitted. In all study periods, breath alcohol measurements were performed 
to ascertain non-use of alcohol. Also, urine drug screening for cocaine, 
amphetamines, opiates (morphine), benzodiazepines, barbiturates and thc 
(Innovacon, Inc., San Diego, California, usa) was performed to ascertain 
non-use of illicit drugs.
Alcohol clamping
The method for attaining constant alcohol levels has been described in detail 
elsewhere (Zoethout et al., 2008; Zoethout et al., 2009). In brief, alcohol 
(ethanol 10% w/v solution in 5% glucose) was infused intravenously over 
a period of five hours, guided by breath alcohol measurements to maintain 
a pseudo-steady state alcohol serum level of 0.6 g/l. This target level was 
chosen because this level produces significant central nervous system effects 
without causing too many inadvertent effects and is considered safe, since 
it is only just above the legal driving limit in the Netherlands (i.e. 0.5 g/l). 
Alcohol infusion started 30 minutes prior to administration of gsk598809. 
The infusion rate for the first ten minutes was determined using demographic 
data of the volunteer (weight, height, age and gender). Infusion rates were 
subsequently adjusted, guided by breath alcohol measurements at baseline 
and at every five minutes for the first 30 minutes after the start of the infusion, 
every 10 minutes for the next 30 minutes and then every half hour until the 
end, using two calibrated Alco-Sensor iv Intoximeters (Honac, Apeldoorn, 
the Netherlands), which were alternated to avoid fatigue of the sensors. To 
prevent local pain at the beginning of the alcohol infusion, an additional 
diluting glucose 5% infusion at 100 mL/h was given to all participants during 
the first 10 minutes after the start of the alcohol infusion over the same 
infusion line. Alcohol clamping was performed in a randomized, double-
blind, placebo-controlled fashion by an infusion assistant, who was not a 
member of the study team. A sham procedure, consisting of saline infusion 
in a manner similar to the alcohol infusion, including repeated breath alcohol 
measurements and subsequent infusion rate adjustments, was used to 
maintain blinding of the subject and the rest of the team. The mock infusion 
rate adjustments were provided by the clamping program.
Safety monitoring
Evaluation of adverse events, 12-lead electrocardiograms (ecg), blood pres-
sure, heart rate, alcohol breath test, urinalysis and blood sampling for haema-
tology and chemistry was performed at regular time points after each dose 
administration. Automated oscillometric blood pressures were measured us-
ing a Nihon-Kohden bsm-1101k monitor or a Colin Pressmate bp 8800. ecgs 
were obtained with Cardiofax v equipped with ecaps12 analysis program 
(Nihon-Kohden, Tokyo, Japan). In addition, telemetry monitoring was start-
ed at the beginning of alcohol infusion and was continued for six hours. Vol-
unteers were evaluated for akathisia and extrapyramidal symptoms, using the 
Barnes Akathisia Rating Scale (Barnes, 1989), Simpson-Angus Scale (Simp-
son and Angus, 1970) and Abnormal Involuntary Movement Scale (Munetz 
and Benjamin, 1988).
Pharmacokinetics
Venous blood samples for gsk598809 concentration analysis were collected 
prior to dose administration and at 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, 12, 
24, 48 and 72 hours after dose administration. Concentration of gsk598809 
in plasma samples was determined using protein precipitation followed by 
hplc/ms analysis with a lower limit of quantification (llq) of 0.5 ng/mL. 
Pharmacokinetic parameters of gsk598809 include the maximum observed 
plasma concentration (cmax), time to reach maximum plasma concentration 
(tmax), area under the plasma concentration-time curve extrapolated to 
infinity (auc∞) and terminal phase half life (t½). 
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Venous blood samples for pharmacokinetic analysis of serum alcohol were 
taken prior to start of infusion and at 15, 30, 45, 60, 90, 150, 210, 270 and 390 
minutes after start of alcohol infusion. Serum alcohol levels were measured 
with an enzymatic assay (Roche Diagnostics, Mannheim, Germany) 
using a Hitachi 911 (Boehringer Mannheim, Mannheim, Germany). In this 
enzymatic assay, alcohol and nicotinamide adenine dinucleotide (nad+) 
are converted to acetaldehyde and nadh by alcohol dehydrogenase (adh). 
The nadh formed during the reaction, measured photometrically as a rate of 
change in absorbance, is directly proportional to the alcohol concentration.
Pharmacodynamic testing
All pharmacodynamic measurements were performed as described previously 
(de Haas et al., 2009; Liem-Moolenaar et al., 2010a). Volunteers were tested 
individually in a quiet room with ambient illumination. Quantitative tests, 
sensitive to the effects of alcohol (Zoethout et al., 2009) and single oral doses 
of antipsychotic drugs (dopamine d₂ receptor antagonists) (de Visser et al., 
2001) such as haloperidol (Liem-Moolenaar et al., 2010a; Liem-Moolenaar 
et al., 2010b) and risperidone (Liem-Moolenaar et al., 2011) in healthy 
volunteers, included measurements of smooth pursuit and saccadic eye 
movements, adaptive tracking, body sway, visual analogue scales, the visual 
verbal learning test (vvlt) and serum prolactin levels. Previous studies 
using the alcohol clamping paradigm and this pharmacodynamic test battery 
(Zoethout et al., 2009) demonstrated that smooth pursuit eye movements 
and body sway were the most sensitive pharmacodynamic parameters for the 
effects of alcohol. In order to obtain accurate time profiles of the effects of 
alcohol and gsk598809, smooth pursuit eye movements and body sway were 
recorded at a high frequency. The other pharmacodynamic tests could not be 
performed as frequently due to limitations in time and logistics.
analysis of eye movements To evaluate oculomotor performance 
and sedation, smooth pursuit and saccadic eye movements were recorded 
as described previously (Baloh et al., 1975; Bittencourt et al., 1983; van 
Steveninck et al., 1991; van Steveninck et al., 1999), using a microcomputer-
based system for data recording and analysis (Cambridge Electronic Design 
Ltd., Cambridge, uk), Nihon-Kohden equipment for stimulus display, signal 
collection and amplification (Nihon-Kohden, Tokyo, Japan), and disposable 
surface electrodes (Medicotest n-oo-s, Olstykke, Denmark). For smooth 
pursuit eye movements, a target light source moves sinusoidally over 20° 
eyeball rotation at frequencies ranging from 0.3 to 1.1 Hz. The time in which 
the eyes were in smooth pursuit was calculated for each frequency and 
expressed as the percentage of stimulus duration. The average percentage of 
smooth pursuit for all frequencies was used as parameter. Smooth pursuit eye 
movements were recorded prior to dose administration and at 10, 20, 30, 60, 
90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 390, 420 and 450 minutes after 
dose administration. For saccadic eye movements, the target light source 
jumps from side to side. Peak velocity (degrees per second), reaction time 
and inaccuracy (%) was calculated of all artifact-free saccades. Saccadic eye 
movements were recorded prior to dose administration and at 30, 90, 150, 210, 
270, 330, 390 and 450 minutes after dose administration.
 
adaptive tracking To evaluate visuo-motor coordination, the adaptive 
tracking task was performed as described previously (Borland and Nicholson, 
1984; Gijsman et al., 1998; van Steveninck et al., 1991; van Steveninck et al., 
1993; van Steveninck et al., 1999), using customized equipment and software 
developed by K.W. Hobbs (Hertfordshire, uk). Adaptive tracking is a pursuit 
tracking task in which a circle moves randomly over a computer screen and 
the volunteer must try to keep a dot inside the moving circle using a joystick. 
If this effort is successful, the speed of the moving circle is increased and if the 
effort is unsuccessful, the speed is reduced. The adaptive tracking task was 
performed prior to dose administration and at 30, 90, 150, 210, 270, 330, 390 
and 450 minutes after dose administration and performance was scored over 
a fixed period of three minutes. Average performance and standard deviation 
of scores were used for analysis.
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body sway Postural stability in the sagittal plane was measured with an 
apparatus similar to the Wright ataxiameter (Wright, 1971), using a string 
attached to the waist of the volunteer. Measurements were performed prior 
to dose administration and at 10, 20, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 
330, 360, 390, 420 and 450 minutes after dose administration. Movements 
over a period of two minutes, while standing still with eyes closed, were 
integrated and expressed as mm sway.
visual analogue scales Subjective effects were quantified prior to 
dose administration and at 30, 90, 150, 210, 270, 330, 390 and 450 minutes 
after dose administration using a Dutch translation of the visual analogue 
scales (vas), originally described by Norris (Norris, 1971), to derive three 
composite factors corresponding to alertness, mood (contentedness) and 
calmness, as described by Bond & Lader (Bond and Lader, 1974). In addition, 
a visual analogue scale was used to quantify the subjective effects of alcohol.
visual verbal learning test The visual verbal learning test (vvlt) 
(Schmitt et al., 2000) is an adapted version of the auditory verbal learning test 
(Rey, 1964) and was performed 150 minutes after dose administration. Three 
trials of 30 words are presented on a computer screen in the same sequence. 
The volunteer is requested to reproduce as many words as possible at the 
ending of each trial (immediate recall) and after 30 minutes (delayed recall). 
The number of correctly reproduced words is analyzed for each trial. Also, 
a recognition test is performed, consisting of 15 previously presented words 
and 15 new words, in which the volunteer has to indicate recognition of the 
word (delayed recognition) as quickly as possible. Response time and the 
number of correctly recognized words are analyzed. 
serum prolactin levels Blood samples for measurement of 
prolactin levels were collected at baseline and at 60, 90, 120, 210, 390, 720 
and 1320 minutes after study drug administration and serum was separated 
by centrifugation (2000 g at 4°c for 10 minutes). Prolactin levels were 
determined using an electrochemiluminescence immunoassay (eclia) on a 
Modular Analytics E170 (Elecsys module) immunoassay analyzer.
Statistical analysis
Analysis of variance models were performed on the pharmacokinetic 
parameters, including the factors treatment and period as fixed effects and 
subject as random effect. auc and cmax pharmacokinetic parameters were 
log-transformed prior to analysis. Comparisons were expressed as ratios of 
the pharmacokinetic parameters after gsk598809 combined with ethanol 
relative to those after alcohol alone or relative to those after gsk598809 alone.
Pharmacodynamic data were compared using a mixed model analysis of 
variance with treatment, gender, period, time, and treatment by time as fixed 
factors, and with subject, subject by treatment and subject by time as random 
factors. vvlt data were compared using a mixed model analysis of variance 
with treatment, gender and period as fixed factors, and with subject as 
random factor. The parameters body sway, prolactin, saccadic eye movements 
and the delayed word variables were log-transformed prior to analysis to 
correct for the expected log-normal distribution of the data. The following 
contrasts were calculated (see figure 1): alcohol versus placebo, gsk598809 
versus placebo, co-administration of gsk598809 and alcohol versus placebo, 
co-administration of gsk598809 and alcohol versus alcohol alone.
Supra-additive effects (defined as effects, resulting from co-administration 
of two independent agents, being greater than the sum of effects of each 
individual agent) were evaluated by analyzing the contrast of the effects of 
co-administration of gsk598809 and alcohol with subtraction of the effects 
of gsk598809 alone versus the effects of alcohol alone with subtraction of the 
effects of placebo.
After identifying gender effects on prolactin levels, analysis of prolactin 
data was repeated using a mixed model analysis of variance with treatment, 
gender, period, time, treatment by gender, treatment by time, gender by time 
and treatment by gender by time as fixed factors, and with subject, subject by 
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treatment and subject by time as random factors. Contrasts were calculated in 
original measurement unit with 95% confidence intervals and the associated 
p-value, except for the log-transformed parameters, which were calculated as a 
percentage relative to placebo or alcohol. All calculations were performed using 
sas for Windows version 9.1.3 (sas Institute Inc., Cary, North Carolina, usa). 
results
Subjects
Twenty volunteers (10 males and 10 females) were included in the study. 
Volunteers had a mean age of 32.8 years (range 18-55), weight of 73.5 kg 
(range 54-108) and body mass index (bmi) of 23.6 kg/m2 (range 18.5 - 29.8). 
One female volunteer tested positive for benzodiazepines on the drug 
screen in study period 2 and thereby violated the exclusion criteria. She was 
subsequently withdrawn from the study and not replaced. This volunteer was 
administered alcohol infusion and placebo capsules in the first study period.
Clinical observations
All adverse events were transient and mild or moderate in severity and no seri-
ous adverse events occurred during the study. Overall, the most frequent ad-
verse effect were headache, somnolence, feeling drunk, dizziness, fatigue, pain 
at infusion site, nausea and vomiting (see table 1). Somnolence and fatigue 
were reported more frequently after gsk598809 administration combined 
with alcohol (n = 18), compared to alcohol alone (n = 8), gsk598809 alone 
(n = 4) or placebo (n = 4). There were no consistent and clinically relevant 
changes on the Barnes Akathisia Rating Scale, Simpson-Angus Scale and Ab-
normal Involuntary Movement Scale. Mild short-lasting akathisia was report-
ed spontaneously once after administration of gsk598809 combined with 
alcohol and once after gsk598809 alone, but these events were not verified 
objectively by the Barnes Akathisia Rating Scale, when this was performed 
as scheduled. There were no consistent and clinically relevant changes in vital 
signs, blood chemistry and haematology or any of the ecg intervals.
Pharmacokinetics of alcohol
Following intravenous infusion, serum alcohol concentration increased 
rapidly and remained constant at the target level all over the time of infusion, 
after which serum concentrations declined (see figure 2).
Pharmacokinetics of gsk598809
Pharmacokinetic parameters are presented in table 2. Oral administration of 
gsk598809 resulted in peak levels after roughly 2 to 3 hours (see figure 3) with 
an apparent bi-exponential decline and a half life of roughly 20 hours.
Pharmacokinetics of gsk598809 combined with alcohol
No relevant effect of gsk598809 on ethanol pharmacokinetic parameters was 
observed. Regarding the effects of alcohol on gsk598809 pharmacokinetic 
parameters, an average 15% increase in auc∞ of gsk598809 (ratio of ls 
geometric means 1.15; 90% confidence interval 1.02/1.30) and an average 
9% decrease in cmax of gsk598809 (ratio of ls geometric means 0.91; 
90% confidence interval 0.83/1.00) was observed after administration of 
gsk598809 combined with alcohol compared to gsk598809 alone. Other 
parameters were roughly similar compared to gsk598809 alone (see table 2).
Pharmacodynamics of alcohol
Following alcohol infusion, a statistically significant decrease in adaptive 
tracking and smooth pursuit eye movements and increase in body sway were 
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observed compared to placebo, but there were no effects on saccadic peak 
velocity, inaccuracy or reaction time (see table 3 and figures 4 to 7). Clear 
increases in the feeling of being drunk were noted. In addition, there was 
some decrease in alertness on the vas Bond & Lader scales, compared with 
placebo (see table 4 and figure 8). Alcohol did not demonstrate any clear 
effect on vvlt performance (see table 5).
Pharmacodynamics of gsk598809
Following administration of gsk598809, transient increases in serum prolac-
tin were observed (see figure 9). Peak prolactin levels, which increased much 
more in females than in males (p < 0.0001), were reached roughly 3 hours 
after study drug administration and normalized within 12 hours. Administra-
tion of gsk598809 also caused a decrease in adaptive tracking performance, 
which was maximal between 2 and 6 hours after dose administration (see 
table 3 and figure 6). No statistically significant effects were observed on any 
of the other pharmacodynamic parameters (see tables 3 to 5 and figures 4, 5, 
7 and 8).
Pharmacodynamics of gsk598809 combined with 
alcohol
Co-administration of gsk598809 and alcohol resulted in additive effects on 
several pharmacodynamic parameters, compared to either treatment alone 
(see tables 3 to 5 and figures 4 to 8). While the effects of administration of 
gsk598809 alone or alcohol alone on saccadic eye movements did not reach 
statistical significance, co-administration of gsk598809 and alcohol resulted 
in a significant impairment. No significant supra-additive effects were 
found on any of the pharmacodynamic parameters, except a small increase 
in saccadic reaction time (see table 3) and a small decrease in delayed word 
recall on the vvlt (see table 5).
discussion
 
The present study was performed to evaluate the pharmacokinetics and 
central nervous system (cns) effects of single oral doses of 175 mg of the 
novel dopamine d₃ receptor antagonist gsk598809 in healthy volunteers 
and possible interactions with alcohol. Within the present group of healthy 
volunteers, single doses of gsk598809 were generally well tolerated. The most 
frequent adverse effects were mild headache, dizziness, somnolence, nausea 
and vomiting. gsk598809 did not induce any significant extrapyramidal 
symptoms. Mild short-lasting akathisia was reported spontaneously once 
after administration of gsk598809, although this was not verified objectively 
by the Barnes Akathisia Rating Scale, when this was performed according 
to protocol. Plasma concentration of gsk598809 increased rapidly after oral 
administration (tmax of roughly 2 to 3 hours) and subsequently decreased in 
an apparent bi-exponential manner (terminal half life of roughly 20 hours). 
No effect of gsk598809 on the pharmacokinetics of alcohol was observed, 
but alcohol decreased cmax and increased the auc of gsk598809 to a limited 
extent, which is not considered to be of any clinical significance.
The cns effects of gsk598809 alone were limited to an elevation of 
serum prolactin and a small decrease in adaptive tracking performance, with 
a time course that corresponds well with the observed pharmacokinetics. 
This study represents the first use of this pharmacodynamic test battery 
to evaluate the effects of a selective dopamine d₃ antagonist in healthy 
volunteers. As a result, no data of other dopamine d₃ receptor antagonists are 
available for comparison with the effects of gsk598809. Antipsychotic drugs 
(dopamine d₂ receptor antagonists) have been evaluated extensively with 
this pharmacodynamic test battery (de Visser et al., 2001; Liem-Moolenaar 
et al., 2010a; Liem-Moolenaar et al., 2010b; Liem-Moolenaar et al., 2011), 
but differences in tissue expression of d₂ and d₃ receptors and differences 
in receptor affinity profiles of the various drugs significantly limit the 
comparison of their effects to those of gsk598809.
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Prolactin secretion by the lactotroph cells of the pituitary gland is 
under inhibitory control by dopamine, released predominantly from 
tuberoinfundibular dopaminergic neurons, acting on lactotrophic dopamine 
d₂ receptors (Ben-Jonathan and Hnasko, 2001; Freeman et al., 2000). 
Pharmacological blockade of dopamine d₂ receptors removes this inhibitory 
influence and subsequently increases prolactin levels. However, the role 
of dopamine d₃ receptor antagonism in the control of prolactin secretion 
is unknown. An autoradiographic study has demonstrated presence of d₃ 
receptors in the pituitary gland (Herroelen et al., 1994), but the density was 
quite low and any possible role for dopamine d₃ receptors in the pituitary 
gland in endocrine function remains unclear. Alternatively, dopamine 
d₃ antagonism may cause prolactin elevation by acting at the level of the 
hypothalamus. The periventricular and arcuate nuclei of the hypothalamus 
constitute the origin of the tuberoinfundibular dopaminergic pathway, 
which projects to the median eminence, where dopamine is released into the 
hypophyseal portal vessels (Albanese et al., 1986; Ben-Jonathan and Hnasko, 
2001; Moore and Bloom, 1978). Hypothalamic expression of dopamine d₃ 
receptors has not yet been examined in full detail, but one study found no 
detectable levels in the arcuate nucleus, whereas the periventricular nucleus 
was not investigated (Gurevich and Joyce, 1999). Therefore, any possible 
effect of dopamine d₃ antagonism on the hypothalamus, leading to prolactin 
elevation, also remains unclear. Another theoretical possibility is that 
gsk598809 could be acting on extra-dopaminergic mechanisms of prolactin 
control. However, a more likely explanation is that, despite a greater than 
100-fold selectivity for d₃ receptors over d₂ receptors, gsk598809 at doses 
of 175 mg might cause enough d₂ receptor antagonism to modestly increase 
prolactin secretion.
The increases in serum prolactin following gsk598809 administration 
were much larger in female volunteers than in male volunteers (see figure 9). 
Similar gender differences in prolactin levels have been previously 
demonstrated after administration of typical antipsychotic drugs (Kuruvilla 
et al., 1992; Meltzer and Fang, 1976; Meltzer et al., 1983; Smith et al., 2002; 
Wode-Helgodt et al., 1977) and atypical antipsychotic drugs (Grunder et 
al., 1999; Kinon et al., 2003; Yasui-Furukori et al., 2010), which have been 
attributed to an enhanced responsiveness of lactotrophs to prolactin-releasing 
stimuli by females, compared to males, due to the effects of estrogens (Ben-
Jonathan and Hnasko, 2001; Buckman and Peake, 1973; Buckman et al., 1976; 
petty, 1999).
The other pharmacodynamic tests used in this study measure complex 
cns functions. The neurophysiological and neurochemical mechanisms 
underlying these cns functions have not yet been fully characterized, but are 
likely to involve multiple neurotransmitter receptor systems. The decrease in 
adaptive tracking performance after administration of gsk598809 indicates 
slight impairment in visuo-motor performance. Similar impairments in 
adaptive tracking performance have also been observed after administration 
of single doses of antipsychotic drugs (dopamine d₂ antagonists) such 
as haloperidol (Liem-Moolenaar et al., 2010a) and risperidone (Liem-
Moolenaar et al., 2011) in healthy volunteers. However, unlike haloperidol 
and risperidone, gsk598809 did not affect smooth pursuit and saccadic eye 
movements, memory performance or any of the visual analogue scales. This 
clearly demonstrates the pharmacological distinctions between gsk598809 
and antipsychotic drugs, but it is not necessarily an argument for d₃ receptor 
selectivity, since most antipsychotic drugs affect other neurotransmitter 
systems in addition to d₂ receptors. Recently, however, we examined the novel 
selective dopamine d₂ receptor antagonist jnj-37822681 in healthy volunteers 
using similar pharmacodynamic tests (te Beek et al, 2011). Single oral doses of 
15 mg jnj-37822681 caused a reduction in adaptive tracking performance of 
about 2%, comparable to 175 mg doses of gsk598809. Also, this dose of jnj-
37822681 caused about 60% d₂ receptor occupancy and produced prolactin 
elevations of more than 700%, much larger than the 117% increase found with 
gsk598809 in this study. jnj-37822681 also impaired saccadic and smooth 
pursuit eye movements, which were unaffected by gsk598809. Although 
these indirect comparisons have their limitations, they provide at least some 
support for the in vivo selectivity of gsk598809 for dopamine d₃ receptors.
applications of alcohol clamping in early drug development
– 224 –
chapter 9 – pk and cns effects of d3 antagonist gsk598809 and alcohol
– 225 –
In addition to obtaining a dopamine d₃ receptor-mediated profile of cns 
effects, our study was specifically designed to evaluate potential pharma-
cokinetic and pharmacodynamic interactions between gsk598809 and 
alcohol. An intravenous alcohol clamping paradigm was used to achieve 
pseudo-steady state levels of alcohol, which produced clear and expected 
cns effects, similar to previously reported results of this alcohol clamping 
paradigm (Zoethout et al., 2008; Zoethout et al., 2009). Co-administration 
of gsk598809 with intravenous alcohol levels at pseudo-steady state was gen-
erally well tolerated. However, somnolence and fatigue were reported more 
frequently, compared with the other treatments. Mild akathisia was reported 
spontaneously once, which was not verified objectively by the Barnes Akathi-
sia Rating Scale, similar to the event after administration of gsk598809 alone. 
Co-administration of gsk598809 and alcohol generally produced additive 
cns effects, without clear signs of supra-additive amplification of the effects 
of each treatment alone. Both gsk598809 and alcohol caused slight impair-
ments of saccadic eye movements that failed to reach statistical significance 
by themselves, but the combination clearly differed from placebo. There was 
a small supra-additive increase in saccadic reaction time (see table 3) and 
there were also some indications that memory might be affected more by 
the combination than by each drug individually. These findings suggest that 
caution may be needed in the use of gsk598809 in individuals who consume 
alcohol moderately or excessively, although the effects will probably be domi-
nated by alcohol.
In conclusion, the present study demonstrates elevation of serum prolactin 
and a small decrease in adaptive tracking performance after administration 
of the novel selective dopamine d₃ receptor antagonist gsk598809 within a 
small group of healthy volunteers. An interaction with intravenous alcohol 
infusion at pseudo-steady state was demonstrated, resulting in a decreased 
cmax and increased auc of gsk598809 and mainly additive effects on 
several cns parameters. Although somnolence and fatigue were reported 
more frequently, the combination was generally well tolerated by healthy 
volunteers.
figure 1 study design
figure 2 serum alcohol levels after intr avenous 
alcohol infusion 
Starting at t = -0.5 hours and continuing until t = 4.5 hours, in combination with 
oral administration (at t = 0 hours) of gsk598809 (open circles) or placebo 
(closed circles). Means are presented with standard deviations as error bars.
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figure 3 plasma concentr ations of gsk598809 after or al 
administr ation 
At t = 0 hours, in combination with intravenous alcohol infusion (open circles)  
or placebo infusion (closed circles) starting at t = -0.5 hours and continuing until 
t = 4.5 hours. Means are presented with standard deviations as error bars.
figure 4 time course of smooth pursuit eye movements 
Following administration of gsk598809 capsules combined with alcohol infusion.  
Least square means are presented with 95% confidence intervals as error bars.
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figure 5 time course of saccadic peak velocity 
Following administration of gsk598809 capsules combined with alcohol infusion. 
Least square means are presented with 95% confidence intervals as error bars.
figure 6 time course of adaptive tr acking performance 
Following administration of gsk598809 capsules combined with alcohol infusion. 
Least square means are presented with 95% confidence intervals as error bars.
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figure 7 time course of body sway 
Following administration of gsk598809 capsules combined with alcohol infusion. 
Least square means are presented with 95% confidence intervals as error bars.
figure 8 time course of alertness (visual analogue 
scales of bond & lader)
Following administration of gsk598809 capsules combined with alcohol infusion. 
Least square means are presented with 95% confidence intervals as error bars.
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figure 9 time course of serum prolactin in female  
(left pan l) and male subjects (right panel)
Following administration of gsk598809 capsules combined with alcohol infusion. 
Means are presented with standard deviations as error bars.
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table 3 neurophysiological effects of administr ation  
of alcohol alone, gsk598809 alone and co-administr ation 
of gsk598009 and alcohol
Treatment differences in least square means are shown with statistically significant 























































































































































table 1 summary of common adverse events, reported  
by two subjects or more










Headache 6 (32%) 9 (45%) 5 (26%) 7 (37%)
Somnolence 1 (5%) 4 (20%) 3 (16%) 11 (58%)
Dizziness 1 (5%) 6 (30%) 6 (32%) 5 (26%)
Akathisia 0 0 1 (5%) 1 (5%)
Feeling drunk 0 7 (35%) 0 6 (32%)
Fatigue 3 (16%) 4 (20%) 1 (5%) 7 (37%)
Infusion site pain 0 3 (15%) 0 2 (11%)
Catheter site related reaction 0 1 (5%) 1 (5%) 0
Nausea 0 1 (5%) 3 (16%) 3 (16%)
Vomiting 0 1 (5%) 4 (21%) 0
Dry mouth 0 0 0 2 (11%)
Upper respiratory tract infection 0 2 (10%) 0 0
Dysmenorrhoea 1 (5%) 0 0 1 (5%)
Oropharyngeal discomfort 1 (5%) 0 0 1 (5%)
Skin reaction 1 (5%) 1 (5%) 0 0
table 2 pharmacokinetic par ameters of gsk598809 with 
and without co-administr ation of alcohol
Data are presented as geometric means (with coefficient of variation), except tmax 
which is presented as median (with range). Note: n = 19 for all calculated values, 
except t½ and auc∞ of gsk598809 alone (n = 11) and combined with alcohol  
(n = 15), because these parameters could not be calculated reliably in 8 subjects 
and 4 subjects, respectively.
Parameter gsk598809 gsk598809 + alcohol
Cmax (ng/mL) 1320 (39) 1190 (39)
tmax (h) 2.07 (2.0-6.05) 3.03 (2.00-7.87)
AUC0-t (ng.h/mL) 14000 (28) 15700 (27)
AUC∞ (ng.h/mL) 14000 (32) 16600 (23)
Terminal half life (h) 19.3 (33) 21.6 (27)
applications of alcohol clamping in early drug development
– 232 –
chapter 9 – pk and cns effects of d3 antagonist gsk598809 and alcohol
– 233 –
table 5 visual analogue scales (vas) results after 
administr ation of alcohol alone, gsk598809 alone and  
co-administr ation of gsk598009 and alcohol
Treatment differences in least square means are shown with statistically  































































































table 4 visual verbal learning test (vvlt) results  
after administr ation of alcohol alone, gsk598809 alone 
and co-administr ation of gsk598009 and alcohol on the
Treatment differences in least square means are shown with statistically  
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Alcohol is one of the most widely used psychoactive substances in Western 
society. This makes it important to study effects of this compound, and its 
interactions with other medications or drugs. Alcohol has complex and 
variable pharmacokinetics, and some of the effects of alcohol are preferably 
studied at stable serum levels. The results of studies investigating alcohol 
clearance or the effects of alcohol on the central nervous system (cns) or 
drug-alcohol interactions are often interpreted more easily when alcohol 
levels are kept within certain limits. Especially, because both its wide inter- 
and intra-individual variability are reduced when alcohol is ‘clamped’ to a 
pre-specified level. Methods to obtain stable serum concentrations are scarce, 
but efforts have been made before (Hartmann et al., 1988; O’Connor et al., 
1998). However, these methods have not gained wide application. This might 
be related to the perceived complexity of the procedures, which seem to 
require specific expertise and frequent alcohol concentration measurements 
for adaptations of the alcohol infusion. The early drug development process 
would benefit from an accurate, user-friendly method, with low variability, 
which is able to maintain constant alcohol levels for prolonged periods of 
time. Such a method would greatly facilitate any (drug) research in which 
alcohol is involved. In this thesis the development and application of a new 
relatively straightforward alcohol clamping procedure is presented.
Reliable studies of the cns-effects of alcohol do not only benefit from 
stable alcohol conditions, but also from sensitive tests that are able to 
reliably detect the acute effects of alcohol. Chapter 2 of this thesis contains 
a systematic review, which attempted to determine the sensitivity to alcohol 
for a large number of cns-tests that are described in the literature. The results 
show that many different tests or biomarkers are currently used to study the 
various cns-effects of alcohol, and that such studies would greatly benefit 
from a certain degree of standardization. Attention tasks, visuo-motor control 
tests and scales of subjective effects were identified as the most sensitive 
functional biomarkers for the acute cns-effects of alcohol. The results of this 
review are helpful in selecting rational tests for studies investigating the acute 
cns-effects of alcohol or for future alcohol-interaction studies.
In chapter 3 we introduced the alcohol clamp. Based on the results of 
O’Connor’s ‘Indiana alcohol clamp’ (O’Connor et al., 1998) we developed a 
new method to maintain stable alcohol serum levels for prolonged periods of 
time. A large data-set of population pharmacokinetics was used to reduce the 
amount of sampling moments that O’Connor’s method requires throughout 
the clamping period. Besides, we introduced an intravenous loading dose 
instead of the oral dose originally described by O’Connor. These adaptations 
were incorporated into a new spreadsheet-based paradigm, to enhance its 
user-friendliness. The new clamping method was compared to a method 
described by Hartmann (Hartmann et al., 1988), which is based on individual 
alcohol pharmacokinetics to predict individual infusion rates to achieve a 
desired target level on a subsequent study occasion. We showed that the novel 
alcohol clamping paradigm was more accurate and user-friendly, with low 
variability and the ability to maintain constant alcohol levels for hours. The 
paradigm provided an opportunity to perform intensive pharmacodynamic 
or functional assessments during the execution of the clamp, which was 
considered to be useful for future studies of alcohol.
The modified alcohol clamping procedure described in Chapter 3 is 
based on fewer actual alcohol samples than the Indiana alcohol clamp 
procedure (O’Connor et al., 1998). This may reduce the variability of 
alcohol levels at a steady-state, but the O’Connor method does not leave 
any room for concomitant pharmacodynamic testing, due to its frequent 
sampling moments. The adapted alcohol clamp as described in this thesis 
was partly developed to overcome this problem. In chapter 4 we showed 
that an intensive battery of cns-tests could be integrated in the course of the 
clamp without interfering with the sampling activities or with the stability 
of the clamp. Furthermore, we showed that attention, subjective effects and 
(visuo-) motor control tests were mainly affected by alcohol. Also, we found 
that some effects closely followed the relatively stable alcohol concentrations, 
whereas others fluctuated during the plateau-phase, which could be an 
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indication for time-related drug-effect changes such as acute tolerance. Based 
on chapter 3 and 4 we conclude that our method provides careful control over 
brac-levels and allows frequent repetition of different cns-measurements. 
These features make this technique eminently suitable to study the complex 
pharmacodynamic effects of acute alcohol administration.
During the alcohol clamp, the levels of ethanol that are infused in 
an attempt to maintain stable breath- and blood-levels provide detailed 
information about the individual disposition of the compound. Consequently, 
differences in the sensitivity to the effects of alcohol can be readily traced to 
pharmacokinetic and pharmacodynamic sources of variability. Japanese 
subjects are often more susceptible to the effects of alcohol, which is at least 
partly related to ethnic differences in alcohol metabolism but may also have 
pharmacodynamic causes. In chapter 5 we explored the pharmacokinetic and 
pharmacodynamic differences between a group of Caucasians and a group 
of Japanese healthy male volunteers at two different clamp levels at two 
different occasions. We found that significantly lower amounts of alcohol 
were needed for the Japanese group to maintain similar stable concentrations 
than for the Caucasians. However, these differences disappeared when values 
were corrected for lean body mass. Despite similar alcohol levels, several 
pharmacodynamic differences between the groups were observed, primarily 
on body sway and on the visual analogue scale (vas) for subjective alcohol 
effects, and mainly at the highest dose level. We concluded that the alcohol 
clamp is a useful method to compare differences in alcohol metabolism 
between groups and that some cns-effects of alcohol differed clearly between 
Japanese and Caucasians, but others did not, even though alcohol levels were 
stable and similar between the two groups.
The selection of cns-tests within the cns-battery we introduced in chap-
ter 4 and 5 was based on a thorough literature review (chapter 2). Together, 
these tests cover a broad range of neuropsychological functioning. However, 
the results are only indirect read-outs of the acute effects of alcohol on the 
cns. Ideally, a generally applicable methodology for repeated measurements 
of direct drug effects on the entire cns, without task-related interactions and 
a priori models, would constitute a major improvement in cns drug devel-
opment. Resting-state functional magnetic resonance imaging (rs-fmri) 
could satisfy many of these requirements, and was hence hypothesized to be 
a promising technique for pharmacological research. The validity and sensi-
tivity of this new method as an instrument in future cns-drug development 
programs was explored in a proof-of-concept study, during which we used the 
alcohol clamp at a low level of 0.6 g/l, to calibrate the new technique under 
steady-state conditions (chapter 6). Besides alcohol, a morphine infusion was 
used on a different occasion to explore the specificity of the effects of cns-
depressants on rs-fmri. Our results revealed dissociable changes in both 
pharmacodynamics and functional connectivity resulting from alcohol and 
morphine. Post hoc analysis of regions of interest revealed adaptive network 
interactions in relation to pharmacokinetic and pharmacodynamic curves for 
both alcohol and morphine. This study suggests that resting-state functional 
brain connectivity could play a role as a drug-class specific and –sensitive 
method in cns drug research.
In the previous chapter, alcohol was used as a positive control for a new 
method to test cns-active drugs, because it has a wide range of cns-effects 
within clearly defined socially and clinically acceptable blood levels. Alcohol 
also has a limited number of established therapeutic effects, for instance 
on essential tremor and methanol intoxication, which makes it a useful 
positive control for novel therapies in these conditions. In chapter 7 and 8 
we investigated the effects of a gabaa α2,3 subtype selective partial agonist 
(tpa023) and a histamine-3 inverse agonist (mk-0249) on essential tremor 
symptoms. In both studies we added an alcohol arm to the study design 
as a positive control. The alcohol clamp was used to obtain steady state 
breath alcohol levels. Although some cns-effects were observed for both 
new compounds, no significant tremor reducing effects were reported. In 
contrast, the stable alcohol levels did result in significant reductions in tremor 
symptoms, and the alcohol clamp successfully fulfilled its role as a positive 
control in both studies. The alcohol clamp procedure seems a valid method to 
use in future studies investigating the effects of new therapeutic options in et 
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research. Additionally, the alcohol clamp can be used during the validation 
process of new methods, which quantify essential tremor or assess tremor 
severity and its responsiveness to therapeutic interventions.
In this thesis a novel alcohol clamping method was introduced, which was 
developed to maintain stable serum levels of alcohol for prolonged periods 
of time by continuous intravenous administration, during which a brac 
input and feedback system is used, based on population pharmacokinetics. 
The procedure provides an environment in which the acute (cns-)effects of 
stable alcohol levels can accurately be investigated, including the metabolic 
disposition of ethanol, the effects on a wide range of cns-functions, and the 
changes in sensitivity across time. One drawback of the clamping paradigm 
is that alcohol levels do not show enough variation during the steady state 
to explore pk/pd relationships. However, prolongation of the clamp-run 
phase or attainment of multiple consecutive steady-state levels will provide 
the opportunity for future studies to investigate such relations in larger detail.
Our alcohol clamp might serve as an interesting tool in the early drug 
development process. We showed that alcohol clamp could be used a 
benchmark in proof-of-concept studies (chapter 6) and as a robust positive 
control during et-studies (chapter 7 and 8). The alcohol clamp may also play 
a future role in the validation process of new tremor registration devices, 
which assist in the search for new pharmacological treatment strategies for 
tremor disorders. The clear legal limits of acceptable alcohol levels and its 
broad spectrum of cns-effects also creates a useful framework for the clamp, 
to serve as a functional benchmark for the effects of new drugs, to get a feel 
for the safety and acceptability of inevitable cns-effects in work and traffic 
and other domains of daily life.
For safety reasons, drug-alcohol interaction studies are incorporated 
into the course of the development program of most new cns-drugs. Both 
pharmacokinetic and pharmacodynamic interactions should be explored to 
generate recommendations and/or restrictions for its future users. We believe 
that the alcohol clamp might be a helpful tool for drug-alcohol interaction 
studies, since steady state alcohol level will allow the measurement of 
multiple pharmacodynamic endpoints with reduced variability. The methods 
described in this thesis have already been implemented in successful drug-
alcohol interaction studies (chapter 9). This thesis has examined several other 
examples where the alcohol clamp has been a useful research instrument to 
the advancement of alcohol research.
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Samenvatting (Dutch summary)
Alcohol is een veel gebruikt genotmiddel in de westerse wereld. Vanwege 
dit frequente gebruik is het belangrijk om interacties met geneesmiddelen 
die gelijktijdig worden ingenomen goed in kaart te brengen. De verwerking 
van alcohol door het lichaam is echter een complex proces en stabiele alco-
hol concentraties zouden theoretisch het bestuderen van dit proces kunnen 
vereenvoudigen. Bovendien zijn de resultaten van studies, waarbij er gekeken 
wordt naar de interactie tussen alcohol en een bepaald geneesmiddel ook 
vaak makkelijker te interpreteren als de alcohol concentratie een vast gege-
ven is. Dit is hoofdzakelijk het gevolg van een afname van de spreiding, die 
optreedt op het moment dat het alcohol niveau op een vast niveau wordt ge-
houden, ofwel op een vast niveau wordt “geclampt”.
In de literatuur worden er wel enkele methoden beschreven (Hartmann et 
al., 1988; O’Connor et al., 1998) om voorspelbare alcohol spiegels te bereiken, 
maar deze worden niet heel veel toegepast door onderzoekers. Dit heeft mo-
gelijk te maken met de complexiteit van deze procedures, waarbij intensieve 
metingen en specifieke expertise vaak een vereiste zijn om een stabiel alcohol 
niveau te bereiken. Een nauwkeurige, maar vooral gebruiksvriendelijke me-
thode met geringe spreiding, waarbij alcohol voor langere tijd op een stabiel 
level in het bloed kan worden gehouden, zou goed van pas kunnen komen 
tijdens het ontwikkelingproces van nieuwe geneesmiddelen. Op deze ma-
nier kunnen interacties tussen alcohol en een bepaald nieuw geneesmiddel 
eenvoudiger en zorgvuldiger worden bestudeerd en kunnen er meer gede-
tailleerde uitspraken worden gedaan over de veiligheid van het gebruik van 
een toekomstig geneesmiddel in combinatie met alcohol. In dit proefschrift 
wordt de ontwikkeling en de toepasbaarheid van een nieuwe procedure be-
schreven (de alcohol clamp), die onderzoekers in staat moet stellen om voor 
langere periodes en op eenvoudige wijze, stabiele alcohol concentraties in het 
bloed te bewerkstelligen.
Naast stabiele alcohol concentraties is het bij studies waarbij acute alcohol 
effecten op het centrale zenuwstelsel (czs) worden onderzocht ook belang-
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rijk om sensitieve testen (ook wel sensitieve ‘biomarkers’ genoemd) te gebrui-
ken om deze effecten te meten. In hoofdstuk 2 wordt aan de hand van wat er 
te vinden is in de literatuur een overzicht gepresenteerd van de gevoeligheid 
van dit soort biomarkers. De resultaten benadrukken de enorme diversiteit 
aan testen. Een vorm van standaardisatie van deze grote hoeveelheid biomar-
kers zou toekomstig onderzoek kunnen faciliteren. Aandachtstaken, visu-
eel motorische testen en testen waarbij subjectieve alcohol effecten worden 
gemeten, bleken de meest sensitieve biomarkers om acute alcohol effecten 
te meten. De resultaten van dit overzichtsartikel zouden kunnen worden ge-
bruikt bij het maken van een rationele keuze bij toekomstig alcohol onder-
zoek en in het bijzonder bij toekomstig onderzoek naar de interacties tussen 
alcohol en geneesmiddelen.
In hoofdstuk 3 wordt de nieuwe alcohol clamp gepresenteerd: een me-
thode om stabiele alcohol concentraties in het bloed te creëren, gebaseerd op 
de eerder gepubliceerde Indiana alcohol clamp, beschreven door O’Connor 
(O’Connor et al., 1998). Eerder verzamelde data van een grote populatie 
proefpersonen werd gebruikt om het optimale sample schema van de nieuwe 
clamp te voorspellen, om zo het aantal momenten te beperken waarop de in-
fuussnelheid van de clamp moet worden aangepast aan de gemeten alcohol 
concentraties. Verder werd de orale oplaaddosis in het begin van de clamp 
vervangen door een oplaaddosis via het infuus.
Het nieuwe paradigma werd verwerkt in een spreadsheet programma 
om de uitvoering van de clamp gebruiksvriendelijker te maken. In ditzelfde 
hoofdstuk wordt de nieuwe alcohol clamp vergeleken met een andere metho-
de beschreven door Hartmann (Hartmann et al., 1988). Bij de Hartmann pro-
cedure wordt er een gewenst alcohol niveau bereikt op basis van gegevens die 
verzameld zijn tijdens een eerdere alcohol toediening. In vergelijking met de 
Hartmann methode is de alcohol clamp nauwkeuriger met een lagere sprei-
ding. De vernieuwde alcohol clamp methode is gebruiksvriendelijk en alco-
hol concentraties in het bloed kunnen urenlang stabiel worden gehouden, er 
is sprake van een zogenaamde steady-state. Deze eigenschap zou van pas kun-
nen komen bij toekomstige alcohol studies.
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Hoewel de oorspronkelijke Indiana clamp zeer nauwkeurig is en consistente 
resultaten laat zien, is het door de intensieve metingen die vereist zijn voor 
het in stand houden van de steady-state concentratie bijna onmogelijk om 
tegelijkertijd testen uit te voeren die alcohol effecten meten. Door op basis 
van populatie gegevens individuele voorspellingen te maken van het alcohol 
concentratie verloop in de tijd blijkt het mogelijk om de frequentie van de 
metingen te reduceren zonder dat de stabiliteit van de steady-state hier be-
langrijk door verandert (hoofdstuk 3). Op deze manier kunnen acute alcohol 
effecten worden gemeten onder stabiele alcohol condities. In hoofdstuk 4 
wordt aangetoond dat er tijdens de clamping procedure een flink aantal czs-
testen kan worden verricht, zonder dat dit interfereert met de alcohol metin-
gen en zonder dat de stabiliteit van het alcohol niveau wordt aangetast. Daar-
naast wordt er in dit hoofdstuk aangetoond dat met name aandachtstaken, 
testen waarbij subjectieve effecten worden gemeten en (visueel) motorische 
testen door het stabiele alcohol niveau worden beïnvloed. Sommige effecten 
blijven heel stabiel tijdens de alcohol infusie, terwijl andere effecten juist veel 
meer variëren over de tijd. Dit laatste zou ten dele verklaard kunnen worden 
door het optreden van acute tolerantie. In hoofdstuk 3 en 4 laten we zien dat 
alcohol spiegels met behulp van de alcohol clamp niet alleen zeer nauwkeurig 
binnen bepaalde grenzen kunnen worden gehouden, maar dat er tegelijker-
tijd voldoende metingen kunnen worden verricht om nauwkeurig het tijds-
verloop van de effecten van alcohol te meten, zonder dat deze belangrijk in-
terfereren met de stabiliteit van het alcohol niveau. Deze combinatie maakt 
de alcohol clamp tot een unieke methode om de complexe acute effecten van 
alcohol op het czs te bestuderen.
De hoeveelheid alcohol die nodig is om een bepaald alcohol niveau in 
stand te houden kan dienen als eenvoudige maat voor de verwerkingscapa-
citeit van alcohol van een individu, dit wordt ook wel de klaring genoemd. 
Bij een stabiele bloedspiegel geldt immers dat wat erin gaat (de infuussnel-
heid), overeenkomt met wat eruit gaat (de klaringssnelheid). Verschillen in 
klaring tussen individuen kunnen zo op simpele wijze met elkaar worden 
vergeleken. De alcohol clamp corrigeert automatisch voor verschillen in kla-
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ring en op deze manier kunnen verschillen in alcohol effecten tussen groepen 
individuen ook eerlijker met elkaar worden vergeleken. Japanners en Kauk-
asiërs verschillen in hun efficiëntie waarmee ze alcohol klaren en in de ma-
nier waarop ze op alcohol reageren. Andere testen (zoals bijvoorbeeld oog-
bewegingen en tracking) lieten daarentegen geen verschillen zien. In hoofd-
stuk 5 worden klaring en de effecten van twee verschillende alcohol niveaus 
bij een groep Japanners en een groep Kaukasiërs met elkaar vergeleken. Er 
blijkt significant minder alcohol nodig te zijn bij de groep Japanners voor het 
onderhouden van een bepaald stabiel alcohol niveau. Dit verschil verdwijnt 
echter als er gecorrigeerd wordt voor het vetpercentage van de vrijwilligers. 
Ondanks de vergelijkbare alcohol concentraties worden er verschillende ef-
fecten waargenomen tussen de groepen, met name tijdens de body sway en 
bij de visual analogue scale (vas), een maat voor subjectieve alcohol effecten. 
In hoofdstuk 5 laten we zien dat de alcohol clamp een bruikbare methode is 
om verschillen in alcohol metabolisme aan te tonen tussen bepaalde ethnici-
teiten. Verder laten we zien dat bij een zelfde alcohol niveau de Japanse groep 
op sommige testen verschilt van de Kaukasische groep, terwijl er bij andere 
testen geen verschil wordt gevonden.
De czs-testen waarmee we alcohol effecten gemeten hebben in hoofdstuk 
4 en 5 zijn zorgvuldig geselecteerd op hun sensitiviteit en gebaseerd op de re-
sultaten van een uitgebreid literatuur onderzoek (hoofdstuk 2). Ondanks het 
feit dat deze verzameling testen ons in staat stelt om over een groot spectrum 
uitspraken te doen over de acute effecten van alcohol op het neuropsycholo-
gisch functioneren, blijven het indirecte metingen van de effecten van alcohol. 
Idealiter, zouden alcohol (of geneesmiddelen) effecten op het czs als geheel 
direct gemeten moeten kunnen worden zonder de tussenkomst van een test 
of taak. Dit zou een grote vooruitgang betekenen in het ontwikkelingsproces 
van geneesmiddelen die werken op het czs.
Resting-state functional magnetic imaging (rs-fmri) lijkt een veelbelo-
vende techniek die voldoet aan bovenstaande criteria. Bij rs-fmri wordt er 
zonder tussenkomst van een bepaalde taak (in een resting-state) direct naar 
bepaalde functionele effecten (bijvoorbeeld de invloed van een genees-
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middel) op het brein gekeken met behulp van magnetic resonance imaging 
(mri). In hoofdstuk 6 hebben we in een pilot-study onderzocht of rs-fmri 
ons in staat stelt om de directe effecten van een stabiele alcohol concentratie 
en een stabiele morfine concentratie op het czs als geheel te meten. Zowel al-
cohol als morfine laten in deze studie meetbare veranderingen zien van zowel 
de indirecte metingen (conventionele czs-metingen) als de directe metingen 
(rs-fmri) uitgedrukt in functionele connectiviteit. Daarnaast blijken er in-
teracties tussen bepaalde netwerken mee te veranderen met zowel de alco-
hol/morfine concentratie als met de effecten gemeten met de conventionele 
testen. Omdat we met rs-fmri blijkbaar geneesmiddelen van elkaar kunnen 
onderscheiden, lijkt het een veelbelovende methode. Daarnaast zijn er ook 
aanwijzingen dat het rs-fmri beloop de plasmaspiegels volgt. Deze eigen-
schappen zouden een aanwinst kunnen zijn voor het ontwikkelingsproces 
van nieuwe geneesmiddelen.
Alcohol heeft ook een aantal therapeutische effecten, bijvoorbeeld bij de 
behandeling van een methanol intoxicatie en bij het reduceren van tremor 
symptomen bij essentiële tremor (et). De alcohol clamp zou daarom kunnen 
dienen als een positieve controle bij studies naar nieuwe behandelingen van 
dit soort aandoeningen.
In hoofdstuk 7 en 8 hebben we de effecten onderzocht van twee nieuwe 
geneesmiddelen (respectievelijk tpa023 en mk-0249) op essentiële tremor, 
een veelvoorkomende bewegingsstoornis, waarbij met name de armen en 
handen trillen bij bewegen. In beide studies hebben we de alcohol clamp 
toegevoegd om de beoogde tremor reducerende effecten van de twee nieuwe 
medicijnen te vergelijken met die van een stabiel alcohol niveau. Er worden 
czs-effecten gemeten bij beide geneesmiddelen, maar tremor reducerende 
effecten blijven uit. De alcohol clamp laat daarentegen wel een verbetering 
van de tremor symptomen zien in beide studies en de clamp lijkt haar rol als 
positieve controle bij et-studies adequaat te vervullen. De alcohol clamp zou 
bij toekomstig onderzoek naar nieuwe therapeutische opties voor et een be-
langrijke bijdrage kunnen leveren. Daarnaast zou de clamp een rol kunnen 
vervullen bij het validatie proces van nieuwe methoden die ontwikkeld wor-
den voor het kwantificeren van tremor symptomen.
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In dit proefschrift is de alcohol clamp geïntroduceerd: een methode waarbij 
alcohol in het bloed op een stabiel niveau kan worden “geclampt” voor lan-
gere perioden door gebruik te maken van een feedback system dat gebaseerd 
is op de hoeveelheid alcohol in de uitademingslucht. De clamp biedt ruimte 
om tijdens de uitvoering ervan testen of taken uit te voeren, waarmee de ef-
fecten van alcohol tegelijkertijd kunnen worden gemeten. Door het principe 
van de clamp kunnen er globale uitspraken worden gedaan over de efficiëntie 
van het alcoholmetabolisme van een individu en over veranderingen van al-
cohol effecten in de tijd (bijv. tolerantie). Een nadeel van de alcohol clamp is 
dat de beoogde alcohol concentratie te weinig variabiliteit bezit om modellen 
te maken die de relatie tussen alcohol concentratie en effect kunnen beschrij-
ven (pk/pd studies). In dit proefschrift worden de alcohol concentraties 
geclampt op verschillende niveaus, maar steeds op andere studiedagen. Om 
concentratie-effect relaties betrouwbaar te onderzoeken, zouden binnen één 
“clamp-run” meerdere opeenvolgende stabiele alcohol levels aangelegd moe-
ten worden om vervolgens de bijbehorende effecten te meten. Dit valt echter 
buiten de scope van dit proefschrift.
Omdat de clamp vanwege haar brede effectprofiel en haar stabiliteit een 
functioneel kader biedt voor proof-of-concept studies (hoofdstuk 6) en 
functioneert als robuuste positieve controle bij studies naar nieuwe thera-
peutische opties voor et (hoofdstuk 7 en 8) is het een interessante methode 
die gebruikt kan worden tijdens het proces van de ontwikkeling van bepaalde 
nieuwe geneesmiddelen. De alcohol clamp zou tevens een rol kunnen gaan 
spelen bij de ontwikkeling en validatie van nieuwe tremor registratie appara-
tuur. Deze apparatuur kan dan uiteindelijk weer gebruikt worden bij de ont-
wikkeling van nieuwe farmacologische behandelingen van et. Daarnaast kun-
nen we met behulp van de clamp en dankzij het brede spectrum aan effecten 
van alcohol en de wettelijk vastgestelde concentratie limieten (met de daarbij 
behorende bekende effecten) een nauwkeurig functioneel kader bieden voor 
acceptabele en ongewenste cns-effecten. Op deze manier zou een nieuw ge-
neesmiddel getoetst kunnen worden aan dit kader om zo een concreet idee 
te krijgen van de veiligheid en verdraagzaamheid van vaak onvermijdelijke 
bijwerkingen van een nieuw cns-middel. Aan de hand hiervan kunnen er 
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ten tijde van de registratie van een bepaald medicament beslissingen worden 
genomen en medico-legale regels worden opgesteld met betrekking tot het 
toekomstig gebruik tijdens verkeersdeelname, tijdens werkgerelateerde akti-
viteiten of gewoon tijdens gebruik in het dagelijks leven.
Om veiligheidsredenen worden er tegenwoordig steeds vaker studies uit-
gevoerd tijdens de ontwikkeling van een nieuw geneesmiddel die de interac-
tie tussen alcohol en het nieuwe geneesmiddel bestuderen. Deze interacties 
moeten nauwkeurig in kaart worden gebracht voor het vormen van aanbeve-
lingen en/of restricties voor haar toekomstige gebruikers ten aanzien van het 
gebruik in combinatie met alcohol. Wij denken dat de alcohol clamp een ade-
quate en nauwkeurige methode is voor het uiteindelijk genereren van zulke 
aanbevelingen, vanwege de stabiliteit van de clamp en de mogelijkheid om 
herhaaldelijk (en onder stabiele concentraties) de effecten van het stabiele 
alcohol niveau te meten. De alcohol clamp is hierbij superieur aan methoden 
die momenteel worden toegepast, omdat deze vaak gehinderd worden door 
zowel hun complexiteit als hun variabiliteit. Wij zien de alcohol clamp als een 
state-of-the-art techniek, die in de toekomst door de autoriteiten als vereiste 
zou moeten worden gezien bij het uitvoeren van alcohol interactie studies. 
Een voorbeeld van het gebruik van de clamp tijdens een interactie studie 
wordt uitgebreid beschreven in hoofdstuk 9. Dit proefschrift is een uiteenzet-
ting van de toepasbaarheid van de alcohol clamp als research instrument bij 
alcohol- en geneesmiddelenonderzoek.
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